Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
1 
 Abbreviated Title:  Perioperative MVT -5873  
CC Protocol #: 19C0039 E 
Version Date:  08/10/2020 
NCT Number  #: [STUDY_ID_REMOVED] 
Title: Perioperative MVT -5873, a Fully Human Monoclonal Antibody A gainst a CA 19-9 Epitope, 
for Operable CA 19 -9 Producing P ancreatic Cancers, Cholangiocarcinomas, and M etastatic 
Colorectal C ancers  
 
NCI Principal Investigator: Jonathan M. Hernandez , MD   
Surgical Oncology Program (SOP) , CCR, NCI  
Building 10, Room 4W-3740 10 Center Drive  Bethesda, MD 20892 Phone: 240-760-6072 E-mail: jonathan.hernandez@nih.gov
  
 
  Investigational Agents:    
Drug Name:  HuMab -5B1 (MVT-5873) 
IND Number:  144112 
Sponsor: NCI Center for Cancer Research   
Manufacturer:  AAIPharma   
 Commercial Agents: None  
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
2 
 PRÉCIS  
Background:  
• Resections to remove tumors in the liver, bile ducts and pancreas are rarely curative, and 
patients frequently succumb to disease recurrence in the ensuing months to year(s) after the operation. 
• Standard adjuvant therapies, which typically begin 6- 12 weeks after surgery, offer little 
demonstrable decreases in the rates of tumor recurrence.  
• The concept and implementation of  immediate perioper ative therapy  has not been 
evaluated given the serious concerns related to healing and recovery with standard cytotoxic chemotherapy and newer targeted agents.  
• A significant percentage of metastatic colorectal cancers, and primary tumors of the pancreas and bile ducts express Sialyl Lewis
a, an epitope on the well -established tumor 
marker, CA  19-9.  
• MVT -5873, a fully human antibody against Sialyl Lewisa, has displayed ADCC and CDC 
in vitro , potentiated chemotherapeutic efficacy in mouse models and demonstrated efficacy 
in Phase 1 trials of patients  with advanced inoperable HPB cancers.  
• MVT -5873 is well tolerated as a single agent; moderate elevations in AST/ALT appear to 
be dose- limiting.   
• Patients with resectable Sialyl Lewisa-expressing cancers represent an ideal population to 
explore the use of  perioperative  MVT -5873 given  moderate level of CA 19 -9 elevations, 
and the potential for extension of recurrence- free survival. 
 
Objectives:  
• Document the safety of perioperative MVT -5873 in patients undergoing pancreas and liver 
resections . 
• Determine if perioperative MVT -5873 can decrease 1- year recurrence rates  for patients 
with operable CA 19-9- producing cancers . 
 
Eligibility:  
• Histologically or cytologically confirmed adenocarcinoma of the 
o Colon (metastatic to liver)  
o Pancreas  
o Bile Ducts  (Cholangiocarcinoma)  
• Serum CA  19-9 l evels greater than the upper limit of normal, but less than 2500.  
• Disease amenable to complete surgical extirpation .   
 
Design:   
• Pre-operative one- time treatment with MVT -5873, r esection to remove all demonstrable 
disease in the liver, bile ducts and pancreas , and continuing MVT -5873 mono-therapy until 
off treatment criteria are met.  
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
3 
 TABLE OF CONTENTS  
PRÉCIS  ........................................................................................................................................... 2  
TABLE OF CONTENTS  ................................................................................................................ 3  
LIST OF TABLES  .......................................................................................................................... 8  
LIST OF FIGURES  ........................................................................................................................ 8  
1 INTRODUCTION  ................................................................................................................ 10  
 Study Objectives ............................................................................................................ 10  
1.1.1  Primar y Objectives .................................................................................................. 10  
1.1.2  Secondary Objective ............................................................................................... 10  
1.1.3  Exploratory Objectives ........................................................................................... 10  
 Background and Rationale ............................................................................................. 10  
1.2.1  HPB Cancers  ........................................................................................................... 10  
1.2.2  Sialyl Lewis A Antigen - CA19 -9 .......................................................................... 11  
1.2.3  MVT -5873 .............................................................................................................. 12  
1.2.4  Preclinical Studies  ................................................................................................... 12  
1.2.5  Effects in Humans  ................................................................................................... 23  
1.2.6  Pharmacokinetics  .................................................................................................... 32  
1.2.7  Reductions in Serum CA19- 9 Levels  ..................................................................... 32  
1.2.8  Responses to Therapy ............................................................................................. 33  
1.2.9  Rationale  ................................................................................................................. 35  
1.2.10  Metastasis Assays Using Ex Vivo  Perfusion of Omentum...................................... 36  
1.2.11  Ex Vivo  Hepatic Perfusion Model  ........................................................................... 36  
1.2.12  Simulated Metastasis Assay with Relevant Tissue (SMART) Chamber  ................ 37  
1.2.13  The SMART System  ............................................................................................... 37  
2 ELIGIBILITY ASSESSMENT AND ENROLLMENT  ....................................................... 40  
 Eligibility Criteria  .......................................................................................................... 40  
2.1.1  Inclusion Criteria  .................................................................................................... 40  
2.1.2  Exclusion Criteria  ................................................................................................... 42  
2.1.3  Recruitment Strategies  ............................................................................................ 42  
 Screening Evaluation ...................................................................................................... 43  
2.2.1  Screening Activities Performed Prior to Obtaining Informed Consent .................. 43  
2.2.2  Screening Activities Performed After a Consent for Screening Has Been Signed  . 43 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
4 
 
 Participant Registration and Status Update Procedures  ................................................. 44  
2.3.1  Treatment Assignment and Randomization/Stratification Procedures  ................... 44  
 Baseline Evaluation  ........................................................................................................ 45  
3 STUDY IMPLEMENTATION  ............................................................................................ 45  
 Study Design .................................................................................................................. 45  
3.1.1  Dose Limiting Toxicity  ........................................................................................... 46  
3.1.2  Safety Lead -In Cohorts ........................................................................................... 46  
3.1.3  Treatment Cohorts .................................................................................................. 48  
 Study Drug Administration ............................................................................................ 50  
3.2.1  Preparation and Administration of MVT-5873....................................................... 50  
3.2.2  Stability of MVT -5873 Following Preparation....................................................... 50  
3.2.3  Upper Limit to Administered Dose in Obese Subjects ........................................... 50  
3.2.4  Infusion Rate of MVT-5873 ................................................................................... 50  
3.2.5  Treatment Guidelines for MVT -5873- Related Infusion Reaction  .......................... 51  
3.2.6  Premedication  ......................................................................................................... 51  
 Dose Modif ications  ........................................................................................................ 52  
 Study Calendar ............................................................................................................... 54  
 Surgical Guidelines ........................................................................................................ 57  
3.5.1  Preoperative Patient Management  .......................................................................... 57  
3.5.2  Patient Management in the Operating Room .......................................................... 57  
3.5.3  Postoperative Care  .................................................................................................. 58  
3.5.4  Discharge  ................................................................................................................ 58  
 Pathological Evaluation.................................................................................................. 58  
 Criteria for Removal from Protocol Therapy and Off Study Criteria ............................ 59  
3.7.1  Criteria for Removal from Protocol Therapy.......................................................... 59  
3.7.2  Off-Study Criteria  ................................................................................................... 60  
4 CONCOMITANT MEDICATIONS/MEASURES  .............................................................. 60  
5 BIOSPECIMEN COLLECTION  .......................................................................................... 60  
 Specimen Collection Table  ............................................................................................ 60  
 Correlative Studies for Research/Pharmacokinetic Studies  ........................................... 62  
5.2.1  Tumor and Tissue Collection .................................................................................. 62  
5.2.2  RNA Evaluation ...................................................................................................... 62  
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
5 
 5.2.3  Metast asis Assays Using Ex Vivo  Perfusion of Omentum...................................... 63  
5.2.4  Ex Vivo  Hepatic Perfusion Model  ........................................................................... 63  
5.2.5  Circulating Tumor Cell Evaluation  ......................................................................... 63  
5.2.6  Monocyte Phagocyte System (MPS) Profiling ....................................................... 64  
 Sample Storage, Tracking and Disposition .................................................................... 64  
5.3.1  Samples Managed by the Blood Processing Core (BPC) ....................................... 64  
5.3.2  Procedures for Storage of Patient Samples in the Laboratory of Dr. Trepel .......... 65  
5.3.3  Procedures for Storage of Tissue Specimens in the Laboratory of Pathology ....... 66  
5.3.4  Procedures for  Storage of Patient Samples in the Laboratory of Dr. Hernandez ... 66  
5.3.5  Protocol Completion/Sample Destruction  .............................................................. 66  
5.3.6  A Certificate of Confidentiality  .............................................................................. 67  
5.3.7  Management of Results ........................................................................................... 67  
5.3.8  Genetic Counseling ................................................................................................. 67  
6 DATA COLLECTION AND EVALUATION  ..................................................................... 67  
 Data Collection  ............................................................................................................... 67  
6.1.1  Routine Data Collection  .......................................................................................... 68  
 Data Sharing Plans  ......................................................................................................... 69  
6.2.1  Human Data Sharing Plan ....................................................................................... 69  
6.2.2  Genomic Data Sharing Plan  .................................................................................... 70  
 Response Criteria  ........................................................................................................... 70  
6.3.1  Definitions ............................................................................................................... 70  
6.3.2  Disease Parameters  ................................................................................................. 70  
6.3.3  Methods for Evaluation of Measurable Disease ..................................................... 71  
6.3.4  Response Criteria  .................................................................................................... 73  
6.3.5  Duration of Response .............................................................................................. 76  
6.3.6  Progression-Free Survival ....................................................................................... 76  
 Toxicity Criteria  ............................................................................................................. 76  
7 NIH REPORTING REQUIREMENTS / DATA AND SAFETY MONITORING PLAN  .. 76  
 Definitions  ...................................................................................................................... 76  
 OHSRP Office of Compliance and Training / IRB Reporting ....................................... 76  
7.2.1  Expedited Reporting ............................................................................................... 76  
7.2.2  IRB Requirements for PI Reporting at Continuing Review ................................... 77  
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
6 
 
 NCI Clinical Director Reporting  .................................................................................... 77  
 NIH Required Data and Safety Monitoring Plan ........................................................... 77  
7.4.1  Principal Investigator/Research Team  .................................................................... 77  
8 SPONSOR SAFETY REPORTING  ..................................................................................... 77  
 Definitions  ...................................................................................................................... 77  
8.1.1  Adverse Even t ......................................................................................................... 77  
8.1.2  Serious Adverse Event (SAE) ................................................................................. 78  
8.1.3  Life-threatening....................................................................................................... 78  
8.1.4  Severity  ................................................................................................................... 78  
8.1.5  Relationship to Study Product ................................................................................ 78  
 Assessment of Safety Events .......................................................................................... 79  
 Reporting of Serious Adverse Events ............................................................................ 79  
 Reporting Pregnancy ...................................................................................................... 79  
8.4.1  Maternal  Exposure  ................................................................................................. 79  
8.4.2  Paternal Exposure ................................................................................................... 80  
 Regulatory Reporting for Studies Conducted Under CCR-Sponsored IND .................. 80  
9 CLINICAL MONITORING ................................................................................................. 80  
10 STATISTICAL CONSIDERATIONS .................................................................................. 81  
 Statistical Hypotheses  ................................................................................................. 81  
10.1.1  Primary Efficacy Endpoints .................................................................................... 81  
10.1.2  Secondary Efficacy Endpoints ................................................................................ 81  
 Sample Size Determination:  ....................................................................................... 81  
 Populations for Analysis ............................................................................................. 82  
10.3.1  Evaluable for Toxicity ............................................................................................ 83  
10.3.2  Evaluable for Objective Response  .......................................................................... 83  
10.3.3  Evaluable Non- Target Disease Response  ............................................................... 83  
 Statistical Analyses  ..................................................................................................... 83  
10.4.1  General Approach  ................................................................................................... 83  
10.4.2  Analysis of the Primary Efficacy Endpoints ........................................................... 83  
10.4.3  Analysis of the Secondary Efficacy Endpoints ....................................................... 83  
10.4.4  Safety Analyses  ....................................................................................................... 83  
10.4.5  Baseline Descriptive Statistics  ................................................................................ 84  
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
7 
 10.4.6  Planned Interim Analyses ....................................................................................... 84  
10.4.7  Exploratory Analyses .............................................................................................. 84  
11 COLLABORATIVE AGREEMENTS  ................................................................................. 85  
 Material Transfer Agreement (MTA)  ......................................................................... 85  
12 HUMAN SUBJECTS PROTECTIONS  ............................................................................... 85  
 Rationale For Subject Selection  ................................................................................. 85  
 Participation of Children  ............................................................................................ 86  
 Participation of Subjects Unable to Give Consent ..................................................... 86  
 Evaluation of Benefits and Risks/Discomforts ........................................................... 86  
12.4.1  Risks ........................................................................................................................ 86  
12.4.2  Risks of Exposure to Ionizing Radiation ................................................................ 87  
12.4.3  Non-Physical Risks of Genetic Research  ............................................................... 88  
12.4.4  Benefits  ................................................................................................................... 88  
12.4.5  Certificate of Confidentiality  .................................................................................. 88  
 Consent Process and Documentation ......................................................................... 88  
12.5.1  Request for Waiver of Consent for Screening Activities ........................................ 89  
13 PHARMACEUTICAL AND INVESTIGATIONAL DEVICE INFORMATION  .............. 89  
 Drug MVT -5873 (IND # 144112) .............................................................................. 89  
13.1.1  Source ..................................................................................................................... 89  
13.1.2  Toxicity  ................................................................................................................... 89  
13.1.3  Formulation and Preparation................................................................................... 90  
13.1.4  Stability and Storage ............................................................................................... 90  
13.1.5  Administration Procedures...................................................................................... 90  
13.1.6  Incompatibilities  ..................................................................................................... 90  
14 REFERENCES  ..................................................................................................................... 91  
15 APPENDICES  ...................................................................................................................... 94  
 Appendix A: Performance Status Criteria .................................................................. 94  
 Appendix B: Toxicity Tables ..................................................................................... 95  
 Appendix C: Investigator Agreement ....................................................................... 114  
 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
8 
 LIST OF TABLES  
Table 1: Pharmacokinetic Parameters for MVT -5873 Following Single Intravenous Doses of 
10, 30, and 100 mg/kg of MVT -5873 to Cynomolgus Monkeys................................ 17  
Table 2: Pharmacokinetic Parameters for MVT -5873 Following Intravenous Administration 
of 30 mg/kg and 100 mg/kg of MVT-5873 to Cynomolgus Monkeys on Day 1 
and Day 8 .................................................................................................................... 17  
Table 3: Dose Cohorts, Cycles Administered and Patient Disposi tion ........................................ 29  
Table 4: Summary of MVT-5873 Dose Limiting Toxicities and Treatment Disposition  ..... 30  
Table 5: All Adverse Events, All Grades, in ≥ 30% of Subjects  .................................................. 31  
Table 6: All Treatment- Related Adverse Events ≥ Grade 3  ......................................................... 32  
Table 7: MVT -5873 Human Pharmacokinetics ............................................................................ 32  
Table 8: Normalization (< 37U/mL) of CA 19-9 Levels Following Adminstration of MVT-
5873............................................................................................................................. 33  
Table 9: Safety Lead -In Study Design .......................................................................................... 46  
Table 10: Safety Lead -In Cohorts ................................................................................................. 47  
Table 11: Treatment Study Design ............................................................................................... 49  
Table 12: Treatment Guidelines (If Two Different Pre-Operative MTDs by LFT Elevation 
are Determined from Safety Lead -In) ......................................................................... 49  
Table 13:Treatment Study Design (If Two Different Pre-Operative MTDs by LFT Elevation 
are Determined from Safety Lead -In) ......................................................................... 50  
 
LIST OF FIGURES  
Figure 1: Top left: pancreas, ductal adenocarcinoma, stage III  .................................................... 13  
Figure 2: Tumor Growth Over Time – BxPC3 Xenograft Model with MVT-5873 Doses of 5, 
15, and 30 mg/kg as a Single Agent and in Combination with Gemcitabine/nab -
paclitaxel  ..................................................................................................................... 14  
Figure 3: Immunohistochemical Staining of BxPC3 Tumor Tissue Samples at 20X 
Magnification; MVT -5873 (top panel) and Human IgG (bottom panel) .................... 15  
Figure 4: Mean MVT-5873 Serum Concentrations Over Time in BxPC3 Tumor- Bearing 
Mice and Nontumor-Bearing Mice ............................................................................. 16  
Figure 5: MVT-5873 Serum Concentration and BxPC3 Tumor Volume Versus Time ............... 16  
Figure 6: Serum Levels (AUC 0-168 and C max) of MVT -5873 after Repeated Intravenous 
Dosing in Cynomolgus Monkeys (Males and Females Combined) on Day 1 and 
Day 8  ........................................................................................................................... 18  
Figure 7: Liver Function Test with 3mg/kg Weekly Dosing of MVT-5873 from Six Subjects ... 28  
Figure 8: Efficacy for MVT-5873................................................................................................. 34  
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
9 
 Figure 9: Percent Ch ange in Target Lesions in Cohort B3 (0.125 mg/kg MVT-5873) ................ 35  
Figure 10: The SMART System Consisting of SMART Platform ............................................... 38  
Figure 11: Ex Vivo Normal and Tumor Preservation in the SMART System ............................. 39  
Figure 12: SMART Platforms are Valuable Tools for Drug Evaluations Such as 
Pembrolizumab  ........................................................................................................... 40  
Figure 13: Operating Room Workflow ......................................................................................... 58  
Figure 14: Pathologic Evaluation of Tumor and Liver Tissue Removed a t the Time of 
Surgery  ........................................................................................................................ 59  
Figure 15: Scientific Endpoints. Evaluation of Circulating Tumor Cells (top) and Ex Vivo 
Tissue Modeling (bottom) ........................................................................................... 63  
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
10 
 1 INTRODUCTION 
 STUDY OBJECTIVES  
1.1.1 Primary Objectives 
• Document the safety of perioperative MVT -5873 in patients undergoing pancreas and liver 
resections . 
• Determine if perioperative MVT -5873 can decrease 1-yea r recurrence rates for subjects  
with operable CA 19-9 producing cancers . 
1.1.2 Secondary Objective  
• Define disease free survival ( DFS) for subjects  treated with pre operative MVT-5873.   
1.1.3 Exploratory Objectives  
• Define overall survival ( OS) for subjects  treated with pr eoperative MVT -5873. 
• Determine the mechanism(s) of liver function test abnormalities associated with MVT -
5873 administration. 
• Determine the tumor penetration of MVT -5873 in primary tumors of the pancreas and bile 
ducts, and in metastatic colorectal cancers to the liver.   
• Evaluate the impact of MVT -5873 therapy on circulating tumor cells. 
• Develop ex vivo models for pancreatic cancer, cholangiocarcinoma, and metastatic 
colorectal cancer . 
• Evaluate chemotherapeutic and immunotherapeutic agent  effects in tumors from  patients 
undergoing pancreas and liver resections  after p re-operative MVT -5873 therapy using a 
novel ex vivo  platform, the SMART System. 
 BACKGROUND AND RATIONALE  
1.2.1 HPB Cancers  
Cancers of the pancreas, liver (primary and metastatic) and bile ducts represent some of the most 
recalcitrant diseases encountered by the practicing oncologist. When identified early, these  cancers 
can be removed with technically challenging operations. Fortunately, experience has decreased the 
perioperative complications associated with these operations. However, the ability to prevent disease re currence following the procedure  has not yet come to fruition. Although resection 
remains the only hope for cure, this end- point is achieved by very few. Analysis of randomized 
prospective trial data and single institution series strongly suggests that nearly half of all patients undergoing resections for pancreatic cancer, cholangiocarcinoma and metastatic colorectal cancer to the liver will experience a recurrence of disease in the first 12 -15 months following removal of 
tumor(s). [1-3] In other words, these patients underwent an operation for likely abbreviated  benefit 
in terms of survival. The recently reported, not yet published, data on the BILCAP (cholangiocarcinoma) is very similar to the se outcomes below. It has been postulated for some 
time that the operation itself may hasten demise for some patients by inciting an inflammatory milieu and triggering an angiogenic switch in remote dormant tumor cells. Substantial data exist 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
11 
 in mice [4] supporting this concept but data in humans is admittedly lacking. We do however know 
that surgery is associated with increases in circulating tumor cell numbers,  likely secondary to 
manipulation during the procedure.[ 5] It would be ideal to give a perioperative agent with efficacy 
against the tumor  cells at the time of resection. Unfortunately, chemotherapy has deleterious 
effects on wound healing that would make resection an extremely -risky endeavor. However, a 
well-tolerated monoclonal antibody targeting a tumor cell epitope may hold promise in mi tigating 
those early recurrences and thereby increasing the efficacy of resection for cancers of the pancreas, 
liver and bile ducts. This concept of immediate perioperative therapy is unique and additive to 
what is generally undertaken with high- risk cancers. For example, patients could receive standard 
neo-adjuvant and/ or adjuvant therapies in addition to immediate perioperative therapy without 
altering the standard regimens. Moreover, antibody penetration and binding to tumor cells would be directly asses sed on resected specimens , as would the effects on circulating tumor cell 
populations (which have been demonstrated to be prognostic [6-8]) , which could be used to stratify 
patients for combination antibody/chemotherapy should disease recur. In short, the employment 
of immediate perioperative therapy, if demonstrated to be safe, could add an additional tool in the 
oncologist’s armamentarium f or resectable high -risk cancers.  
1.2.2 Sialyl Lewis A Antigen - CA19 -9 
The Sialyl Lewis A (sLe
a) antigen is an epitope present on Carbohydrate Antigen 19- 9 (CA  19-9), 
defined by the mouse monoclonal antibody 116- NS-19-9, shown to be overexpressed on epithelial 
cell tumors. [9, 10] SLea is an oligosaccharide expressed primarily as a proteoglycan that is secreted 
and circulates as a mucin form, and  also as a less well studied glycolipid form. [10, 11] The sLea 
antigen is predominantly expressed on cancer cells.[ 12] As a ligand for E selectin, sLea facilitates 
tumor adhesion and extravasation, key events for tumor metastasis, and is thus a marker of an aggressive tumor phe notype.[ 13] Glycolipids, such as sLe
a, are established targets for cancer 
immunotherapies.[ 14] The monoclonal antibody MVT -5873 (also referred to as HuMab- 5B1 or 
5B1), the investigational agent in this study, specifically targets the sLea antigen.  
CA 19-9 is widely expressed on tumors of the gastrointestinal tract, with up to 94% of pancreatic 
cancers positive for CA  19-9 expression and high expression rates also seen in bile duct carcinomas 
and transitional cell carcinomas. [15, 16] Additional ly, expression of CA  19-9 is frequently seen in 
ovarian, colon, stomach, and distal esophagus/stomach cancers. Circulating serum levels of CA  
19-9 have been validated as a biomarker for assessing the metastatic potential of pancreatic ductal 
adenocarcinoma s (PDAC)[ 17, 18] and have been used to evaluate the aggressiveness of other 
epithelial cell cancers. [19, 20] As a known ligand for endothelial leukocyte adhesion molecules, 
CA 19-9 expression is associated with increased metastatic potential in colon cancer [13, 21, 22] 
and pancreatic adenocarcinoma.[ 23]  
Serum CA  19-9 levels have also been found to be informative with respect to prognosis and 
treatment effect in patients with pancreatic cancer, with several studies correlating increasingly higher serum levels with poorer survival outcomes.[ 17, 18, 24] In a P hase I/II clinical trial of nab -
paclitaxel and gemcitabine in patients with advanced pancreatic cancer, decreases in CA  19-9 
levels correlated with  tumor response, PFS, and OS.[ 25] In a P hase II study of 5-fluorouracil- based 
chemoradiotherapy in patients with locally advanced pancreatic cancer, a greater than 90% reduction in CA  19-9 levels f rom baseline was associated with significantly improved median 
survival time, with a multivariate analysis finding a -post therapy CA  19-9 level of less than 85.5 
U/mL to be an independent prognostic factor for survival.[ 26]  
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
12 
 On normal cells, expression of CA  19-9 is restricted to the apical brush border, a relatively 
inaccessible location due to the basement membrane and the tight junctions of mature and 
polarized ductal epithelium.[ 27] In patients with CA  19-9 positive tumors, a bout 5% are negative 
for circulating levels of CA  19-9, and this appears to be related to poor secretion or release of CA  
19-9 into the blood stream, not necessarily to expression of the CA  19-9 antigen by the tumor 
cell.[28-30] Because CA  19-9 has a high expression rate in patients with pancreatic cancer, this 
antigen was identified as a target for antibody- based biopharmaceuticals, and specifically this 
investigation of MVT-5873 in pati ents with PDAC.  
1.2.3 MVT -5873 
MVT -5873 (HuMab -5B1) is a fully human IgG1  lambda antibody discovered by MabVax in 
collaboration with investigators at Memorial Sloan Kettering Cancer Center (MSKCC). MVT -
5873 was identified from blood lymphocytes from a breast can cer patient following immunization 
with a sLea-KLH vaccine. [31] This vaccine has been shown to induce high titers of both IgG and 
IgM antibodies against sLea in mice and humans without cross -reactivity to other similar blood 
group carbohydrate antigens .[31] Two human monoclonal antibodies (5B1 and 7E3) with high-
affinity for sLea were identified, subsequently expressed as a recombinant  antibodies, and further 
characterized. [32]  
Evaluation of the specificity of MVT -5873 demonstrated cell surface binding in sLea positive 
colon cancer (HT29 and Colo205), ovarian cancer (SW626), small cell lung cancer (DMS79), and pancreatic cancer (BxPC3) cell lines, but not  to a sLe
a negative melanoma (SK -MEL28) cell 
line.[32] Importantly, MVT -5873 did not bind to Lea, sLex, Ley, or other related carbohydrates 
when evaluated by enzyme- linked immunosorbent assay (ELISA) and surface plasmon 
resonance. [32] In addition, an independent binding analysis conducted by the Consortium on 
Functional Glycomics Core H group using a glycan array with 465 distinct carbohydrates revealed that MVT -5873 had exquisite specificity for the carbohydrate epitope of the sLe
a antigen.  
MVT -5873 has been shown to be potent in complement -dependent cytotoxicity (CDC) assays and 
antibody- dependent cell mediated cytotoxicity (ADCC) assays ( see below ). Both of these 
mechanisms are consistent with  antitumor activity. Based on these findings, MVT -5873 was 
selected for further development as a potential therapy for patients with CA  19-9 expressing tumor 
types. 
1.2.4 Preclinical Studies  
1.2.4.1 Tissue Specificity  
MVT -5873 binding to tumor TMA  appeared to be specific, differentially expressed, and restricted, 
with most normal tissues lacking reactivity. Expression of sLea was present on several 
adenocarcinomas, including pancreatic cancers, a finding consistent with literature reports of sLea 
expression identified by CA  19-9 antibody binding ( Figure 1). Most of the human specimens 
evaluated in the TMA analysis were negative for staining. However, expression of  sLea antigen 
was found on mucous glands of the small intestine, colon  (goblet cells) , and rectum. There was 
also expression in exocrine pancreas, germinal center of lymph node, gallbladder, breast  (ductal 
cells) , and uterine cervix of normal human tissue. The observed binding pattern is consistent with 
expression in tissues producing exocrine secretions, i.e. mucins that carry the sLea antigen.  
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
13 
 Strong positive staining was seen in 23/34 colon adenocarcinomas (68%), 3 4/58 adenocarcinoma 
metastases to the ovary (5 9%), and 7/9 pancreatic ductal cancers (62%)  at various stages. As shown 
in the figure below , typical reactivity shows as diffuse cytoplasmic staining, with some tumor cells 
clearly showing distinct staining at the cell membrane level. In addition, signet ring- metastatic to 
ovaries, some lung (i.e. bronchioalveolar, mucoepidermoi d) and metastatic breast cancer lymph 
node biopsy cores were found to be strongly positive, albeit at lower frequencies. In contrast, only 
2/43 prostate cancer samples (5%) and 0/51 gastrointestinal stromal tumors (GIST) specimens were positive (data not s hown). 
 
Figure 1: Top left: pancreas, ductal adenocarcinoma, stage III 
Top center: sigmoid colon, carcinoma stage IIIB  
Top right: lung adenocarcinoma, stage IB 
Bottom left: urinary bladder, mucinous adenocarcinoma, stage IV 
Bottom center: ovary, metastatic carcinoma from colon Bottom right: lymph node, breast carcinoma, stage IIIA 
 
1.2.4.2 Evaluation of MVT-5873 in Murine Xenograft Models 
In an early exploratory study, the antitumor potential of MVT -5873 was assessed using a Colo205-
luc xenograft model of metastatic colon cancer in SCID mice. [32] Across two experiments, groups 
of 5 mice were given either 4 doses of MVT -5873 at 5 mg/kg (20 mg/kg total dose) or 6 doses of 
MVT -5873 at 5 mg/kg (30 mg/kg total) intraperitoneally, each over the course of 21 days, while 
animals in the control groups received injections of phosphate buffered saline (PBS). Across all 
the control animals, the average median survival was 102 days and all died within 155 days. Treatment improved survival significantly; median survival in animals that received 4 doses of MVT -5875 was 207 days (p < 0.05; HR = 3.46), and in the animals that received 6 doses of MVT -
5873, median survival had not yet been reached at day 301, the termination of the experiment (p < 0.01; HR =6.375). 

Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
14 
 To further evaluate the antitumor activity of MVT -5873, a series of in vivo  studies were conducted 
utilizing human pancreatic cancer (BxPC3) xen ograft models.  
The combination of MVT -5873, both a single agent and in combination with gemcitabine and nab -
paclitaxel in mice bearing BxPC3 tumor xenografts  was evaluated . In this study MVT -5873 was 
administered as doses of 5, 15, and 30 mg/kg, blood sam ples for PK analysis were collected from 
all study groups, and tumor tissues were harvested at the end of study for IHC staining. 
As had been observed in the previous BxPC3 xenograft experiment s, single -agent MVT -5873 
demonstrated tumor growth inhibition and growth delay at all dose levels compared to controls 
(Figure 2).  
 
Figure 2: Tumor Growth O ver Time – BxPC3 Xenograft Model with MVT-5873 D oses of 5, 15, and 
30 mg/kg as a S ingle A gent and in C ombination with Gemcitabine/nab -paclitaxel 
Tumor tissue samples taken at the end of treatment were sectioned and stained for the presence of the sLe
a target using MVT -5873 as a probe Figure 3.  H uman IgG using goat anti -human IgG 
antibody was used as a probe  for residual MVT -5873 bound to tumor post administration. 
Representative tissue staining samples are depicted. IHC staining signal intensities, recorded as optical densities, across the two panels are shown in the Figure 3 below.  
In the Figure 3, top panel, staining the presence of the sLe
a was high and similar  in all samples, 
indicating a relative abundance of the sLea target in these tissues. These data provide evidence that 
upon treatment of gemcitabine plus nab- paclitaxel there is no change in expression of the target 
epitope.  In the bottom panel, when stained with human IgG that lacks binding to the target epitope, 
the presence of residual MVT -5873 in tumor tissue was observed across all MVT -5873 treatment 
groups, with staining density correlating with response.  The  complete lack of staining in the 
chemoth erapy alone group serves as a negative control . 

Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
15 
 As shown in the Figure 3, signal intensities of IgG staining across all MVT -5873 treatment groups 
were higher than that of the human IgG control, indicating binding selectivity of MVT -5873 in 
tumor tissue. There was a significant difference in signal intensity between the MVT -5873 5 mg/kg 
+ chemotherapy group and the  MVT -5873 15 mg/kg + chemotherapy group (P < 0.05), suggesting 
dose-dependent binding of MVT-5873 to tumor tissues. 
 
  
Figure 3: Immunohistochemical Staining of BxPC3 T umor Tissue Samples at 20X Magnification; 
MVT -5873 (top panel) and H uman IgG (bottom panel)   
These xenograft studies indicate that MVT -5873 has activity in the known sLea-bearing tumor 
models. 
Analysis of MVT -5873 binding to tumor tissue by IHC revealed an apparent dose -dependent 
uptake of MVT-5873 in tumor tissue. Serum concentrations were measured.  Further analysis of these data shown in Figure 4 and Figure 
5 indicate an inverse relationship between MVT -5873 serum concentrations and tumor volume. 
This suggests that the presence or expansion of the sLe
a target, either on tumor tissue or in 
circulation, decreases the amount of free MVT -5873 in the serum and contributes to the systemic 
clearance of MVT -5873. 
  

Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
16 
  
Figure 4: Mean MVT -5873 Serum Concentrations O ver Time in BxPC3 Tumor -Bearing Mice and 
Nontumor -Bearing Mice  
 
 
Figure 5: MVT -5873 Serum Concentration and BxPC3 Tumor Volume V ersus Time  
These studies support the clinical evaluation of MVT -5873, as a single agent and in combination 
with chemotherapy, in subjects  with pancreatic cancer and other sLea positive tumor types. 
1.2.4.3  Pharmacokinetics  
1.2.4.4 Single- Dose Pharmacokinetics  
In a single -dose IV PK study in cynomolgus monkeys ( non-GLP Study 20068188), MVT -5873 
serum levels were determined over a one-month period using an ELISA procedure. MVT -5873 
exhibited a low clearance from serum (0.384 to 0.503 mL/min/kg) and a low volume of distribution 
(40.9 to 83.0 mL/kg), with a resultant long half-life (65.2 to 217 hours) at dose levels of 10, 30 or 100 mg/kg MVT-5873 ( Table 1).  

Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
17 
 Table 1: Pharmacokinetic Parameters for MVT -5873 Following Single Intravenous Doses of 10, 30, 
and 100 mg/kg of MVT -5873 to Cynomolgus Monkeys  
Dose 
(mg/kg)  Sex Tmax 
(h) Cmax 
(µg/mL)  AUC 0-t 
(µg∙h/mL)  t1/2 
(h) CL 
(mL/min/kg)  Vd 
(mL/kg)  
10  Female  0.250  141 12,800  NC NC NC 
Male  0.250 254 22,900 65.2 0.424 40.9 
30  Female  0.280 499 41,900 NC NC NC 
Male  0.250 736 64,700 217 0.384 120 
100  Female  0.750 1780 169,000 103 0.503 74.9 
Male  0.750  2190  213,000  126 0.456  83.0 
Abbreviation: NC=Not Calculated (coefficient of determination less than 0.800 or the extrapolation of the 
AUC to infinity represented more than 20% of the total area)  
The low serum clearance seen with MVT -5873 is typical of monoclonal antibodies , where the 
main route of elimination is generally thought to be by receptor binding and internalization and/or 
protein catabolism.  The low volume of distribution is typical for a monoclonal antibody, since it 
is similar to the volume of plasma for the cynomolgus monkey and suggests limited distribution 
into tissue.  
1.2.4.5 Repeat -Dose Pharmacokinetics  
A multiple -dose toxicity study in cynomolgus monkeys ( non-GLP Study 20068122) evaluated the 
effects of MVT -5873 (30 or 100 mg/kg) administered IV once a week for 2 weeks (2 doses). The 
toxicokinetic evaluations were conducted over each dosing interval on Days 1- 7 and Days 8-15, 
revealing that exposure, measured by AUC 0-168, was approximately dose-proportional and similar 
across the dosing interval for both sexes, ranging from 26,600 to 146,00 µg•hr/mL for dose levels of 30 and 100 mg/kg, respectively ( Table 2, Figure 6). There was minor MVT -5873 plasma 
accumulation when administered once weekly. Similarly, in a GLP 4- week once weekly (4 doses) 
IV toxicity study, trough plasma levels measured  weekly were either similar to or greater than 
Week 1 indicating good exposure to MVT-5873 over the 4-week dosing period. 
Table 2: Pharmacokinetic Parameters for MVT -5873 F ollowing Intravenous Administration of 30 
mg/kg and 100 mg/kg of MVT- 5873 to C ynomolgus Monkeys on Day 1 and Day 8 
Day Dose (mg/kg)  Sex Cmax (μg/mL)  AUC 0-168 (μg•h/mL)  
1 30 Female  843 33,300  
30 Male  977 34,800  
30 Mean (M&F)  910 34,050  
100 Female  2260  151,000  
100 Male  2380  118,000  
100 Mean (M&F)  2320  134,500  
8 30 Female  760 38,400  
30 Male  881 48,900  
30 Mean (M&F)  821 43,650  
100 Female  2540  212,000  
100 Male  2450  148,000  
100 Mean (M&F)  2495  180,000  

Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
18 
 Day Dose (mg/kg)  Sex Cmax (μg/mL)  AUC 0-168 (μg•h/mL)  
M= Male; F = Female  
 
Figure 6: Serum Levels (AUC 0-168 and C max) of MVT -5873 after Repeated Intravenous Dosing in 
Cynomolgus Monkeys (Males and Females Combined) on Day 1 and Day 8 
In addition to assessing PK in cynomolgus monkeys, serum levels of MVT -5873 were measured 
at various times during a multiple dose PK study in both nontumor - and tumor -bearing SCID mice. 
After intraperitoneal administration, MVT -5873 serum levels were maintained at an average of 
46.1 µg/mL in nontumor -bearing mice. Mice with established CA  19- 9 expressing tumor 
xenografts demonstrated lower serum levels, indicating a relatively higher clearance compared to 
nontumor- bearing mice.  
Further information on the pharmacokinetics of MVT -5873 in mice the presence and absence of 
tumor was collected as part of the second BxPC3 xenograft study described above, which evaluated MVT -5873 as a single agent at doses of 5, 15, and 30 mg/kg as a single agent and in 
combination with 80 mg/kg of gemcitabine plus 20 mg of nab- paclitaxel. This study included an 
additional treatment group of nontumor -bearing mice that were treated with MVT -5873  
15 mg/kg. 
Serial pre -dose (C
min) concentrations of MVT -5873 were collected on Days 13, 16, 23, 30, and 37, 
with an additional sample collected 1 week later, on Day 44. As shown in the figure below, in the 
absence of tumor, serial C min MVT -5873 concentrations (15 mg/kg dose level) appeared to slightly 
accumulate throughout treatment. However, in all tumor -bearing animals, serial C min values 
declined over time, as had been observed previously.  
1.2.4.6 Preclinical Safety  
The preclinical studies conducted to determine the safety of MVT -5873 are summarized in  the 
table below . Several toxicology studies have been conducted with MVT -5873 in cynomolgus 
monkeys and include d a 4-week (4 dose) GLP safety study, a 2- week (2 dose) exploratory non-
GLP toxicology study, and a single dose tolerability study. All studies were conducted at Charles 
River Laboratories (Reno, NV). 
To support the cynomolgus monkey as an appropriate model for MVT -5873 toxicology studies, 
pivotal (GLP) tissue cross -reactivity studies were conducted to assess the binding of MVT -5873 
to cryosections (or to fixed blood) of normal human tissues ( GLP Study 20067038) and normal  

Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
19 
 cynomolgus monkey tissues ( GLP Study 20074271); these studies were conducted at Charles 
River L aboratories (Pathology Associates, Frederick, MD). 
Study Type and 
Duration  Route / Mode of 
Administration  Species  Doses  Study No. 
Compliance  
Single dose  
Single -dose tolerability 
and pharmacokinetics 
with 4 week postdose 
observation/blood 
sampling period  IV slow bolus (1 -3 min) or 
30-min infusion via a 
saphenous vein  Monkey/ 
Cynomolgus 0, 10, 30  mg/kg 
(slow bolus)  
100 mg/kg (30-
min infusion)  20068188  
Non-GLP  
Repeat -dose studies  
Once weekly (2 doses) 
toxicity and 
toxicokinetic study 
with terminal sacrifice 
2 weeks after the last 
dose IV slow bolus (1 -3 min) or 
30-min infusion via a 
saphenous vein  Monkey/ 
Cynomolgus 0, 30  mg/kg 
(slow bolus)  
100 mg/kg (30-
min infusion)  20068122  
Non-GLP  
Once weekly (4 doses) 
toxicity and 
toxicokinetic study 
with terminal sacrifice 
1 week after the last 
dose and with a 4- week 
recovery  IV slow bolus (1 -3 min) or 
30-min infusion via a 
saphenous vein  Monkey/ 
Cynomolgus 10, 30  mg/kg 
(slow bolus)  
0, 100 mg/kg 
(30-min 
infusion)  
Recovery (0, 
30, 1 00 mg/kg)  20068123  
GLP  
Other toxicity studies  
Tissue cross -reactivity  
(40 tissues from 
3 donors)  In vitro (cyrosectioned 
tissue)  Monkey/ 
Cynomolgus 2 and 10 µg/mL  20067038 
GLP  
Tissue cross -reactivity  
(40 tissues from 
3 donors)  In vitro (cyrosectioned 
tissue)  Human  2 and 10 µg/mL  20074271 
GLP  
Blood compatibility 
(hemolysis and 
erythrocyte clumping) In vitro heparinized blood 
from Lewis A positive 
phenotype on red blood 
cells Human  Final blood 
concentrations: 57.5 – 384 
µg/mL  323966  
1.2.4.7 Species Selection  
The cynomolgus monkey is considered a relevant biological species for evaluating the safety of 
MVT -5873, since this species, like humans, expresses the gene ( FUT3 ) responsible for expression 
of the pharmacologic target sLea. In contrast, both mice and rats lack a functional FUT3  and do 
not express sLea. To establish the tissue expression of the sLea target in standard toxicology animal 
models, binding of MVT -5873 to tissue microarrays obtained from cynomolgus monkey, mouse, 
and rat was stu died. As expected from the literature and from previous studies with MVT -5873 
using normal human tissue, binding of MVT -5873 to cynomolgus monkey tissue was seen in 
mucus secreting epithelium in the gastrointestinal tract, as well as in other related tissu es (e.g., 
salivary glands). Unlike cynomolgus monkey tissue microarrays, the tissue microarrays from mouse and rat showed no specific binding for MVT -5873. These results confirm literature reports 
that rodents do not express sLe
a and thus are not appropriate for nonclinical safety testing, and that 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
20 
 cynomolgus monkeys do express the pharmacologic target and are appropriate for toxicity testing 
with MVT -5873.   
1.2.4.8 Repeat Dose Toxicity  
1.2.4.8.1 MVT -5873: 2- Week Once Weekly (2 Doses) Toxicity Study 
In a pilot toxicity study in cynomolgus monkeys (nonGLP Study 20068122), MVT -5873 was 
administered IV as a slow bolus dose at 0 and 30 mg/kg or as a 30- min infusion at 100 mg/kg on 
study Days 1 and 8. T he vehicle was 25  mM h istidine, 150 mM sucrose, 55 mM sodium chloride, 
0.02% Tween 80 at  pH 6.0. O bservations were recorded  during the study. Samples for hematology, 
coagulation, urinalysis and clinical chemistry were collected for all animals once prestud y and on 
Day 23 or, for urinalysis, on Day 25. Animals were necropsied on D ay 25, organs weighed and 
tissue collected for histopathological examination.  
Toxicokinetic samples were drawn f or all animals on Days 1 and 8 at 0.25, 6, 12, 24, 72, and  
168 hours post dose.  Samples were also collected on Day 23 prior to sacrifice (see Section 1.2.4.8.2  
for discussion of repeat- dose toxicokinetics). 
There was  no mortality, no changes in clinical observations, no changes in food consumption, or 
adverse reactions to MVT -5873. There were no MVT -5873- related changes in hematology, serum 
chemistry , urinalysis  or coagulation parameters , and no MVT -5873- related macroscopic findi ngs 
noted at terminal necropsy. 
Non-adverse m icroscopic findings considered related to MVT -5873 were noted at  100 mg/kg in 
the gallbladder ( minimal eosinophilic infiltration)  in both the male and female monkeys and in the 
liver (mild Kupffer cell hypertrophy)  in the male. Mild mononuclear cell infiltrates  noted in the 
kidney of the female  at 100 mg/kg was of uncertain relationship to the test article.  These 
histological changes were not seen in the pivotal GLP 4- week st udy. 
1.2.4.8.2 MVT -5873: 4- Week Once Weekly (4 Doses) Toxicity Study 
In the pivotal GLP 4- week toxicity study in cynomolgus monkeys (GLP Study 20068123), 
MVT -5873 was administered IV as a 30- minute infusion at 0 and 100 mg/kg and as a slow bolus 
dose at 10 and 30 mg/kg on study Days 1, 8, 15 and 22. The vehicle was the same as the clinical 
formulation and consisted of 25 mM histidine, 150 mM sucrose, 55 mM sodium chloride, 0.02% 
Tween 80 , pH 6.0. Observations were recorded during the study. Ophthalmic examinations we re 
conducted predose and during Weeks 4 and 8. Electrocardiograms, heart rate, and waveform intervals (PR, QRS, RR, QT, and QTc Bazett’s) were recorded predose and during Weeks 4 and 8. Samples for hematology, coagulation, and clinical chemistry were colle cted for all animals once 
predose, on Day 30, and at the end of the 4- week reversal period (Day  58). Samples for assessment 
of anti -MVT -5873 antibodies were drawn predose, on Day 29, and near the end of the 4- week 
reversal period (Day  57). Animals were necropsied, organs weighed and tissue collected for 
histopathological examination on D ay 30 for the main sacrifice groups (3/sex/group) and on 
Day 58 for the reversal groups (2/sex at 0, 30 and 100 mg/kg). 
Toxicokinetic samples were drawn at various times over a one -week period following the first 
dose administration, at weekly intervals until the main sacrifice, and then again at the end of the 4-week reversal period.  
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
21 
 There was no mortality and no MVT -5873 related changes in clinical observations, body weight , 
food consumption, ophthalmic exams, or cardiac parameters. There were no MVT -5873 related 
changes in hematology, serum chemistry, or coagulation parameters and no MVT -5873 related 
macroscopic findings noted at the main necropsy or at the reversal necropsy. In contrast to the 
previous cynomolgus monkey toxicity study, no MVT -5873 related microscopic findings were 
observed in this GLP study. 
The toxicokinetics of MVT -5873 in female and male cynomolgus monkey serum demonstrated 
similar systemic exposure as in the previous toxicity study, with mean weekly trough values over 
the 4 -week study period being similar to, or greater than, those observed during W eek 1. Although 
MVT -5873, a fully human monoclonal antibody, generated anti -MVT -5873 antibodies in most 
animals at all dose groups, the presence of these antibodies had no apparent effect on serum levels 
of MVT -5873 and was not associated with any microscopic changes. Two monkeys tested positive 
for anti -MVT -5873 antibodies prior to treatment with MVT -5873 and also demonstrated higher 
serum clearance of MVT -5873 on Day 1 versus monkeys with no predose antibodies; these results 
indicate that the p ositive results prestudy were likely cross -reactive antibodies. Development of 
antibodies during the study was expected following administration of a human monoclonal antibody to cynomolgus monkeys. 
In summary, intravenous administration of MVT -5873 up to 100 mg/kg once weekly for 4 weeks 
generated no adverse toxicological effects. The dose of 100 mg/kg is near the maximum feasible 
dose based on maximum formulation concentration and maximum acceptable dose volume in monkeys. An expected immune reaction was induced in cynomolgus monkeys after treatment with MVT -5873, but had no apparent effect on serum levels of MVT -5873, w hich generally remained 
constant throughout the 4-week study period. 
1.2.4.9 Tissue Cross-R eactivity Studies  
The objective of this study was to determine the potential cross -reactivity of MVT -5873, a 
monoclonal human IgG antibody directed against Sialyl Lewis (a), with cryosections of human 
tissues. Sialyl Lewis (a) is a carbohydrate antigen present on O -glycans on the surfaces of cells 
and is often associated with high grade tumors from various tissues.[ 12, 33]  Sialyl Lewis (a) has 
been reported to be expressed in a number of normal tissues as well.[ 34-37]  
Pivotal (GLP) tissue cross -reactivity studies of MVT -5873 with cryosections (or with fixed blood) 
of normal human tissues (GLP Study 20067038) and normal  cynomolgus monkey tissues (Study 
20074271) were conducted using 41 different tissue types from typically 3 donors/tissue. In 
addition, positive control (cryosections of human DMS 79 cells), negative control (cryosections of human Jurkat cells), and ancillary control (cryosections of  human colon which was previousl y 
shown to cross react with MVT -5873) tissues were used to ensure integrity of the staining. As a 
further control to ensure adequacy of the tissue sample, sections were immunostained for  
β
2-microglobulin, a relatively ubiquitous epitope. To ensure specificity of the MVT -5873 
antibody, all tissue sections were concurrently stained with a negative control human IgG1 kappa antibody. 
The optimal concentration of MVT -5873 was determined by finding the lowest concentration of 
test article tha t produced the maximum (plateau)  binding to the target antigen ( 2 µg/mL ). This 
concentration and a 5 -fold increase (10 µ g/mL ), which did not incur excessive nonspecific staining 
of control samples and/or test tissues , were used for the definitive tissue cross -reactivity studies . 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
22 
 MVT -5873 produced moderate to intense membrane, cytoplasm, and cytoplasmic granule staining 
of the positive control material (cryosections of human DMS 79 cells) at both staining 
concentrations. MVT -5873 did not specifically react with the negative control material 
(cryosections of human Jurkat cells) at either staining concentration.  The control article, HuIgG1, did not specifically react with either the positive or negative control materials or with the any of the tissue slides.  There also was no staining of the assay control slides.  MVT -5873 produced 
moderate to intense staining of membrane, membrane granules, cytoplasm, and cytoplasmic granules in frequent mucosal epithelial cells and weak to strong staining of occasional extracellular material with morphology and location expected for mucus in the ancillary control material (cryosections of human colon) at both staining concentrations.  There was no staining of any human colon tissue elements from the ancillary control material with either concentration of HuIgG1 or in the respective assay control slide.  The excellent specific reactions of MVT -5873with 
the positive control material and the lack of specific reactivity with the negative control material, as well as the lack of reactivity of the control article, indicated that the assay was sensitive, specific, and reproducible. 
The results of human tissue staining with MVT -5873 at 10 and 2 µg/mL and with the control 
article, HuIgG1, at 10 and 2 µg/mL are presented in GLP Study 20067038 and summarized below. 
Epithelium  
MVT -5873 variably stained membrane, membrane granules, cytoplasm, and/or cytoplasmic 
granules in epithelium in a variety of human tissues including bladder (transitional), breast, colon 
(mucosa), eye (conjunctiva), Fallopian tube (mucosa), gallbladder (mucosa), esophagus (squamous, submucosal glands), small intestine (mucosa), stomach (mucosa), kidney (tubular), liver (bile duct), lung (bronchial, bronchiolar), ovary (surface, follicle), pancreas (acinar, ductal), pituitary (adenohypophysis), prostate (glandular, ductal), rectum (mucosa), salivary gland (acinar, ductal), skin (sweat gland, hair follicle, epidermis), testis (seminiferous tubules), thymus, tonsil (squamous, surface, crypt), ureter (transitional), cervix (external ostium [squamous], internal ostium, endocervical glands), and uterus (endometrium, surface, glandular).  This staining was 
equivalent, reduced in intensity and/or frequency, or absent at the lower staining concentration.  Sialyl Lewis
 (a) background expression has been reported in a variety of tissues including 
pancreas, gallbladder, stomach, colon, bronchial tree, endometrium, salivary glands, kidney and prostate.  Based on the wide range of Sialyl Lewis (a) background expression, the observed staining of epithelium in the human tissues was judged expected.[ 34-37 ] 
Mononuclear cells 
MVT -5873 weakly to moderately stained cytoplasm and cytoplasmic granules in rare to occasional 
resident, migrating, and/or infiltrating mononuclear cells in lymph node at the higher staining 
concentration.  This staining was reduced in frequency to rare at the lower staining concentration.  No literature was available describing Sialyl L ewis (a) expression by mononuclear cells; thus, the 
observed staining of this cell type was judged unexpected. 
Extracellular material MVT -5873 variably stained extracellular material in a number of tissues including bladder, colon, 
eye, Fallopian tube, gall bladder, esophagus, small intestine, stomach, kidney, lung, ovary, 
pancreas, pituitary, placenta, prostate, rectum, salivary gland, testis, thymus, thyroid, tonsil, ureter, 
cervix, and uterus.  This staining was generally equivalent at both staining concentrations.  MVT -
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
23 
 5873 stained extracellular material generally had morphology and location consistent with that 
expected for mucus, serum components, colloid, lens protein, and/or serum components. Sialyl Lewis
a is reported to be secreted into the  serum in the form of high- molecular mucin -like 
glycoproteins; thus, the observed staining of extracellular material was judged expected.[ 12, 33]   
Mesothelium 
In one testis sample, MVT -5873 weakly to moderately stained the cytoplasm of occasional 
mesothelial cells at both staining concentrations.  No litera ture was available describing Sialyl 
Lewis (a) expression by mesothelium; thus, the observed staining of this cell type was judged 
unexpected. 
Summary Consistent with the literature for expression of sLe
a, MVT -5873 stained a variety of epithelial cell 
types and related extracellular mucus -like material in both human and cynomolgus monkey tissues, 
all consistent with epithelial cell secretions.  The structures stained included mucosal/secretory 
epithelium of the bladder, breast, eye (conjunctiva), Fallopian tube, gastrointestinal tract, kidney 
tubules, liver (bile duct), lung (bronchial, bronchiolar) ovary, pancreas (acinar ducts), pituitary 
(adenohypophysis), prostate (ducts), salivary gland (ducts), skin (sweat gland, hair follicle, epidermis), testis (seminiferous tubules), thymus, tonsils, ureter, cervix, and uterus. These epithelial cells were similarly stained in both human and cynomolgus monkey tissues, except for the ovary and testes , which were only stained in human tissue; however, extracellular mucus 
material in cynomolgus monkey testes did stain positive. 
Additional staining was seen intracellularly in lymph node of one human and one cynomolgus 
monkey donor tissue and in the mesothelium of one human teste.  Staining of these tissues is considered to be of little -to-no toxicologic relevance as the cytoplasmic compartment is generally 
thought to be inaccessible to monoclonal antibodies when administered intravenously to animals.  The lack of toxicological significance of the epithelial secretory cell s taining is supported by the 
lack of toxicology findings at doses up to 100 mg/kg/week in the GLP 4- week MVT -5873 
toxicology study in cynomolgus monkeys. 
1.2.5 Effects in Humans  
MVT -5873 is currently being evaluated in a P hase I/II study both as a single agent and in 
combination with gemcitabine/nab- paclitaxel . Trial MV -0715- CP-001.01 is a  Phase 1 Safety and 
Tolerability Study of Human Monoclonal Antibody 5B1 (MVT -5873) as Monotherapy and with 
Chemotherapy in Subjects with Pancreatic Cancer or Other CA  19-9 Positive Malignancies . The 
primary objective for this trail is to determine the safety and maximum tolerated dose of MVT -
5873 administered as monotherapy, determine safety and maximum tolerated dose of MVT -5873 
administered in combination with nab- paclitax el plus gemcitabine and to determine the 
pharmacokinetics of MVT -5873.  Secondary objectives are to e valuate tumor response rate ( based 
on RECIST 1.1) to MVT -5873 and evaluate the duration of response  This study is currently 
ongoing in the dose escalation phase for both the monotherapy arm and the combination 
chemotherapy arm  is being evaluated in an expansion cohort at an MVT -5873 dose of 0.125 
mg/kg.  
Trial MV -0715- CP-001.01 enrolled the first subject on 17- Feb 2016 and as of 15- Dec 2017 had 
accrued 32 subjects with pancreatic adenocarcinoma or other CA  19-9 positive malignancies  in 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
24 
 the single agent study as summarized below .   The population of this study consists of adults (males 
and females), 18 years of age and older who have locally advanced or metastatic pancreatic ductal 
adenocarcinoma or other CA 19-9 positive malignancies. 
Demographics/Baseline Characteristics  Single Agent Subjects  
Male : Female  16 : 16  
Median age, (range), years  65 (51 -87) 
ECOG PS 0 : 1, n (%)  7(22) : 25(78)  
Prior Therapy:  
 No. of systemic therapies  
    1 
    2 
    3 
    4+ 
Radiation  
Surgery  
  Primary tumor  
  Metastatic disease    
  
8 
5 
11 
8 
9 
17 16 
2 
Primary Disease Site (n)  
  Pancreas  
Colon/rectum 
Other (unknown primary)    
29 1 
2 
Stage at entry (n)  
  III 
  IV   
2 
30 
 
MVT -5873 was administered on an every -other- week schedule (Q2W) (Cohorts A1 and A2) and 
then modified to a weekly schedule (QW) based dose limiting toxicity at 3  mg/kg and on initial 
PK data. The QW dose escalation schema is shown below and further summarized in the 
subsequent table. 
 

Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
25 
  
Parameter Cohort Identifier  
A1 A2 A4 A5 A6 A7 
Number of subjects  6 3 4 3 6 4 
Dose (mg/kg)  1 3 1 2 3 2.5 
Schedule  Q2W  Q2W  QW QW QW QW 
Dose intensity (weekly mg/kg 
equivalent)  0.5 1.5 1 2 3 2.5 
1.2.5.1 Summary of Safety Information 
As of December 15, 2017, the single agent MTD for every other week (Q2W) and weekly (QW) 
schedules were defined as 1 mg/kg with dose limiting liver toxicity observed at 3 mg/kg for Q2W and 2 mg/kg for QW. The single agent weekly schedule has explored MVT -5873 doses ranging 
from 1 to 3.0 mg/kg (1.0, 2.0, 2.5 and 3.0 mg/kg). Based on the occurrence of dose limiting liver toxicity characterized by increased transaminases (AST/ALT) and blood bilirubin ( Grade 3 and 
single G rade 4), MVT -5873 doses ≥ 2.0 mg/kg were considered to have exceeded the maximum 
tolerated dose (MTD).   
The MTD for single agent MVT -5873 was  determined to be 1 mg/kg. However, based on clinical 
data single -agent MVT -5873 at a dose of 3  mg/kg appears to demonst rate dose limiting toxicity 
with increases in liver transaminases and blood bilirubin. When seen, these abnormalities occur red 
within a few days of drug administration, were self -limited and resolved spontaneously within 
eight days and resulted in no permanent liver abnormalities. Moreover, dosing >1.0 mg/kg appeared  to be a more effective dose in terms of RECIST responses than  
1.0 mg/kg, and subjects  on doses >1.0 mg/kg received more doses before PD was documented. A 
secondary aim of Trial MV -0715- CP-001.01 was to determine the mechanism(s) of this DLT, 
which may be related to Kupffer cell activation and not necessarily any direct injury related to the antibody. Non-human primate data support this hypothesis.  
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
26 
 Patient #1  
 
Patient #2  
 

Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
27 
 Patient #3  
 
Patient #4  
 
 
Patient #5  
 

Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
28 
 Patient #6  
 
Figure 7: Liver Function Test with 3mg/kg Weekly Dosing of MVT- 5873 from Six Subjects  
As a single agent, severe (Grade 3+) toxicities considered related to MVT -5873 have 
predominately included reversible liver function abnormalities (manifest as increased 
transaminases and blood bilirubin), and infusion reactions. Infusion reactions decreased in 
frequency and severity following initiation of a prophylactic regimen (slower infusion rate and IV 
steroids). Low -grade (Grades 1 and 2) treatment -related toxicities consist predominately of 
toxicities related to immune activation (chills, fever, malaise, pruritus, rash, and skin induration). No significant related hematologic toxic ity has been observed. 
To date, no significant EKG changes (e.g., increases in QTcF) have been observed. 
In summary, the predominate toxicity of MVT -5873 as a single agent and/or in combination with 
gemcitabine/nab -paclitaxel is dose limiting liver function test abnormalities. Increases in liver 
function tests are generally seen early (Day 3) and are reversible. Infusion reactions, when seen, 
generally appear during the infusion or shortly thereafter and appear less likely with slower infusion rates or with the use of steroid premedication. 

Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
29 
 A summary of the safety profile and adverse events are summarized below. 
Table 3: Dose Cohorts, C ycles A dministered and P atient Disposition 
 
Cohort 
 
 
  Baseline CA19 -9 (U/mL)  Patient Disposition 
< 2500 ≥ 2500  
On 
Study  Off Study  
n Median Cycles 
(range)  n Median Cycles 
(range)  Toxicity  PD Other  
A1 1 4 5 1.25 (1-3) 0 0 5 1 
A2 2 4.5 (4-5) 1 7.5 0 0 2 1 
A4 4 5.625 (1.5-13.5) 2 2 (1.25-2.75) 0 0 5 1 
A5 5 2 (1.5-6.25) 1 2 0 0 6 0 
A6 0 - 6 1.375 (1- 2) 0 0 6 0 
A7 4 4.375 (0.25-10.75) 1 1 1 1 3 0 
Total  16 4 (0.25-10.75) 16 1.375 (1-7.5) 1 1 27 3 
B3 2 0.875 (0.75 – 1.0) 1 1 0 0 1 2 
B0 3 2.0 (0.5-6.75) 1 3.5 2 0 1 1 
Total  5 1 (0.5-6.75) 2 2.25 (1-3.5) 2 0 2 3 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
30 
 Table 4: Summary of MVT-5873 D ose L imiting T oxicities and T reatment D isposition  
Cohort (n)  Individual Patient Events (Cycle 1)  Treatment Disposition  
 Day Toxicity  CTCAE  
Grade  Duration  
(days)  Adjustment  Total  
Cycles  
A1 (6) None 
A2 (3) 3 ↑ Bilirubin  3 12 ↓ dose  4 
3 ↑ ALT  3 2 ↓ dose  5 
A4 (6) None 
A5 (6) 8 ↑ Bilirubin  3 7 ↓ dose  1.5 
3 ↑ ALT,↑ AST  3, 3 3,3 ↓ dose  1.25* 
A6 (6) 5 ↑ ALT,↑ AST  3, 3 3, 3 ↓ dose (x2)  1.25 
3 ↑ AST  3 6 ↓ dose  1.5 
A7 (5) 3 ↑ ALT,↑ AST  3, 3 5,5 d/c 0.25# 
29 ↑ ALT,↑ AST  3, 3 2,2 ↓ dose  3.25* 
3 ↑ ALT,↑ AST  3, 4 3,5 ↓ dose  3* 
B3 (3) 8 ↑ ALT  3 7 delay  0.75 
3 ↑ Bilirubin  3 5 delay  1 
*Continued on treatment; #discontinued (d/c) after 1st dose, resolution to Grade 2 by Day 5 
 
The adverse event experience for MVT -5873 as a single agent is listed in the Appendix B and 
summarized  below in the accompanying Table 5 and Table 6. 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
31 
 Table 5 : All Adverse Events, All Grades, in ≥ 30% of Subjects  
Preferred Term  n (%)  Cohort At MTD Cohort Exceeds MTD  
A1 
(n = 6)  A4 
(n = 6)  A2 
(n = 3)  A5 
(n = 6)  A6 
(n = 6)  A7 
(n = 5)  
↑ AST  23 (72) - 2 - 5 5 11 
↑ ALT  18 (56) - 1 1 4 2 10 
↑ Alkaline phosphatase  22 (69) 4 4 - 2 4 8 
↑ Bilirubin  20 (63) 3 1 - 9 1 6 
Fatigue 19 (59) 4 4 1 1 5 4 
Nausea  13 (41) 3 1 2 5 - 2 
Hypoalbuminemia 12 (38) 1 2 - - 1 8 
Hyperglycemia 10 (31) 4 2 - 2 - 2 
Vomiting  10 (31) 4 1 3 1 1 - 
Back Pain  10 (31) 1 - 1 2 6 - 
Anemia  10 (31) 1 2 - - - 7 
Pneumonitis - - - - - - - 
Total*  (n = 32)  
 
  
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
32 
 Table 6 : All T reatment -Related A dverse E vents ≥ Grade 3  
Preferred Term  n (%)  Cohort At MTD Cohort Exceeds MTD  
A1 
(n = 6)  A4 
(n = 6)  A2 
(n = 3)  A5 
(n = 6)  A6 
(n = 6)  A7 
(n = 5)  
↑ ALT  9 (30) - - 1 2 1 5 
↑ AST  8 (27) - - - 2 2 4 
↑ Alkaline phosphatase  5 (17) - 1 - 1 - 3 
↑ Bilirubin  4 (13) 1 - - 3 - - 
Pneumonitis - - - - - - - 
↓ Lymphocyte count  2 (7) - - - 1 - 1 
↑ Lipase  1 (3) - - - 1 - - 
Hyperbilirubinemia 1 (3) - - 1 - - - 
Infusion reaction 1 (3) 1 - - - - - 
*Total adverse events recorded in all subjects across all cycles; #data as of 08/30/2017 
1.2.6 Pharmacokinetics  
MVT -5873 displays a half -life of 117.6 ± 33.4 h, clearance of 279.6 ± 313.0 mL/h, and volume of 
distribution at steady -state of 17.7 ± 21.0 L. These data demonstrate that MVT -5873 displays 
properties that are in the typical range for monoclonal antibodies. These initial PK values for the 
two different schedules of administration using a two- compartment model are summarized in the 
Table 7.  
Table 7 : MVT -5873 Human Pharmacokinetics  
Regimen  Subject  Initial t1/2 
(h) Terminal t1/2 
(h) AUC 0-∞ 
(ng•h/mL)  Vss (mL) Cl (ml/h)  
Q2W  Mean  20.8 193.0  2339353  17147  226.3  
SD 9.5 93.4 3256439  27582  290.1  
QW  Mean  37.3 833.1  2812486  14922  65.1 
SD 14.1 1164.4  3247729  12999  68.9 
1.2.7 Reductions in S erum CA19 -9 Levels  
In study MV -0715- CP-001.01, serum CA  19-9 levels are assessed both pre- and post -MVT -5873 
administration. Data on serum CA  19-9 levels indicate that serum CA  19-9 levels are uniformly 
reduced in all subjects regardless of dose. However, the probability of a CA  19-9 level within 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
33 
 normal limits (i.e., < 37 U/mL) post MVT -5873 appears to be related to dose. As shown in the 
table below , at a dose of 1 mg/kg, MVT -5873 appears to normalize an elevated CA  19-9 level in 
about 50% of subjects on Cycle 1 Day 1 and in about 20% of subjects across all administration 
days. In contrast, doses of 2 mg/kg or higher normalize CA 19- 9 levels in essentially all subjects.  
Table 8 : Normalization (< 37U/mL) of CA 19-9 L evels  Following A dminstration of MVT -5873 
Dose MVT -5873  
(mg/kg)  # Normal  
Post C1D1 *  Percent  # Normal  
Post All Days**  Percent  
1 3/6 50% 4/20 20% 
2 3/3 100%  10/10  100%  
3 1/1 100%  12/13  92% 
TOTAL  7/10 70%  26/43  60%  
*Number of subjects with CA  19-9 level > 37U/mL pre MVT -5873 that was reduced to < 37U/mL 
post MVT-5873 on Cycle 1 Day 1 only. 
**Number of subjects with CA  19-9 level > 37U/mL pre MVT -5873 that was reduced to < 
37U/mL post MVT-5873 for all administration days. 
1.2.8 Responses to Therapy  
Upon review of the single agent dosing cohorts, dosing >  1 mg/kg appears to be a more effective 
dose based on RECIST responses than 1 mg/kg. Moreover, subjects  on doses >  1 mg/kg remained 
on therapy longer  before PD was documented  indicating longer duration of response. Most 
importantly however the data clearly indicate efficacy for MVT -5873 when given as a single agent, 
and the subjects  that experienced the most efficacy were those with CA 19 -9 values less than 2,500 
U/ml ( Figure 8).  
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
34 
  
Figure 8: Efficacy for MVT-5873 
The preliminary response data for MVT -5873 in combination with a standard of care 
chemotherapy  are promising with 5 PR and 1 SD as best response. Figure 9 illustrates the percent 
change in target lesion for the first six subjects at a dose of 0.125 mg/kg (Cohort B3). 

Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
35 
 
 
Baseline CA19 -9  
▌ < 2500 U/mL  
▌ ≥ 2500 U/mL  
Figure 9: Percent C hange in T arget Lesions in Cohort B3 (0.125 mg/kg MVT-5873) 
1.2.9 Rationale 
In this study we are planning to give subjects  a pre-operative, one -time infusion  of 1 mg/kg of 
MVT -5873 at Day - 3 before surgery, perform the resection and continue treatment with MVT -
5873 at the  dose of 1 mg/kg.  We believe that peri -operative use of MVT -5873 adds “systemic” 
treatment during a time when none is given, despite the fact that the resection is associated with 
large increases in circulating tumors cells, and an inflammatory milieu believed to be, at least in part, responsible for the early recurrences observed in a substantial number of subjects . We believe 
peri-operative MVT -5873 will decrease early recurrence rates and increase DFS for subjects with 
CA 19 -9 producing cancers included in this study.  
To assess safety of the combination of treatment with MVT -5873 and surgery, we are planning to 
start with enrollment into safety lead -in cohorts and carefully monitor status of the subjects  during 
10 days after initial treatment and surgery.  We will continue enrollment into the study only if treatment in the safety lead -in cohorts are proven to be safe.  
If safety is documented with the safety -lead in cohorts at 1 mg/kg, we will dose escalate the 
single pre-operative dose of MVT-5873 to 3 mg/kg.   We want to explore this higher dose for pre-operative treatment because we consider the drug to be more effective at this dose, and we 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
36 
 believe the days following the operation are the most critical time to for the reasons outlined 
above. We do not believe there will be undo risk as subjects  will receive the 3  mg/kg dose once.  
1.2.10 Metastasis Assays Using Ex  Vivo  Perfusion of Omentum   
A major goal of Dr. Hernandez’s lab is to understand how tumor cells adapt to and co -opt the liver 
microenvironment for eventual metastatic outgrowth. With tumor cells labelled and observable throughout week- long time courses, many downstream applications will be possible, including 
(but not limited to) interrogation of the tumor cells at various time -points and at various stages of 
the metastatic cascade, with and without forced over -expression of various genes of interest. In 
order to accomplish this, cholangiocarcinoma and pancreatic cancer  tissue removed during 
pancreatic resections will be submitted to Dr. Hernandez’s laboratory. Tumor cells will be immediately dissociated into single cells using the Miltenyi Tumor Dissociator and labelled using 
fluorescent protein tags  (Cell tracking Dyes). Labelled single tumor cells will then be injected back 
into the perfusate to simulate the metasta tic process. The cells will be tracked using specialized 
camera/detector system in combination with our multi-photon microscope. 
1.2.11 Ex Vivo  Hepatic Perfusion Model  
This study is an important step toward our goal of implementing an ideal tumor model system. 
The ability to recapitulate the complexities of solid human tumors for the purposes of drug 
development and testing has been, and remains, a major obstacle in the progress of cancer care. Despite great efforts expended on pre -clinical optimization using existing validation models, most 
drugs simply fail to demonstrate efficacy when subjected to P hase III clinical trial scrutiny.  
Our interpretation is that the currently available model systems lack the appropriate clinical predictive power. The reasons for the inadequacies of these model systems, which are largely based upon cell lines, mouse models or patient -derived xenografts, a re myriad but are almost certainly 
related to the absence of the human stromal component and its intricate relationship with tumor cells. Indeed, modeling the multi -faceted interactions between human cancer cells and the 
multitude of various stromal components, including activated fibroblasts, immune cell infiltrate and the abnormal vasculature is, at present, an impossibility. The advent of a model system capable of accurately reproducing human tumors ex vivo  carries broad implications across many fields o f 
investigational medicine  and brings with it the potential to fundamentally alter the translational 
research landscape. Moreover, if it were possible to represent a given patient’s tumor in that model system, the benefits of personalized medicine could leap from generating lists of potentially useful drugs to designation of efficacious agents. 
We intend to satisfy all the requirements of an ideal tumor model system by utilizing resected 
segments of tumor -containing liver and repurposing the Liver -Assist pe rfusion device for 
prolonged ex vivo animation  via native blood vessel  perfusion. This is entirely novel  and has not 
been attempted elsewhere in the world. Moreover, the expertise required to accomplish this make it unlikely to be successful anywhere other  than the clinical center. This study expands our CRC 
patient population and importantly expands it to include subjects with intrahepatic cholangiocarcinoma. 
We will start the model with optimization of perfusion conditions for maintenance of both tumor 
and normal liver with serial evaluation to include the following:  
1) Ultrasonographic evaluation to document preservation of tumor echogenic properties.  
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
37 
 2) Co re needle biopsy to document histopathologic preservation of the microscopic 
architecture and cellular viability. Sufficient tissue will be obtained for any necessary 
staining.  
3) Transcriptomic profiling will be undertaken using snap- frozen biopsies. Sam ples from 
a given tumor will be run together to minimize variability. Standard HiSeq RNA platform 
with a read depth of 30- 40 million will be employed.  
4) Metabolomic profiling will be undertaken using snap- frozen biopsies. Samples from a 
given tumor will be run together to minimize variability . 
We’ve chosen strategically to use Genomic Expression’ s OneRNA platform in the present protocol  
(refer to  Section 5.2.2) . This technology is designated to quickly sequence 20K genes and provide 
lists of potentially usable drugs in addition to the sequencing data from tumor and normal liver. The platform will be of use to us as we move forward with our ex  vivo tumor model, a s we 
anticipate patterns will emerge among tumors such that likely drug combinations can be estimated for use in our ex vivo model. We will facilitate transfer of material from any pre -operative 
biopsies/tumor removal to genomic expressions for evaluation. This will allow us to utilize various 
agents predicted by OneRNA as efficacious. This  model system will enable us to evaluate drug 
delivery, cell based therapies, etc. given the unlimited use of repeat biopsies. The perfusate is also the ideal medium for biomarker discovery, which can be related to actual changes demonstrable in the tumor. Although we will not be able to use efficacious drugs in the model to treat subjects, we believe the information will be of immediate value in guiding subjects toward su bsequent trials 
should they recur. 
Finally, we will be able to conduct metastases assays using the ex vivo tumor containing liver as 
the target organ and the tumor dissociator as above ( see Section  1.2.10).  
1.2.12 Simulated Metastasis Assay with Relevant Tissue (SMART) Chamber  
Dr. Hernandez’s laboratory in the Surgical Oncology Program is also developing a novel tumor 
modeling system, referred to as the Simulated Metastasis Assay with Relevant Tissue (SMART) Chamber. C orrelative studies in proteogenomic characterization of primary and metastatic cancers  
and ex vivo  tumor tissue modeling of peritoneal metastasis  will be added to this study, utilizing the 
SMART Chamber.  In conjunction with ongoing laboratory work, segments of the peritoneum are 
removed from patients with peritoneal carcinomatosis at the time of operation. This peritoneal tissue is utilized in the SMART Chamber system to imitate conditions of metastasis within the abdominal cavity. This ex vivo  tissue model system allows for observation of peritoneal metastasis, 
real-time cellular imaging, and manipulation of tumor -environment interactions.  
1.2.13 The SMART System  
The SMART System  is an important s tep toward our goal of realizing personalized translational 
cancer care. The ability to recapitulate the complexities of solid human tumors for the purposes of drug development and testing has been, and remains, a major obstacle in the progress of cancer therapy. Despite great efforts expended on pre -clinical optimization using existing validation 
models, most drugs simply fail to demonstrate efficacy when subjected to P hase III clinical trial 
scrutiny. Our interpretation is that the currently available model systems lack the appropriate clinical predictive power. The reasons for the inadequacies of these model systems, which are 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
38 
 largely based upon cell lines, mouse models or patient -derived xenografts, are myriad but are 
almost certainly related to the abse nce of the human stromal component and its intricate 
relationship with tumor cells.  
There has been a sizable expansion of oncologic pharmaceuticals that have targeted and/or 
immunomodulatory effects. However, the predictive accuracy of drug testing is predicated on models that accurately represent the architectural/cellular organization of the tumor and faithfully reflect the in vivo  biology. We have satisfied many of the requirements of an ideal tumor model 
utilizing resected mesothelial metastases to cre ate the SMART ( Sample Microenvironment of 
Resected Metastatic Tumor) System. Multiple solid tumors commonly manifest with metastatic 
disease to the mesothelial surface (peritoneum, pleura, liver capsule) and some are candidates for metastasectomy. During these operations, resected tumor -bearing mesothelial tissue is affixed to 
a specialized platform and perfused in a sterile, oxygenated circuit at 37
0C to maintain normal 
physiologic parameters  (Figure 10). Circulating oxygenated perfusate within the system is 
comprised of human plasma (from the patient), DMEM media, antibiotics, insulin (slow i nfusion).  
 
Figure 10: The SMART System Consisting of SMART Platform 
The SMART platform (Top Left) is designed to mount the human mesothelial tissue containing 
tumor and be suspended in the reservoir of perfusate (Bottom Left), the SMART chamber. The 
chambers suspend maximum of 4 SMART platforms and placed on stir plate in the incubator 
(Middle). The SMART system boasts a physiologic oxygenated perfusion circuit that is suitable to 
keep tissue viable for up to four days. The Right Panel demonstrates the customized holder for each 
SMART platform that is imaged using complex imaging techniques.  
 
We have evaluated gastric adenocarcinoma, pancreatic adenocarcinoma, gastrointestinal stromal 
tumor, and breast adenocarcinoma in the SMART system and documented ex vivo viability at 4 
days with expected immune cell populations, intact architecture, and expected mitotic activity 
(Figure 11A). RNA sequencing was performed as well to compare transcriptomics between D ay 

Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
39 
 0 and D ay 4. Genes associated with hypoxia, oncogenes/tumor suppressor, cancer stem cells, 
metabolism, and epithelial- mesenchymal transition were isolated from the sequencing data and 
demonstrated conservation of transcriptomics ( Figure 11B). These results ultimately demonstrate 
that tumor nodules in their native, functional microenvironment can be preserved ex vivo  for 4 
days with fidelity.  
 
Figure 11: Ex Vivo Normal and Tumor Preservation in the SMART System  
A (Left): Demonstration of various histologies on H&E, CD3, CD68 and Ki67 stains on Day 0 and 
Day 4.  
B (Right): Conservation of transcriptomics in hypoxic panel, oncogene/tumor suppressor, cancer 
stem cell, metabolism and EMT panels over breast, gastric, pancreatic and mesothelioma histology. 
 
Due to the translucent nature of the mesothelial tissue, the system is readily amenable to dynamic 
interrogation with confocal, two photon and light sheet microscopy. This avenue of investigation is supported by a research collaborative agreement (RCA) with BioLegend and our affiliation with CAT -I to develop fluorescently labelled Fab fragment for live cell labelling. For example, with the 
increasing use of checkpo int inhibitors like Pembrolizumab in solid tumors,  we decided to evaluate 
the drug in the SMART system using tumor from a patient with gastric adenocarcinoma and a patient  with  colorectal  adenocarcinoma.  We demonstrated immune cell engagement with tumors 
cells for both gastric and colorectal adenocarcinoma, and captured tumor cell lysis with the latter 
(Figure 12). Such responses at the cellular level are key to understanding why some cells respond 
to the immune system while others are ostensibly resistant.  
As the only currently known platform that has an intact, immunocompotent tumor 
microenvironment, the SMART System allows for the analysis of a gents utilizing  real controls to 
increase current understandings of the tumor microenvironment . Analyses can be readily image d 
(taking video up to an hour) to obtain tangible visualiz ations of the tested agent effects (see 
Figure 12).  
 

Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
40 
  
Figure 12: SMART Platforms are Valuable Tools for Drug Evaluations Such as Pembrolizumab  
Left: SMART platforms with peritoneum from a patient with gastric cancer incubated with 
immune checkpoint inhibitor Pembrolizumab for 2 days followed by Alexa488CD44/ 
Alexa594CD45 antibodies. Maximum projections of 2-photon images illustrate the intimate contact 
between CD45 -positive cells and the cancer cells.  
Right: Timeseries montage taken from liver capsule tissue mounted on SMART platforms from a colorectal cancer patient with liver metastases incubated with 5 g/mL pembrolizumab for 4 hours. CD45 -positive cells bound to CD44- positive cancer cell undergoing apoptosis.  
 
  2 ELIGIBILITY ASSESSMENT AND ENROLLMENT 
 ELIGIBILITY CRITERIA  
2.1.1 Inclusion Criteria  
2.1.1.1 Subjects  must have histologically or cytologically confirmed diagnoses of 
adenocarcinoma in one of the following scenarios: 
o Primary tumors of the pancreas 
o Primary tumors of the bile duct and ampulla  
o Metastatic colorectal cancers to the liver  
2.1.1.2 Subjects  must have disease resectable with a standard pancreatectomy 
(pancreaticoduodenectomy or dista l pancreatectomy) or liver resection.  
2.1.1.3 Subjects  may have received prior therapy, including neoadjuvant regimens.  
2.1.1.4 Subjects  must have serum CA 1 9-9 elevations greater than  the upper l imit of normal but 
less than 2500 U/m L.  
2.1.1.5 Age ≥ 18 years. 
2.1.1.6 ECOG performance status ≤  1 (Appendix A ). 
2.1.1.7 Subjects  must have adequate organ and marrow function as defined below:  
o leukocytes    > 3,000/mcL 

Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
41 
 o absolute neutrophil count  > 1,500/mcL 
o platelets     > 90,000/mcL 
2.1.1.8 For subjects  with Periampullary cancers that require a pancreaticoduodenectomy for 
complete tumor extirpation: 
o total bilirubin    < 10 ULN* 
o AST(SGOT)/ALT(SGPT)  < 5 X institutional upper limit of normal 
o creatinine     < 1.5 X institutional upper limit of normal 
*Subjects  with periampullary cancers typically present with biliary obstruction 
resulting in s ignificant abnormalities in liver function tests that do not reflect liver 
dysfunction. These values normalize after tumor removal. They can be normalized pre -
operatively with biliary stenting but  several large studies have demonstrated an increase 
in infectious complications with drainage . As such, a practice standard has been to 
avoid stenting until bilirubin level rises above 10 X ULN.  
2.1.1.9 For subjects  with liver tumors (cholangiocarcinoma or metas tatic colorectal cancer) 
requiring a hepatectomy for complete tumor extirpation: 
o total bilirubin    < 2.5 X institutional upper limit of normal* 
o AST(SGOT)/ALT(SGPT)  < 5 X institutional upper limit of normal* 
o creatinine     < 1.5 X institutional upper limit of normal 
*Liver abnormalities in this range are consistent with parenchymal destruction from 
the tumor.  
2.1.1.10 For subjects  with pancreas tumors that require a distal pancreatectomy for extirpation:  
o total bilirubin    < 1.5 X institutional upper limit of normal*  
o AST(SGOT)/ALT(SGPT)  < 2 X institutional upper limit of normal*  
o creatinine     < 1.5 X institutional upper limit of normal 
*Liver abnormalities in this range are consistent with pancreas cancer destruction  from 
the tumor. 
2.1.1.11 The effects of MVT -5873 on the developing human fetus are unknown. For this reason,  
women of child-bearing potential and men must agree to use adequate contraception 
(hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and for 3 months after completion of study treatment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. 
2.1.1.12 Ability of subject to understand and the willingness to sign a written informed consent document. 
2.1.1.13 Subjects must agree to co -enroll ment  on the tissue collection protocol 13C0176, 
“Tumor, Normal Tissue and Specimens from Patients Undergoing Evaluation or Surgical Resection of Solid Tumors ”. 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
42 
 2.1.2 Exclusion Criteria  
2.1.2.1 Presence of disease outside the confines of a standard operation for subjects  with  peri-
ampullary cancers  (pancreatic and cholangiocarcinoma) . 
2.1.2.2 Presence of disease outside th e liver for subjects  with intr ahepatic/hilar  
cholangiocarcinoma or metastatic colorectal cancer, other than a primary tumor for 
subjects  with metastatic colorectal cancer . 
2.1.2.3 Subjects  who are receiving any other investigational agents. 
2.1.2.4 Fewer than 28 days (or 5 half-lives for systemic agents, whichever is shorter) from the last day of prior anticancer therapy, including chemotherapy, hormonal, investigational, and or biological therapies and irradiation. 
2.1.2.5 Uncontrolled inter- current illness including, but not limited to , ongoing or active 
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. 
2.1.2.6 Active concurrent malignancies within the last five years other than the primary tumor in subjects  with metastatic colorectal cancer, basal or squamous cell skin carcinoma or 
non- medullary thyroid carcinoma. 
2.1.2.7 Pregnant women are excluded from this study because of the potential for teratogenic or aborti facient effects of the MVT -5873. Because there is an unknown but potential risk 
for adverse events in nursing infants secondary to treatment of the mother, breastfeeding should be discontinued if the mother is treated. These potential risks may also apply to other agents used in this study. 
2.1.2.8 Subjects  with active , Hepatitis B or C infection because of the potential for increased 
liver toxicity given the damaging effects of the virus. 
2.1.2.9 Allergic to chimeric, humanized or human antibodies. 
2.1.2.10 Received live vaccine w ithin 4 weeks prior to the first da te of study intervention. 
2.1.2.11 Infection requiring hospitalization or herpes zoster treatment within 2 weeks prior to the first date of  study intervention. 
2.1.2.12 Long-term infectious diseases (tuberculosis, fungal infections) active within 2 years prior to the first  date of  study intervention. 
2.1.3 Recruitment Strategies  
This protocol may be abstracted into a plain language announcement posted on NIH websites and on NIH social media platforms . This study will also be lis ted on available websites ( e.g., 
www.clinicaltrials.gov ) and participants will be recruited from the current patient population at 
NIH. Participants may also be recruited through self -referrals  and physician referrals . Dr. 
Hernandez is a member of the clin ical trials committee of America’s HepatoPancreatoBiliary 
Association and will also solicit eligible subjects  through the organization.  
Advertisements approved under this protocol may be distributed in local media (electronic and print) with recruitment e fforts focused on, but not limited to,  NIH and the greater Washington DC 
area; s ome recruitment efforts may tak e place nationwide. 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
43 
 
 SCREENING EVALUATION  
2.2.1 Screening Activities Performed Prior to Obtaining Informed Consent  
Minimal risk activities that may be performed before the subject has signed a consent include the 
following:  
• Email, written, in person or telephone communications with prospective subjects.  
• Review of existing medical records to include H&P, laboratory studies, etc.   
• Review of existing MRI, x-ray, or CT images. 
• Review of existing photographs or videos. 
• Review of existing pathology specimens/reports from a specimen obtained for diagnostic purposes. 
A waiver of consent for these activities has been requested in Section 12.5.1. 
2.2.2 Screening Activities Performed After a Consent for Screening Has Been Signed  
The following activities will be performed only a fter the subject has signed  the study consent OR 
the consent  for study 01C0129 (provided the procedure is permitted on that study) on which  
screening  activities may also be performed . Assessments performed at outside facilities or on 
another NIH protocol within the timeframes below may also be used to determine eligibility once 
a patient has signed the consent. 
Studies should be done within 6 weeks  prior to being registered for treatment , unless otherwise 
noted below: 
• History and Physical Examination:  o Complete medical history and physical examination (including height, weight, vital 
signs, EKG and ECOG performance status). 
• Laboratory Evaluation: 
o CA 19 -9 levels  
o Hematological profile: CBC with differential and platelet count.  
o Biochemical profile: e lectrolytes, BUN, creatinine, AST, ALT, total bilirubin, alkaline 
phosphatase, calcium, phosphorus, albumin, magnesium, amylase.  
o Hep B and C 
o Serum or urine pregnancy test for female participants of childbearing age (in the 
absence of prior hysterectomy), performed within 7 days prior to treatment .  
• CT of chest, abdomen and pelvis . (Note : This scan does not need to be repeated at NIH if 
it has already been done at an external institute within 6 weeks  prior to treatment and the 
investigator determines that the scan is of sufficient detail for study diagnostics.) 
• Histologic confirmation by the Laboratory of Pathology, NIH (at any time point prior to enrollment). If there is no available tumor sample, biopsy will be performed to confirm the diagnosis. 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
44 
 • MRI (for subjects with liver disease) . (Note: This scan does not need to be repeated at NIH 
if it has already been done at an external institute within 6 weeks prior to treatment and the 
investigator determines that the scan is of sufficient detail for study diagnostics.) 
 PARTICIPANT REGISTRATION AND STATUS UPDATE PROCEDURES  
Registration and status updates (e.g., w hen a participant is taken off protocol therapy and when a 
participant is taken off -study) will take place per CCR SOP ADCR -2: CCR Participant 
Registration & Status Updates found here . 
2.3.1 Treatment Assignment and Randomization/Stratification Procedures  
2.3.1.1 Cohorts 
Number  Name  Description  
1 Cohort 1 Subjects with pancreatic cancer , cholangiocarcinoma or metastatic  
to the liver  colorectal cancer , having low elevated LFTs  (AST/ALT 
≤ 2 X ULN and/or bilirubin ≤ 1.5 X ULN) , enrolled into pre-
operative MVT -5873 escalation dose level s. 
2 Cohort 2 Subjects with pancreatic cancer, cholangiocarcinoma or metastatic 
to the liver colorectal cancer, having moderate elevated LFTs  (LFTs 
above what is required for C ohort 1 AND AST/ALT < 5  X ULN 
and/or bilirubin ≤  3 X ULN) , enrolled into pre- operative MVT -5873 
escalation dose levels.  
3 Cohort 3 Subjects with pancreatic cancer enrolled at the pre -operative 
recommended dose (RD) of MVT-5873. 
4 Cohort 4 Subjects with cholangiocarcinoma enrolled at the pre-operative recommended dose (RD) of MVT-5873. 
5 Cohort 5 Subjects with metastatic to the liver  colorectal cancer enrolled at the 
pre-operative recommended dose (RD) of MVT-5873. 
2.3.1.2 Arms  
Number  Name  Description  
1 Arm 1 Pre-operative e scalation dose s of MVT -5873, pancreatectomy or 
hepatectomy  and post- operative MVT -5873 treatment.   
2 Arm 2  Pre-operative RD of MVT -5873, pancreatectomy  or hepatectomy  
and post-operative MVT -5873 treatment. 
2.3.1.3 Arm Assignment 
Subjects  in Cohorts 1 and 2 will be directly assigned to Arm 1. 
Subjects  in Cohorts 3-5 will be directly assigned to Arm 2.  
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
45 
 
 BASELINE EVALUATION  
Tests listed below that were performed within the appropriate timeframe at screening need not be 
repeated.  
Within 3 weeks prior to study intervention unless otherwise indicated : 
• Compl ete physical examination (including weight, vital signs , EKG  and ECOG 
performance status) . 
• Laboratory Evaluation: 
o CA 19 -9 levels  
o Hematological profile: CBC with differential and platelet count.  
o Biochemical profile: electrolytes, BUN, creatinine, AST, ALT, total bilirubin,  alkaline 
phosphatase, calcium, phosphorus, albumin, magnesium, amylase.  
o PT/PTT/INR  
o Serum or urine pregnancy test for female participants of potential childbearing age (in 
the absence of prior hysterectomy), performed within 3 days prior to resection. 
• CT of chest, abdomen and pelvis  
• MRI (for subjects  with liver disease)  
• Concomitant medic ations 
• Baseline adverse events  
3 STUDY IMPLEMENTATION  
 STUDY DESIGN  
This is a trial designed to determine  if perioperative MVT -5873 is safe and effective for subjects  
with operable cancers of the pancreas and liver.  Eligible candidates will receive one dose of MVT -5873 ( 1 mg/kg (DL1) or 3 mg/kg ( DL2) 3 days 
prior to resection (Day -3) as part of the safety lead -in cohorts  (Cohorts 1 and 2) . See Table 9 
below for expected course.  
Once the pre -operative safe dose of MVT -5873 is identified,  additional subjects will be evaluated 
within the treatment cohorts (Cohorts 3- 5) at that MTD .  
Resection will be undertaken to remove  all demonstrable disease  in the liver, bile ducts and 
pancreas on Day 0. The operation may  be delayed for up to 4 days until any AST/ALT elevations 
are ≤ 10 X ULN, and Bilirubin is ≤  2 X the baseline value or < 3 X ULN. All s ubjects  will start 
post- operative infusions of MVT -5873 (1 mg/kg) in cycles consisting of 21 days.  During Cycle 
1, subjects  will receive 2 weekly infusions of MVT -5873 (on D ay 1 and D ay 8). During Cycle 2 , 
subjects  will receive an infusion of MVT -5873 every 2 weeks  (Day 1 and D ay 15) . Evaluations 
will be performed on C1D1, C1D8, C2D1 and C2D15 (+/ - 48 hours) as indicated in  Section  3.4. 
Cycle 1 Day 1 will be on any day between Day 4 and Day 10 after surgery, when AST/ALT 
elevations ≤ 10 X ULN  and decreasing for 2 consecutive days, and Bilirubin ≤  2 X ULN or 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
46 
 decreasing for 2 consecutive days. If LFTs do not decrease as described within 14 days after 
surgery, patient will be taken off treatment.  
Treatment with MVT -5873 will continue until off treatment criteria are met.  
Table 9: Safety Lead-I n Study Design  
Pre-operative Dose  Operation  Weekly dosing  Q2 W eekly dosing  
Day -3 Day 0 Cycle 1:  
Days 1 and 8 Cycle 2:  
Days 1 and 15  
DL1 MVT -5873  
1 mg/kg Pancreatectomy  
or Hepatectomy  1 mg/kg MVT -
5873* 1 mg/kg MVT-5873* 
DL2 MVT -5873 
3 mg/kg 
* Post-operative infusions of MVT -5873 will consist of 1 mg/kg in all  cycles . MVT -5873  dose 
variability is only with in the single pre-operative dose.   
3.1.1 Dose Limiting Toxicity  
The DLT period is 10 days after pre-operative MVT -5873 treatment.  
Any Grade ≥ 3 adverse event (AE), occurring during the DLT evaluation period, possibly or 
definitely attributed to MVT -5873 with the exception of: 
• Bilirubin < 6X ULN if resolved to < 3 or ≤  2X the baseline in 7 days after first MVT -5873 
treatment . 
• AST/ALT < 20X ULN if resolved to < 10X ULN in 7 days after first MVT -5873 treatment . 
Resection will be undertaken to remove all demonstrable  disease in the liver, pancreas or bile ducts 
on Day 0.  
Note:  The operation may be delayed until AST/ALT elevations are ≤  10X ULN, and Bilirubin is 
≤ 2X the baseline value or < 3X ULN. If the operation is delayed for more than 4 days due to 
failure of LFT to fall within the values outlined above, this will be considered DLT. 
3.1.2 Safety L ead-In Cohorts 
In order to minimize patient risk, we will initially ac crue six (6) subjects  sequentially in two safety 
lead-in cohorts based upon AST/ALT/Bili abnormalities and irrespective of tumor histology.   
For each safety lead -in cohort we will evaluate two dose levels, 1 mg/kg and 3 mg/kg as 
summarized in  Table 10 below.   
The safety lead -in continues unt il at least two subjects  among the  cohort of six subjects  experience 
dose- limiting toxicities (ie, ≥ 33% of subjects  with a dose- limiting toxicity at that dose level) .   
If none (0) or one (1) of the six  subjects  at 1 mg/kg experiences a dose- limiting toxicity, then 
escalation to 3 mg/kg may proceed within each safety lead-in cohort and 1 mg/kg is deemed safe. 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
47 
 If none (0) or one (1) of the six  subjects  experiences a dose- limiting toxicity at 3 mg/kg within 
each safety lead -in cohort,  then 3 mg/kg is deemed safe at the respective safety lead in cohort . 
Dose esclation maxi mum will be 3 mg/kg. 
Table 10: Safety Lead- In Cohorts  
LFT  Safety Lead -In 
Cohort 1 (Low elevated LFTs)  
N=6 Safety Lead -In 
Cohort 2* ( Moderate elevated  
LFTs)  
N=6 
AST/ALT  ≤ 2X ULN , and/or  < 5X ULN , and/or  
Bilirubin ≤ 1.5X ULN  ≤ 3X ULN  
*LFTs above what is required for Cohort 1 AND AST/ALT < 5X ULN and/or bilirubin ≤ 3X ULN .  
Note: LFT s determined at  screening  for cohort assignment .   
Every subject of each s afety lead -in cohort  will be observed for at least 10 days after first dose of 
MVT -5873 before the subsequent subject can be treated.  
Subjects who do not complete the DLT observation period for reasons other than a DLT will be 
replaced and will not be included in the response evaluation. 
Intra -patient dose de- escalation is not permitted for subjects enrolled in the safety lead -in cohort s. 
Subject s will receive assigned dose and in case of DLT will be taken off protocol. Every subject 
enrolled onto safety lead -in cohorts will be part of the DLT evaluation of its respective dose level . 
Subjects who experience DLT after pre -operative dose of MVT -5873 may have surgery when DLT 
is resolved and will be taken off MVT -5873 treatment after operation (see Section 3.5 for surgical 
guidelines and post- operative care) .  
 
Safety Lead-In Cohort 1 (Low E levated LFTs)  
Cohort 1 Dose Level 1 (1 mg/kg)  Six ( 6) subjects will be enrolled at Dose Level 1, treated with MVT -5873 ( 1 mg/kg on Day -3) 
and have surgery on Day 0.  
If two (2) subject s experience a DLT during DLT period at dose level DL1, no further attempts at 
completing the safety run- in of MVT -5873 in combination with surgery will be conducted, and 
the trial will be closed to accrual . 
If < 2 of 6 subject s experience DLT during DLT period, DL1 will be considered to be safe to use 
in subjects  with low elevated LFTs and enrollment into Cohort 2 will begin at DL1.  Concurrently, 
enrollment into Cohort 1 Dose Level 2 will begin.  
 
Cohort 1 Dose Level 2 (3 mg/kg) 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
48 
 Six ( 6) subjects will be enrolled at Dose Level 2, treated with MVT -5873 ( 3 mg/kg on D ay -3) 
and have surgery on Day 0.  
If two ( 2) subjects experience a DLT during DLT period at dose level DL2, no further attempts at 
completing the safety run- in at DL 2 will be conducted at trial will continue with DL1 only . 
If < 2 of 6 subjects experience DLT during DLT period, DL 2 will be considered to be safe to use 
in subjects  with low elevated LFTs.   
 
Safety Lead-In Cohort 2 (Moderate elevated LFTs)  
Cohort 2 Dose Level 1 (1 mg/kg) If DL 1 is proved to be safe in Cohort 1 Dose Level 1 , 6 subjects will be enrolled in Cohort 2  Dose 
Level 1. Subjects  will be treated with MVT -5873 ( 1 mg/kg on Day -3) and have surgery on Day 
0.  If two ( 2) subjects  experience a DLT during DLT period at dose level DL1, no further attempts at 
completing the safety run -in of MVT -5873 in combination with surgery in subjects  with moderate 
elevated LFTs will be conducted . 
If < 2 of 6 subjects experience DLT during DLT period, DL1 will be considered to be safe to use 
in subjects  with moderate elevated LFTs.  
If DL1 is  safe to use in subjects  with moderate elevated LFTs , 6 subjects will be enrolled at Dose 
Level 2 in Cohort 2.   Cohort 2 Dose Level 2 (3 mg/kg) Six (6) s ubject s will be treated with MVT -5873 ( 3 mg/kg on Day -3) and have surgery on Day 0.  
If two ( 2) subjects  experience a DLT during DLT period at dose level DL2, no further attempts at 
completing the safety run- in at DL 2 will be conducted at trial will continue with DL1 only . 
If < 2 out of 6 experience DLT during DLT period, DL 2 will be considered to be safe to  use in 
subjects  with moderate elevated LFTs.  
3.1.3 Treatment Cohorts  
3.1.3.1 Treatment Cohorts at P re-Operative MTD  
Once the pre- operative safe dose of MVT -5873 and allowed elevated level of LF Ts is estimated, 
additional subjects will be evaluated at that MTD  (see Table 11) within Cohorts 3-5.   
Treatment s ubjects will be accrued with the following histologies:  
o Metastatic Colorectal Cancer (n=24)  
o Cholangiocarcinoma (n= 24) 
o Pancreatic Cancer (n=23)  
Note:  Subjects treated during the safety lead -in (Cohorts 1 and 2)  will complete the study as 
indicated in Sections 3.1.2 and  3.5. 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
49 
 Table 11 : Treatment Study Design  
Pre-operative Dose  Operation  Weekly dosing  Q2 Weekly dosing  
Day -3 Day 0 Cycle 1:  
Days 1 and 8 Cycle 2:  
Days 1 and 15  
MVT -5873 at MTD  Pancreatectomy  
or Hepatectomy  1 mg/kg MVT -
5873* 1 mg/kg MVT-5873* 
3.1.3.2 Treatment Cohorts at T wo D ifferent P re-Operative MTDs by LFT Elevation are 
Determined from Safety Lead -In 
If  two different pre -operative safe doses of MVT -5873 are determined from  the safety lead -in 
due to the difference of LFT elevation , subjects within the treatment cohorts  will each be treated 
by their elevated level of LFT s as identified  at screening  (refer to Table 12 and   
Table 13).  
Table 12 : Treatment Guidelines (If Two Different Pre- Operative MTDs by LFT Elevation are 
Determined from Safety Lead -In) 
Treatment  
Cohorts  Low elevated LFTs  
(AST/ALT ≤ 2X ULN and/or 
bilirubin ≤ 1.5X ULN)  Moderate elevated LFTs  
(LFTs above what is required for 
Cohort 1 AND AST/ALT < 5X ULN 
and/or bilirubin ≤ 3X ULN)  
Cohort s 3-5 
 MVT -5873  at  
Low elevated LFT s MTD  MVT -5873  at  
Moderate elevated LFT s MTD  
Note: LFTs determined at screening . 
* Baseline LFTs for a subject may be used if the subject’s screening and baseline LFTs are different 
and the change is determined by the PI to be clinically indicated. 
 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
50 
 Table 13:Treatment Study Design  (If Two Different Pre -Operative MTDs by LFT Elevation are 
Determined from Safety Lead -In) 
Pre-operative Dose  Operation  Weekly dosing  Q2 Weekly dosing  
Day -3 Day 0 Cycle 1:  
Days 1 and 8 Cycle 2:  
Days 1 and 15  
Low 
elevated LFTs MVT -5873  at  
Low elevated 
LFTs MTD  Pancreatectomy  
or Hepatectomy  1 mg/kg MVT -
5873* 1 mg/kg MVT-5873* 
Moderate elevated LFTs MVT -5873  at  
Moderate elevated LFT s 
MTD  
* Post-operative infusions of MVT -5873 will consist of 1 mg/kg in all cycles . MVT -5873 dose 
variability is only within the single pre -operative dose.   
 STUDY DRUG ADMINISTRATION  
3.2.1 Preparation and Administration of MVT -5873 
MVT -5873 is provided as a single -use vial containing 3.0 mL of sterile solution at 10 mg/mL in a 
buffer at pH 6.0, containing 25 mM histidine, 150 mM sucrose, 55 mM sodium chloride, and 0.02% polysorbate 80.  
Prior to infusion, MV T-5873 is diluted in normal saline to obtain a final concentration of less than 
5 mg/mL. The administration apparatus must include a 0.2- micron inline filter.  
3.2.2 Stability of MVT -5873 Following Preparation 
MVT -5873 should be administered within 24 hours of pr eparation.  
3.2.3 Upper Limit to Administered Dose in Obese Subjects  
In subjects who weigh more than 100 kg (220 pounds), the administered dose should be calculated based on a theoretical weight of 100 kg. 
3.2.4 Infusion Rate of MVT -5873 
The first dose of MVT -5873 for each subject will be administered as an intravenous infusion over 
at least 120 minutes. In subjects who tolerate an initial infusion without difficulty, subsequent 
infusions may be reduced by 30 minutes to a minimum infusion duration of 60 minutes (i.e., a  120-
minute infusion during the first infusion, a 90 -minute infusion during the second infusion, a 60-
minute infusion during the third and subsequent infusions). The duration of infusion for MVT -
5873 should never be less than 60 minutes. 
Vital signs will b e taken pre -and post- MVT -5873 administration. 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
51 
 3.2.5 Treatment Guidelines for MVT -5873- Related Infusion Reaction  
Please refer to table, Treatment Guidelines for MVT -5873- Related Infusion Reaction, for 
guidance on managing infusion related reactions during MVT-5873 administration.  
Treatment Guidelines for MVT -5873- Related Infusion Reaction  
Grade  
(CTCAEv4)  Definition  Treatment Guideline  
1 Mild transient reaction; infusion 
interruption not indicated; intervention not indicated Monitor for at least 2 hours (120 minutes) after end of infusion; provide patient instructions and prophylactic medications at discharge as appropriate 
2 Therapy or infusion interruption indicated but responds promptly to symptomatic treatment Infusion may be restarted once following a minimal 60 -minute delay. A second 
infusion interruption requires discontinuation of MVT-5873 administration.  
Administration of medications (e.g., anti-histamines, steroids, NSAIDS and IV fluids etc.) as appropriate; monitor in clinic for at least 2 hours (120 minutes) after completion of infusion; provide prophylactic medications as appropriate for subsequent MVT-5873 doses 
3 Prolonged (e.g., not rapidly responsive to symptomatic medication and/or brief interruption of infusion); recurrence of symptoms following initial improvement, hospitalization indicated for clinical sequelae  Administration of medications (e.g., anti-histamines, steroids, NSAIDS and IV fluids etc.) as appropriate; hospitalization for medical care and observation; Discontinue MVT- 5873 permanently  
4 Life-threatening consequences; 
urgent intervention indicated Hospitalization for urgent medical treatment; Discontinue MVT -5873 
permanently  
3.2.6 Premedicatio n 
Subjects should receive their initial dose of MVT -5873 in the absence of premedication. In subjects 
who experience infusion reactions that are manageable and allow for additional administration of MVT -5873, premedication may be administered for subsequent doses consistent with institutional 
guidelines. 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
52 
 Starting in February 2017 (as documented in the MabVax 0715 Clinical S tudy Note to File dated 
13-Feb 2017), the Safety Committee allowed for the use of prophylactic medications for the 
control of infusion reactions. The recommended dose was 12 – 20 mg of decadron IV at least 30 
minutes prior and 4 mg BID PO of decadron for two days following each MVT -5873 
administration. The investigator was free to manage the taper of decadron in those subjects who 
did not demonstrate infusion reactions. 
 DOSE MODIFICATIONS  
Adverse Events: All adverse events in this trial will be graded using the NCI Common  
Terminology Criteria for Adverse Events (CTCAE) version 5.0 - a complete listing is available at 
the CTEP website: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm .  
Dose adjustments for pre -operative MVT -5873 are explained in Section 3.1.2. 
Summary of dose holding/interruptions for MVT -5873 in case of MVT -5873- related adverse 
events (graded according to NCI- CTCAE v 5.0). 
 
General Adverse Events  Action  
Non-hematological, Grade 1 or 2  Continue MVT -5873 therapy at full dose prescribed. 
Apply maximum supportive care recommendations.  
If prolonged duration of Grade 2 adverse event (≥  7 
days) is affecting quality of life, consider 
discontinuation of the drug. 
Non-hematological, Grade 3 or 4 
(excluding cardiac and hepatobiliary events)  Apply maximum supportive care  recommendations. 
Hold MVT -5873 therapy until recovery to Grade ≤ 1 
(up to 14 days).  
For Grade 3 or 4 interstitial pneumonitis or Grade 3 or 
4 rash manifested as toxic epidermal necrolysis (e.g. Stevens -Johnson Syndrome etc.) MVT -5873 must be 
discontinued. 
If recurrence of adverse even t after drug hold/ 
interruptions is observed, and maximum supportive 
care measures applied, hold drug once again until 
recovery to Grade ≤  1 (up to 14 days).  If no recovery, 
consider discontinuation of the drug. 
Non-hematological, Grade 3 or 4 
adverse ev ents NOT resolved to 
Grade ≤ 1 within a maximum of 2 
weeks from last planned 
administration  Action (discontinue or resume MVT -5873 therapy) in 
individual cases after discussions with the Sponsor. 
 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
53 
 General Adverse Events  Action  
Cardiac Adverse Events   
Cardiac (Severity corresponding to 
NYHA criteria)  MVT -5873 therapy to be discontinued permanently in 
case of symptomatic NYHA  class III and IV CHF. 
MVT -5873 therapy to be held, continued, or resumed 
accordingly for subjects  with NYHA class I or II CHF.  
Hepatobiliary Adverse Events  
Grade 1 -2 bilirubin or Grade 1- 2 
AST/ALT  Continue MVT -5873 therapy at full dose prescribed. 
Apply maximum supportive care recommendations. 
Grade 3 bilirubin or Grade 3 
AST/ALT  Apply maximum supportive care recommendations. 
Hold MVT -5873 therapy until recovery to Grade < 1 
If not resolved for 14 days, discontinue treatment.  
Grade 2 bilirubin and Grade 3 
AST/ALT  
Grade 4 events  *Discontinue MVT-5873 
*Unless Surgery -related cause  
Note:  In case of multiple short interruptions of dose due to either adverse events or drug 
supply or other reasons the sum of days without MVT -5873 treatment should not exce ed 28 
days between two treatments or in any 90-day treatment period.  
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
54 
 
 STUDY CALENDAR  
 Screening1   
Baseline1  D-3  D0
1 Cycle 1  Cycle  2 
EOT2 Safety 
FU3 Long Term 
FU
4 D15 D8 D1 D15 
MVT -5873    X  X X X X    
Surgery    X        
Informed Consent  X           
Medical H istory  X           
Concomitant Medication s  X X  X X X X X X  
Adverse E vent Evaluation   X X  X X X X X X  
Physical Exam X X X X X X X X X X  
Vital S igns X X X X X X X X X X  
Height  X           
EKG  X X          
Weight  X X X X X X X X X X  
Performance Status  X X X X X X X X X X  
CBC w/ Differential, Platelets  X X X X X X X X X X  
PT, INR, PTT   X X X X X X X X X  
Serum C hemistry6  X X X X X X X X X X  
CA 19 -97 X X X7 X X7 X7 X7 X7 X X X 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
55 
  Screening1   
Baseline1  D-3  D0
1 Cycle 1  Cycle  2 
EOT2 Safety 
FU3 Long Term 
FU
4 D15 D8 D1 D15 
Hepatitis B and C Serology and/or 
Viral Load  X           
Radiologic Evaluation8  X X   X X X X X   
Serum or U rine Pregnancy T est X X          
Confirmation of dx by NCI LP  X           
Tissue Collection for R esearch     X        
Research Blood  Collection (see 
Section 5.1)    X X X    X   
Annual Telephone or Other NIH 
Approved Remote Platforms 
Contact            X 
 
 
 
  
 
  
 
  
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
56 
  
 
1 Day 0 operation may be delayed for 4 days until AST/ALT elevations are ≤ 10X ULN, and Bilirubin is ≤ 2X the baseline value or < 3X ULN.  
2 Day 7 (+/- 7 days) after treatment discontinuation. If patient is taken off treatment on the day of regular visit to Clinical Center, th is day will be 
EOT visit.  
3 Safety Follow Up visits/labs will occur if patient is agreeable to coming back and physically able to return for the visit. This visit should occur 
around Day 28 post the last dose of study drug. If toxicities cause discontinuation of therapy, subjects will be followed until resolution of toxicity 
to at least Grade 1. If the patient cannot return to the Clinical Center for this visit, a request will be made to collect required clinical labs from a 
local physician or laboratory (as these are routine, standardized laboratory tests, interlaboratory variability is not a concern). If this is not possible, 
subjects may be assessed by telephone or  other NIH approved remote platforms for symptoms. 
4 Follow-up will be telephone  or other NIH approved remote platforms contact of patient or medical oncologist every 4 months (+/- 2 weeks) to 
assess disease and survival status.  Medical records from visits done with the home physician may be securely sent to the study team per CC policy 
and procedures. 
5 Cycle 1 Day 1 will be on any day between Day 4 and Day 10 after surgery, when AST/ALT elevations ≤ 10 X ULN and decreasing for 2 
consecutive days, and Bilirubin ≤ 2 X ULN OR decreasing for 2 consecutive days.  
6 Electrolytes, BUN, creatinine, AST, ALT, total bilirubin, alkaline phosphatase, calcium, phosphorus, albumin, magnesium, amylase. 
7 Serum CA19 -9 collection pre -dose and 2 hours post dose (+30 minutes) as noted in treatment cycles. 
8 Evaluations will be performed on C1D1, C1D8, C2D1 and C2D15 (+/- 48 hours)  and EOT. CT scan of chest, abdomen and pelvis in all 
subjects. MRI with contrast for subjects with liver disease. Note: Exceptions for the use of contrast during this MRI may be made using the best clinical judgement of the investigator.  
  
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
57 
 
 SURGICAL GUIDELINES  
Pancreas tumors will be extirpated according to standard practice. Resections involving the 
pancreas may require either a pancreaticoduodenectomy or distal pancreatectomy, with or without splenectomy. Liver operations will be undertaken according to practice norms.  
3.5.1 Preoperative Patient Management  
Subjects  will receive standard preoperative care as appropriate to the planned surgical intervention 
and the patient’s underlying health status. This will include: 
• Clear liquid -diet the evening prior to operation, without additional bowel preparation. 
• Hibiclens shower the night before operation. 
• CA 19-9 levels will be drawn the morning of the procedure. 
• 20 mL of peripheral blood will be drawn prior to induction of anesthesia for circulating 
tumor cell acq uisition and analysis (see Section 5.2.6).  
• Preoperative IV antibio tics administered in pre -op holding. 
• Subcutaneous heparin administration for venous thromboembolism prophylaxis just prior 
to operation start. 
• Sequential compression devices will be placed on the lower extremities prior to induction 
of general anesthesia. 
3.5.2 Patient Management in the Operating Room 
3.5.2.1 At Operation: 
• Subjects  will undergo a  midline line or sub- costal incision . A thorough examination of the 
abdomen will ensue to rule -out occult metastatic disease on the peritoneal surfaces, or 
unrecognized suspicious lymphadenopathy. The operation will then be carried out accor ding to standard practice.  
• Prior to tumor extirpation, a 24-gage needle will be used to draw 20 mL of blood from the portal vein OR suprahepatic vena cava.   
• Normal liver core biopsies and excisional biopsies will take place for exploratory endpoints 
but will not exceed 100 grams.  
 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
58 
   
Figure 13: Operating Room Workflow  
3.5.3 Postoperative Care  
3.5.3.1 Patient Monitoring  
• The subjects  will be monitored in the ICU or on the surgical ward per routine. 
• On the ward, vital signs (blood pressure, temperature, pulse, respirations) will be taken per 
routine (every 2-6 hours and as clinically indicated).  
• Subjects  will receive routine post- operative care; early ambulation will be encouraged. 
Note: Other standa rd of care may be performed as deemed clinically necessary by the PI.  
• Laboratory evaluations will include:  
o CBC, platelets, acute care, mineral and hepatic panel on  post- operative Days  
1 through 7, and then as clinically indicated until discharge.  
o Subjects  will be transfused as appropriate to maintain a hemoglobin greater than or 
equal to 8 g/dl. 
3.5.4 Discharge  
• Total hospitalization may be approximately 7-14 days.  
Subjects  who are discharged within this time frame should be able to tolerate an oral diet  
with or without dietary supplements. 
 PATHOLOGICAL EVALUATION  
The histopathologic evaluation, in addition to standard practice of lymph nodes, margin status, etc, 
will involve an evaluation by a third party laboratory for anti body/tumor cell binding ( Figure 14 
top image) and a detailed eval uation of the liver parenchyma under the supervision of Dr. David 
Kleiner ( Figu re 14 bottom image). The liver parenchyma evaluation will include standard 
immunohistochemical agents as well as any special evaluative measures as deemed necessary by Dr. Kleiner.  

Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
59 
    
Figure  14: Pathologic Evaluation of T umor and L iver T issue R emoved at the T ime of Surgery  
 
 CRITERIA FOR REMOVAL FROM PROTOCOL THERAPY AND OFF STUDY CRITERIA  
Prior to removal from study, effort must be made to have all subjects complete a safety visit 
approximately 28 days following the last dose of study therapy. 
3.7.1 Criteria for Removal from Protocol T herapy  
• Excessive toxicity  (see Section s 3.1.1 and  3.3). 
• Completion of 2 cycles of post- operative MVT -5873 treat ment . 
• Recurrent  disease . 
• CA 19 -9 level > 2 X the lowest recorded post- operative dose AND > ULN . 
• Participant requests to be withdrawn from active therapy. 
• Investigator discretion . 
• Positive pregnancy test. 
• Start of standard adjuvant chemotherapy (per medical oncologist decision) . Note:  
Patients need to be removed from therapy so that MVT -5873 will not be given within 
2 weeks of the planned start date for adjuvant chemotherapy. 
• Elapse of > 84 days from the start of Day 1, Cycle 1. 

Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
60 
 3.7.2 Off-Study Criter ia 
• Participant requests to be withdrawn from study. 
• Death . 
• Investigator discretion . 
• Loss of follow up. 
• PI decision to end the study. 
• Screen failure. 
4 CONCOMITANT MEDICATIONS/MEASURES  
During the post -operative period, subjects  will receive all standard of care supportive measures, 
including possible nasogastric tube drainage and bowel rest for ileus, pulmonary toilet teaching 
and incentive spirometry to prevent atelectasis, transfusions, and antibiotics as indicated. During receipt of study drug, standard adjunctive medications inclusive of anti -emetic, anti -nausea and 
bowel function therapy will be employed.  
5 BIOSPECIMEN COLLECTION  
 SPECIMEN COLLECTION TABLE  
Test/Assay  Volum e 
Blood 
(approx.) Type of Tube  Collection Points  
(+/-48hrs)  Location of 
Specimen Processing/  
Storage Location of Specimen Analysis 
Circulating Tumor Cell Analysis  20 mL CellSave Preservation Tubes D-3, D0 & C1D1  
(Delivered by 
study team to) 
Trepel Lab  Trepel Lab  
Monocyte Phagocyte System (MPS) Profiling  17 mL SST D-3 & D0  
Hernandez Lab 
for storage 
until shipment Zamboni Lab at         
UNC Chapel Hill  
 
Biomarker Studies  10 mL EDTA (Lavender)  D-3, D0, C1D1 & EOT  Hernandez Lab  
(Blood Processing 
Core (BPC) as 
necessary , see 
Section 5.2.1) Hernandez Lab  
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
61 
 Metastasis 
Assays Using Ex Vivo Perfusion of Omentum Omentum N/A D0 (at time of surgery)  (Immediately  
to)  
Hernandez Lab  Hernandez Lab  
Ex Vivo 
Hepatic 
Perfusion Models Tumor tissue  N/A D0 (at time of surgery)  (Immediately , 
when  
necessary)  
Hernandez Lab  Hernandez Lab  
Proteogenomic Analysis  Tumor 
tissue  
with mesothelial metastases  
 N/A D0 (at time of surgery)  Hernandez Lab  
(Blood Processing 
Core (BPC) as 
necessary, see 
Section  5.2.1) Hernandez Lab  
 
Drug Penetration Analysis Tumor tissue  N/A D0 (at time of surgery)  Hernandez Lab  
(Blood Processing 
Core (BPC) as 
necessary, see 
Section 5.2.1) Hernandez Lab  
RNA Analysis 10 mL EDTA (Lavender)  D0 Hernandez Lab for storage until shipment (by study team)  Genomic Expression 
RNA- Seq Tumor tissue  
(and 
normal tissue, as available)  N/A D0 (at time of surgery)  Hernandez Lab for storage until shipment (by study team)  Genomic Expression 
 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
62 
 
 CORRELATIVE STUDIES FOR RESEARCH /PHARMACOKINETIC STUDIES  
5.2.1 Tumor and Tissue Collection  
Tumor and normal tissue  samples will be collected at the time of surgery. Tissue will only be taken 
for research purposes after it is removed as part of the standard operation, as viable tissue that will 
otherwise be removed as part of the operation, or as core needle biopsies of normal liver for 
subjects  undergoing pancreatectomies. The total amount of normal liver tissue removed for 
research purposes will not exceed 100 grams. 
Some of the s ample s will be immediately used in the Dr. Hernandez ’s lab (see Section  5.3.4  
below), and the rest will be sen t for barcoding and initial storage  to Blood Processing Core (BPC)  
as necessary  per PI instruction. 
RNA-S eq data will be analyzed for correlation with recurrence patterns. The analysis will utilize 
logistic regression and corrections for false discovery (5%). The analysis will be undertaken in 
conjunction with the Branc h’s bioinformatics specialist.  
5.2.2 RNA Evaluation 
Tumor and normal  tissue  samples  (coded -linked) will be sent to Genomic Expression for RNA  
analysis  under MTA  (Section  11.1):  
Gitte  Pedersen,  CEO  
Genomic Expression, Inc.  
100 Cummings Center,  Suite  451C 
Beverly,  MA 01915 
Phone: 203-812-0690 Email: glp@genomicexpression.com
  
 
Samples  sent to Genomic Expressions for RNA analysis  will be coded  before  shipment. 
Genomic Expression has reengineered quantitative RNA sequencing for clinical applications, with the goal of enabling oncologists to routinely use tumor gene expression profiles to help select the best treatment options for their subjects . OneRNA, the propr ietary platform from Genomic 
Expression, uses a novel approach to prepare sequencing libraries from tumor messenger RNA. The OneRNA library preparation technology, generates a library of nucleic acid tags from the 3’ ends of mRNA molecules. These tag libraries can be “read out,” meaning sequenced and counted, on next generation sequencers. This method reduces the number of reads to detect weakly expressed genes by 5- to 10-fold and simplifies the generation of a global expression profile from the sequencing data. OneRNA proprietary sample prep is integrated with proprietary analytics. 
After correcting for PCR duplicates, the sequenced tags are mapped to the human genome and/or transcriptome and compiled into gene expression profiles. Tumor expression profile s are 
normalized alongside normal tissue expression profiles to put them on a common scale. Using outlier detection methods, over and under expressed genes are identified by comparing the expression level of each gene in the tumor to the distribution of expression levels for that same gene in normal tissue(s). 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
63 
 5.2.3 Metastasis Assays Using Ex  Vivo  Perfusion of Omentum  
For instances in which a standard Whipple procedure is done, omentum obtained  from the 
operating room ( as part of the standard Whipple procedure) w ill be immediately transported to Dr. 
Hernandez’s lab. The gastroepiploic arterial arcade will be cannulated and the omentum kept 
viable using Dr. Hernandez’ s Liver Assist Device ( Figure 4 bottom).  
5.2.4 Ex Vivo  Hepatic Perfusion Model  
Resected tumor -bearing liver and pancreas  will be perfused through native blood vessels in order 
to develop ex vivo models for pancreatic cancer, cholangiocarcinoma, and metastatic colorectal 
cancer  as indicated in Section 1.2.11.  
 
 
Figure 15: Scientific Endpoints. Evaluation of C irculating Tumor Cells (top) and Ex  Vivo Tissue 
Modeling (bottom)  
5.2.5 Circulating Tumor Cell Evaluation 
Blood will be collected for circulating tumor cell (CTC) assays  to be performed in the Dr. Trepel 
Laboratory ( Developmental Therapeutics Branch , CCR). 
Peripheral blood will be  drawn  from a peripheral vein and the portal or supra -hepatic IVC (intra -
op) for enumeration and characterization of CTCs. CTCs will be assessed using ferrofluidic 
enrichment and multiparameter flow cytometric detection. CTCs will be identified as viable, nucleated cells, that positively express one or more epithelial or tumor markers and are negative for expression of hematopoietic markers. The number of CTCs in peripheral blood will be counted.   
In addition to quantification, we will evaluate CTCs for C A 19- 9 expression using flow cytometry.  

Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
64 
 5.2.6 Monocyte Phagocyte System (MPS) Profiling  
Blood will be collected for monocyte phagocyte system (MPS) profiling, to be performed in the 
Zamboni Laboratory – U niversity of N orth Carolina at Chapel Hill. MPS  profiling will be used  to 
evaluate the impact of MVT -5873 therapy on circulating tumor cells. 
Coded linked samples will be sent to Dr. Zambroni at the Zamboni La boratory under MTA ( see 
Section 11.1):  
Zamboni Laboratory – UNC at Chapel Hill 
Attn: Andrew Lucas 120 Mason Farm Road 1022A Genetic Medicine Building, CB#7361 Chapel Hill, NC  27599 Lab Phone: (919) 966-1622 
 SAMPLE STORAGE , TRACKING AND DISPOSITION  
Samples will be ordered in CRIS and tracked through a Clinical Trial Data Management system.  
Should a CRIS screen not be available, the CRIS downtime procedures will be followed. Samples 
will not be sent outside NIH without appropriate approvals and/or agreements, if required. 
Tissue samples will be sent to Blood Processing Core (BPC) for barcoding and initial storage until 
they are distributed to Dr. Hernandez for sample analysis as described in the protocol.  
5.3.1 Samples Mana ged by the  Blood Processing Core (BPC)  
5.3.1.1 BPC C ontact Information  
Please e- mail NCIBloodcore@mail.nih.gov  at least 24 hours before transporting samples (the 
Friday before is preferred).  
For sample pickup, page 102-11964. 
For immediate help, call 240 -760- 6180 (main blood processing core number) or, if no answer, 
240-760-6190 (main clinical pharmacology lab number). For questions regarding sample processing, contact NCIBloodcore@mail.nih.gov
. 
5.3.1.2 Sample Data Collection  
All samples sent to the Blood Processing Core (BPC) will be barcoded, with data entered and 
stored in the Labmatrix  utilized by the BPC. This is a secure program, with access to Labmatrix  
limited to defined Figg lab personnel, who are issued individual user accounts. Installation of Labmatrix  is limited to computers specified by Dr. Figg. These computers all have a password 
restricted login screen.  
Labmatrix  creates a unique barcode ID for every sample and sample box, which cannot be traced 
back to subjects without Labmatrix  access. The data recorded for each sample includes the patient 
ID, name, trial name/protocol number, time drawn, cycle time point, dose,  material type, as well 
as box and freezer location. Patient demographics associated with the clinical center patient number are provided in the system. For each sample, there are notes associated with the processing method (delay in sample processing, storage conditions on the ward, etc.). 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
65 
 5.3.1.3 Sample Storage and Destruction 
Barcoded samples are stored in barcoded boxes in a locked freezer at either -20 or - 800C according 
to stability requirements. These freezers are located onsite in the BPC and offsite at NCI  Frederick 
Central Repository Services in Frederick, MD. Visitors to the laboratory are required to be 
accompanied by laboratory staff at all times.  
Access to stored clinical samples is restricted. Samples will be stored until requested by a 
researcher named on the protocol. All requests are monitored and tracked in Labmatrix . All 
researchers are required to sign a form stating that the samples are only to be used for research purposes associated with this trial (as per the IRB approved protocol) and that any unused samples must be returned to the BPC. It is the responsibility of the NCI Principal Investigator to ensure that the samples requested are being used in a manner consistent with IRB approval. 
Following completion of this study, samples will remain  in storage as detailed above. Access to 
these samples will only be granted following IRB approval of an additional protocol, granting 
the rights to use the material.  
If, at any time, a patient withdraws from the study and does not wish for their existing samples to 
be utilized, the individual must provide a written request. Following receipt of this request, the 
samples will be destroyed or returned to the patient, if so requested. The PI will record  any loss or 
unanticipated destruction of samples  as a d eviation. Reporting will be per the requirements of 
Section 7.2. 
Sample barcodes are linked to patient demographics and limited clinical information. This 
information will only be provided to investigators listed on this protocol, via registered use of the Labmatrix . It is critical that the sample remains linked to patient information such as race, age, 
dates of diagnosis and death, and histological information about the tumor, in order to correlate genotype with these variables.  
5.3.2 Procedures for S torage of Patient Samples in the Laboratory of Dr. Trepel  
Contact the Trepel Lab by email (Jane Trepel: trepel@helix.nih.gov
; Min -Jung Lee: 
leemin@mail.nih.gov; Akira Yuno: akira.yuno@nih.gov and Sunmin Lee: lees@pop.nci.nih.gov ) 
when the patient is scheduled and by phone as soon as the blood is drawn at 240-760-6330.  
A lab member will come to pick up the blood. Please keep blood at ambient te mperature. Members 
of the lab will enter the samples in to a secure  password protected patient ’s sample tracking 
database  (Translational Pharmacodynamics Research Group Patient Sample Management System ) 
and process the samples.  
Sample barcodes are linked t o patient demographics and limited clinical information. This 
information will only be provided to investigators listed on this protocol.  It is critical that the 
sample remains coded and linked to patient information such as race, age, dates of diagnosis and death, and histological information about the tumor, in order to correlate with these variables. 
Blood samples will be stored initially in the Trepel Lab in the Magnuson Clinical Center. If, at any 
time, a subject withdraws from the study and does not wish for their existing samples to be utilized, the individual must provide a written request. Following receipt of this request, the samples will be destroyed (or returned to the patient, if so requested). When a patient withdraws consent the 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
66 
 participant’ s data will be excluded from future distributions, but data that have already been 
distributed for approved research use will not be able to be retrieved. 
The PI will re cord any loss or unanticipated  destruction of samples  as a deviation. Reporting will 
be per the requirements of Section 7.2. 
5.3.3 Procedures for Storage of Tissue Specimens in the Laboratory of Pathology  
Tissues designated for clinical diagnostics are transported to the Laboratory of Pathology (LP) 
where they are examined grossly and relevant portions are fixed, embedded in paraffin and sectioned and stained for diagnostic interpretation. Unutilized excess tissue that is not embedded in paraffin is stored in formalin for up to three months, in accordance with College of American Pathologists/Joint Commission on Accreditation of Healthcare Organizations (CAP/JCAHO) guidelines, and then discarded. Following completion of the diagnostic workup, the slides and tissue blocks are stored indefinitely in the LP’s clinical archives. All specimens are catalogued and retrieved utilizing the clinical laboratory information systems, in accordance with CAP/JCAHO regulations. The use of any stored specimens for research purposes is only allowed when the 
appropriate IRB approval has been obtained. In some cases, this approval has been obtained via 
the original protocol on which the patient was enrolled. 
5.3.4 Procedures for S torage of Patient S amples in  the Laboratory of Dr. Hernandez 
Patient samples, collected for the purpose of research under IRB approved protocols where Dr. 
Hernandez is Principal Investigator, may be archived in the Laboratory of Dr. Hernandez. All data associated with archived clinical research samples is entered into the NCI Labmatrix database. All staff in Dr. Hernandez’s laboratory have received updated NIH/CIT training and maintain standards of computer security. 
The data recorded for each sample includes the patient ID, trial nam e/protocol number, date 
drawn/collected, treatment cycle/time point, cell source (e.g. peripheral blood, marrow, biopsy) as 
well as box and freezer location. Patient demographics that correlate treatment outcomes and therapies with the samples can be obtai ned only through the NCI clinical records. All received 
samples will receive a unique bar code number, which will be added to the sample NCI Labmatrix database. Only this bar code will be recorded on the sample vial and the vials will not be traceable back  to patients without authorized access to the NCI Labmatrix database. 
Samples are stored in freezers at -80° C (sera, plasma, tissue samples) or under liquid nitrogen 
(cells), according to stability requirements. These freezers are located onsite at Dr. Her nandez’s 
laboratory. Access to samples from a protocol for research purposes will be by permission of the Principal Investigator.  
5.3.5 Protocol Completion/Sample Destruction  
All specimens obtained in the protocol are used as defined in the protocol. Any specime ns that are 
remaining at the completion of the protocol will be transferred to protocol 13C0176.  
Subjects  will be co -enrolled on protocol 13C0176. Thus , all tissue will be stored, tracked and 
disposed after transfer as specified in protocol 13C0176. 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
67 
 If the patient withdraws consent the participant’s data will be excluded from future distributions, 
but data that have already been distributed for approved research use will not be able to be 
retrieved.  
The PI will record any loss or unanticipated destruction of samples as a deviation. Reporting will 
be per the requirements  of Section  7.2.  
5.3.6 A Certificate of Confidentiality  
A Certificate of Confidentiality will be obtained for this  study. 
5.3.7 Management of Results  
Subjects will be contacted if a clinically actionable gene variant is discovered. Clinically actionable findings for the purpose of this study are defined as disorders a ppearing in the American 
College of Medical Genetics and Genomics recomm endations for the return of incidental findings 
that is current at the time of primary analysis. (A list of  current guidelines is maintained on the 
CCR intranet: https://ccrod.cancer.gov/confluence/display/CCRCRO/Incidental+Findings+Lists
). 
Subjects will be contacted at this time with a request to provide a blood sample  to be sent to a 
CLIA cert ified laboratory.  
5.3.8 Genetic C ounseling  
If the research findings are verified in the CLIA certified lab, the subject will be offered the opportunity to come to NIH (at our expense) to have genetic education and counseling with the NCI Genetics Branch to expl ain this result.  If the subject does not want to come to NIH, a referral 
to a local genetic healthcare provider will be provided (at their expense).  
This is the only time during the course of the study that incidental findings will be returned. No 
interro gations regarding clinically actionable findings will be made after the primary analysis . 
6 DATA COLLECTION AND EVALUATION  
 DATA COLLECTION  
For the purposes of the research sample  analyses and correlation with clinical outcomes, 
demographic information, histology, operative and peri -operative interventions, pathologic 
findings, laboratory and imaging parameters (performed as part of routine or protocol specified patient care) may  be collected on this study. The PI will be responsible for overseeing entry of data 
into an in- house password protected electronic system (C3D and Labm atrix) and ensuring data 
accuracy, consistency and timeliness.  The principal investigator, associate investigators/research 
nurses and/or a contracted data manager will assist with the data management efforts. All data obtained during the conduct of the protocol will be kept in secure network drives or in approved alternative sites that comply with NIH security standards. Primary and final analyzed data will have identifiers so that research data can be attributed to an individual human subject participant. 
All adverse events , including clinically significant abnormal findings on laboratory evaluations, 
regardless of severity, will be followed until return to baseline or stabilization of event.  
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
68 
 Document AEs from the first study intervention, Study Day -3, through the last study intervention 
on Cycle 2 Day 15. Beyond 28 days after the last intervention, only adverse events which are 
serious and related to the study intervention need to be recorded . 
End of S tudy Procedures: Data will be stored according to HHS, FDA regulations and NIH 
Intramural Records Retention Schedule as applicable.  
Loss or D estruction of Data: Should we become aware that a major brea ch in our plan to protect 
subject confidentiality and trial data has occurred, this will be reported expeditiously per 
requirements in Section 7.2.1.  
6.1.1 Routine Data C ollection  
Following enrollment  and for the duration of the study, graded adverse events will be described in 
the source documents, reviewed by the designated research nurse, and captured in C3D  unless 
otherwise indicated below .  
Note:  No Grade 1 adverse events will be recorded.  
6.1.1.1 Concomitant Medications (captured in source documents only)  
o Only those medications that the patient is taking at baseline on a routine basis or medications that cause an AE will be captured. (Thus, one time medications, PRN medications, and medications given to treat adverse events will not be captured.) 
6.1.1.2 Laboratory Events 
Laboratory events that will be described in the source documents and captured  in C3D: 
• During hospitalization for the procedure , only the  following labs  will be uploaded into  
C3D:   
o Admission labs,  
o First morning labs drawn after 4:00 AM , and  
o Labs that support the diagnosis of a reportable event. 
• In the immediate post- operative period  (7 days) , only the following values will be 
captured  (including laboratory values obtained at sites other than the NIH Clinical Center ): 
o Hemoglobin, total white blood cell count, absolute neutrophil count, platelet count 
o PT, PTT, or INR  
o Creatinine, ALT, AST, total bilirubin   
Any unexpected laboratory abnormality ≥ G rade 3 AND associated with symptoms or an 
intervention will be reported. We recognize that laboratory abnormalities are the norm for subjects  undergoing the procedures as outlined in this study and therefore will exercise PI 
discretion in reporting of abnormalities outside the reported ULN. 
6.1.1.3  Exceptions to Adverse Event Recording 
An abnormal laboratory value will be recorded in the database as  an AE only if the laboratory 
abnormality is characterized  by any of the following: 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
69 
 o Results in discontinuation from the study 
o Is not directly attributable to the operation  
o Is associated with clinical signs or symptoms  
o Requires treatment or any other therapeutic intervention  
o Is associated with death or another s erious adverse event, including hospitalization.  
o Is judged by the Investigator to be of significant clinical impact 
o If any abnormal laboratory result is considered clinically significant, the 
investigator will provide details about the action taken with respect to the test drug and about the patient’s outcome. 
Non-laboratory, non- concomitant medication events  that will be captured only in the source 
documents: 
• During hospitalization for surgical resection 
o ≤ Grade 3 events except  unexpected  events that are possibly or definitely related 
to the research . 
• Post-operative recovery period (following discharge)  
o ≤ Grade 3 events except unexpected  events that are possibly or definitely related 
to the research . 
o Note: E vents that result in hospitalization for convenience will not be reported.  
 DATA SHARING PLANS  
6.2.1 Human Data Sharing Plan 
What data will be shared? 
I will share human data generated in this research for future research as follows :  
o Coded, linked data in an NIH -funded or approved public repository. 
o Coded, linked data in BTRIS (automatic for activities in the Clinical Center) . 
o Identified or coded, linked data with approved outside collaborators under appropriate 
agreements.  
How and where will the data be shared?  
Data will be shared through: 
o An NIH -funded or approved public repository, clinicaltrials.gov , dbGaP. 
o BTRIS (automatic for activities in the Clinical Center) . 
o Approved outside collaborators under appropriate individual agreements. 
o Publication and/or public presentations. 
When will the data be shared?  
o Before publication. 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
70 
 o At the time of publication or shortly thereafter.  
6.2.2 Genomic Data Sharing Plan 
Unlinked genomic data will be deposited in public genomic databases such as dbGaP in 
compliance with the NIH Genomic Data Sharing Policy.  
 RESPONSE CRITERIA  
For the purposes of this study, patients should be re- evaluated for response at C1D1, C1D8, 
C2D1 and C2D15 (+/- 48 hours) and at EOT .  
Response and progression will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1).[ 1
] Changes in the largest diameter (unidimensional measurement) of the tumor 
lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST criteria.  
6.3.1 Definitions  
Evaluable for toxicity : All patients will be evaluable for toxicity from the time of their first 
treatment with  MVT -5873. 
Evaluable for Objective Response : Only those patients who have measurable disease present at 
baseline, have received at least one dose of the monoclonal antibody, undergone a resection and have had their disease re- evaluated will be considered evaluable for DFS response. (Note:  
Patients who exhibit objective disease progression prior to the end of C ycle 1 will also be 
considered evaluable.)  
Evaluable Non- Target Disease Response: Patients who have lesions present at baseline that are 
evaluable but do not meet the definitions of mea surable disease, have received at least dose of 
the monoclonal antibody, undergone a resection and have had their disease re- evaluated will be 
considered evaluable for non- target disease. The response assessment is based on the presence, 
absence, or unequivocal progression of the lesions. 
6.3.2 Disease Parameters  
Measurable disease:  Measurable lesions are defined as those that can be accurately measured in 
at least one dimension (longest diameter to be recorded) as:  
• By chest x -ray: >20 mm;  
• By CT scan:  
o Scan sl ice thickness 5 mm or under: as >10 mm  
o Scan slice thickness >5 mm: double the slice thickness   
• With  calipers on clinical exam:  >10 mm.   
All tumor measurements must be recorded in millimeters  (or decimal fractions of centimeters).  
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
71 
 Malignant lymph nodes. To  be considered pathologically enlarged and measurable, a lymph node 
must be >15 mm in short axis when assessed by CT scan (CT scan slice thickness recommended 
to be no greater than 5 mm). At baseline and in follow-up, only the short axis will be measured 
and followed. 
Non-measurable disease. All other lesions (or sites of disease), including small lesions (longest 
diameter <10 mm or pathological lymph nodes with ≥10 to <15 mm short axis), are considered non-measurable disease.  Bone lesions, leptomeningeal disease, ascites, pleural/pericardial 
effusions, lymphangitis cutis/pulmonitis, inflammatory breast disease, and abdominal masses (not followed by CT or MRI), are considered as non- measurable.  
Note:  Cystic lesions that meet the criteria for radiographically defined simple cysts should not be 
considered as malignant lesions (neither measurable nor non-measurable) since they are, by definition, simple cysts.  
‘Cystic lesions’ thought to represent cystic metastases can be considered as measurable lesions, if they meet the definition of measurability described above. However, if non- cystic lesions are 
present in the same patient, these are preferred for selection as target lesions.  
Target lesions.  All measurable lesions up to a maximum of 2 lesions  per organ and 5 lesions in 
total, representative of all involved organs, should be identified as target lesions  and recorded 
and measured at baseline.  Target lesions should be selected on the basis of their size (lesions 
with the longest diameter), be representative of all involved organs, but in addition should be those that lend themselves to reproducible repeated measurements. It may be the case that, on 
occasion, the largest lesion does not lend itself to reproducible measurement in which circumstance the next largest lesion which can be measured reproducibly should be selected. A sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all target lesions will be calculated and reported as the baseline sum diameters.  If lym ph nodes are to be 
included in the sum, then only the short axis is added into the sum. The baseline sum diameters will be used as reference to further characterize any objective tumor regression in the measurable dimension of the disease. 
Non-target lesio ns. All other lesions (or sites of disease) including any measurable lesions over 
and above the 5 target lesions should be identified as non- target lesions and should also be 
recorded at baseline.  Measurements of these lesions are not required, but the pre sence, absence, 
or in rare cases unequivocal progression of each should be noted throughout follow-up.  
6.3.3 Methods for Evaluation of Measurable Disease 
All measurements should be taken and recorded in metric notation using a ruler or calipers. All baseline evaluations should be performed as closely as possible to the beginning of treatment and never more than 4 weeks before the beginning of the treatment. 
The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during follow- up. Imaging-based evaluation is 
preferred to evaluation by clinical examination unless the lesion(s) being followed cannot be imaged but are assessable by clinical exam.  
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
72 
 Clinical lesions : Clinical lesions will only be considered measurable when they are superficial 
(e.g., skin nodules and palpable lymph nodes) and ≥10 mm diameter as assessed  using calipers 
(e.g., skin nodules). In the case of skin les ions, documentation by color photography, including a 
ruler to estimate the size of the lesion, is recommended.  
Chest x -ray: Lesions on chest x- ray are acceptable as measurable lesions when they are clearly 
defined and surrounded by aerated lung. Howeve r, CT is preferable.  
Conventional CT and MRI: This guideline has defined measurability of lesions on CT scan based 
on the assumption that CT slice thickness is 5 mm or less.  If CT scans have slice thickness 
greater than 5 mm, the minimum size for a measurable lesion should be twice the slice thickness.  
MRI  is also acceptable in certain situations (e.g. for body scans). 
Use of MRI remains a complex issue.  MRI has excellent contrast, spatial, and temporal 
resolution; however, there are many image acquisition variables involved in MRI, which greatly 
impact ima ge quality, lesion conspicuity, and measurement. Furthermore, the availability of MRI 
is variable globally. As with CT, if an MRI is performed, the technical specifications of the scanning sequences used should be optimized for the evaluation of the type a nd site of disease.  
Furthermore, as with CT, the modality used at follow-up should be the same as was used at baseline and the lesions should be measured/assessed on the same pulse sequence. It is beyond the scope of the RECIST guidelines to prescribe spec ific MRI pulse sequence parameters for all 
scanners, body parts, and diseases. Ideally, the same type of scanner should be used and the image acquisition protocol should be followed as closely as possible to prior scans. Body scans should be performed with breath -hold scanning techniques, if possible. 
PET- CT: At present, the low dose or attenuation correction CT portion of a combined PET- CT is 
not always of optimal diagnostic CT quality for use with RECIST measurements. However, if the site can document that the CT performed as part of a PET- CT is of identical diagnostic 
quality to a diagnostic CT (with IV and oral contrast), then the CT portion of the PET- CT can be 
used for RECIST measurements and can be used interchangeably with conventional CT in accurately measuring cancer lesions over time.  Note, however, that the PET portion of the CT 
introduces additional data which may bias an investigator if it is not routinely or serially performed.  
Ultrasound: Ultrasound is not useful in assessment of lesion size and should not be used as a 
method of measurement. Ultrasound examinations cannot be reproduced in their entirety for independent review at a later date and, because they are operator dependent, it cannot be guaranteed that the same technique and measuremen ts will be taken from one assessment to the 
next. If new lesions are identified by ultrasound in the course of the study, confirmation by CT or MRI is advised. If there is concern about radiation exposure at CT, MRI may be used instead of CT in selected instances.  
Endoscopy, Laparoscopy: The utilization of these techniques for objective tumor evaluation is 
not advised. However, such techniques may be useful to confirm complete pathological response when biopsies are obtained or to determine relapse in trial s where recurrence following complete 
response (CR) or surgical resection is an endpoint. 
Tumor markers:  Tumor markers alone cannot be used to assess response. If markers are initially 
above the upper normal limit, they must normalize for a patient to be considered in complete 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
73 
 clinical response.  Specific guidelines for both CA-125 response (in recurrent ovarian cancer) and 
PSA response (in recurrent prostate cancer) have been published. [ 2-4]   I In addition, the 
Gynecologic Cancer Intergroup has developed CA-125 progression criteria which are to be 
integrated with objective tumor assessment for use in first- line trials in ovarian cancer .[5]  
Cytology, Histology: These techniques can be used to differentiate between partial responses 
(PR) and complete responses (CR) in rare cases (e.g., residual lesions in tumor types, such as germ cell tumors, where known residual benign tumors can remain). 
The cytological confirmation of the neoplastic origin of any effusion that appears or worsens during treatment when the measurable tumor has met criteria for response or stable disease is mandatory to differentiate between response or stable disease (an effusion may be a side effect of the treatment) and progressive disease.  
FDG -PET:  While FDG -PET response assessme nts need additional study, it is sometimes 
reasonable to incorporate the use of FDG-PET scanning to complement CT scanning in assessment of progression (particularly possible 'new' disease). New lesions on the basis of FDG-PET imaging can be identified according to the following algorithm:  
a. Negative FDG -PET at baseline, with a positive FDG -PET at follow -up is a sign of 
PD based on a new lesion. 
b. No FDG -PET at baseline and a positive FDG- PET at follow -up: If the positive FDG-
PET at follow -up corresponds to a new site of disease confirmed by CT, this is PD. If 
the positive FDG- PET at follow -up is not confirmed as a new site of disease on CT, 
additional follow-up CT scans are needed to determine if there is truly progression occurring at that site (if so, the da te of PD will be the date of the initial abnormal 
FDG -PET scan).  If the positive FDG -PET at follow -up corresponds to a pre-existing 
site of disease on CT that is not progressing on the basis of the anatomic images, this is not PD. 
c. FDG -PET may be used to upgrade a response to a CR in a manner similar to a biopsy 
in cases where a residual radiographic abnormality is thought to represent fibrosis or scarring.  The use of FDG -PET in this circumstance should be prospectively described 
in the protocol and supported by disease- specific medical literature for the indication.  
However, it must be acknowledged that both approaches may lead to false positive CR due to limitations of FDG -PET and biopsy resolution/sensitivity. 
Note:  A ‘positive’ FDG- PET scan lesion means o ne which is FDG avid with an uptake greater 
than twice that of the surrounding tissue on the attenuation corrected image. 
6.3.4 Response Criteria  
6.3.4.1 Evaluation of Target Lesions 
Complete Response (CR) : Disappearance of all target lesions.  Any pathological lymph nodes 
(whether target or non-target) must have reduction in short axis to <10 mm. 
Partial Response (PR) : At least a 30% decrease in the sum of the diameters of target lesions, 
taking as reference the baseline sum of diameters.  
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
74 
 Progressive Disease (PD) : At lea st a 20% increase in the sum of the diameters of target lesions, 
taking as reference the smallest sum on study (this includes the baseline sum if that is the 
smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.  (Note:  the appearance of one or more new lesions is also 
considered progressions). 
Stable Disease (SD) : Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify for PD, taking as reference the smallest sum of diameters while on study.  
6.3.4.2 Evaluation of Non-Target Lesions 
Complete Response (CR) : Disappearance of all non -target lesions and normalization of tumor 
marker level.  All lymph nodes must be non-pathological in size (<10 mm short axis).  
Note:  If tumor markers are initially above the upper normal limit, they must normalize for a 
patient to be considered in complete clinical response. 
Non-CR/Non -PD: Persistence of one or more non-target lesion(s) and/or maintenance of tumor 
marker level above the normal limits.  
Progressive Disease (PD) : Appearance of one or more new lesions and/or unequivocal 
progression of existing non- target lesions.  Unequivocal progression should not normally trump 
target lesion status.  It must be representative of overall disease status change, not a single lesion 
increase.  
Although a clear progression of “non-target” lesions only is exceptional, the opinion of the treating physician should prevail in such circumstances, and the progression status should be confirmed at a later time by the review panel (or Principal Investigator).  
6.3.4.3 Evaluation of Best Overall Response 
The best overall response is the best response recorded from the s tart of the treatment until 
disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started).  The patient's best response assignment will 
depend on the achievement of both measureme nt and confirmation criteria.  
For Patients with Measurable Disease (i.e., Target Disease) 
Target 
Lesions  Non-Target 
Lesions  New 
Lesions  Overall 
Response  Best Overall Response when 
Confirmation is Required*  
CR CR No CR >4 wks. Confirmation** 
CR Non-
CR/Non -PD No PR 
>4 wks. Confirmation** 
CR Not 
evaluated  No PR 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
75 
 Target 
Lesions  Non-Target 
Lesions  New 
Lesions  Overall 
Response  Best Overall Response when 
Confirmation is Required*  
PR Non-
CR/Non -
PD/not 
evaluated  No PR 
SD Non-
CR/Non -
PD/not 
evaluated  No SD 
Documented at least once >4 
wks. from baseline** 
PD Any Yes or 
No PD 
no prior SD, PR or CR Any PD*** Yes or 
No PD 
Any Any Yes PD 
* See RECIST 1.1 manuscript for further details on what is evidence of a 
new lesion. 
** Only for non-randomized trials with response as primary endpoint. 
*** In exceptional circumstances, unequivocal progression in non- target 
lesions may be accepted as disease progression.  
Note : Patients with a global deterioration of health status requiring 
discontinuation of treatment without objective evidence of disease 
progression at that time should be reported as “ symptomatic 
deterioration.”  Every effort should be made to document the objective 
progression even after discontinuation of treatment. 
For Patients with Non -Measurable Disease (i.e., Non -Target Disease)  
Non-Target Lesions  New Lesions  Overall Response  
CR No CR 
Non-CR/non- PD No Non-CR/non- PD* 
Not all evaluated  No not evaluated  
Unequivocal PD Yes or No  PD 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
76 
 Non-Target Lesions  New Lesions  Overall Response  
Any Yes PD 
* ‘Non -CR/non-PD’ is preferred over ‘stable disease’ for non- target disease since 
SD is increasingly used as an endpoint for assessment of efficacy in some trials 
so to assign this category when no lesions can be measured is not advised 
6.3.5 Duration of Response 
Duration of overall response: The duration of overall response is measured from the time 
measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment  started).  
The duration of overall CR is measured from the time measurement criteria are first met for CR until the first date that progressive disease is objectively documented.   
Duration of stable disease: Stable disease is measured from the start of the  treatment until the 
criteria for progression are met, taking as reference the smallest measurements recorded since the treatment started, including the baseline measurements.  
6.3.6 Progression -Free Survival  
Intrahepatic PFS is defined as the duration of time from date of operation to the date of first observation of progressive disease within the liver or death, whichever comes first.  
Extrahepatic PFS is defined as the duration of time from date of operation to the date of first 
observation of progressive disease outside of the liver or death, whichever comes first. 
 TOXICITY CRITERIA  
The following adverse event management guidelines are intended to ensure the safety of each patient while on the study.  The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be utilized for AE reporting.  All appropriate treatment areas should have access to a copy of the CTCAE version 
5.0.  A co py of the CTCAE version 5.0 can be downloaded from the CTEP web site 
(http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50
).  
7 NIH REPORTING REQUIREMENTS / DATA AND SAFETY MONITORING PLAN 
 DEFINITIONS  
Please refer to definitions provided in Policy 801: Reporting Research Events found here . 
 OHSRP  OFFICE OF COMPLIANCE AND TRAINING / IRB REPORTING  
7.2.1 Expedited Reporting  
Please refer to the reporting requirements in Policy 801: Reporting Research Events and Policy 802 Non-Compliance Human Subjects Research found here
.  
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
77 
 Note: Only IND Safety Reports that meet the definition of an unanticipated problem will need to 
be reported  per these policies . 
7.2.2 IRB Requirements for PI Reporting at Continuing Review  
Please refer to the reporting requirements in Policy 801: Reporting Research Events found here . 
 NCI  CLINICAL DIRECTOR REPORTING  
Problems expeditiously reported to the OHSRP in iRIS will also be reported to the NCI Clinical Director.  A separate submission is not necessary as reports in iRIS will be available to the Clinical Director.  
In addition to those reports, all deaths that occur within 28 days  after  receiving a research 
intervention s hould be reported via email to the Clinical Director  unless they are due to 
progressive disease.   
To report these deaths, please sen d an email describing the circumstances of the death to Dr. 
Dahut at NCICCRQA@mail.nih.gov
 within one business day of learning of the death. 
 NIH  REQUIRED DATA AND SAFETY MONITORING PLAN 
7.4.1 Principal Investigator/Research Team  
The clinical research team will meet on a weekly  basis when patients are being actively treated on 
the trial to discuss ea ch patient. Decisions about dose level enrollment and dose escalation if 
applicable will be made  based on the toxicity data from prior patients.  
All data will be collected in a timely manner and reviewed by the principal investigator or a lead 
associate investigator. E vents meeting requirements for expedited reporting as described in Section 
7.2.1 will be submitted within the appropriate timelines .  
The principal investigator will review adverse event and response data on each patient to ensure safety and data accuracy. The principal investigator will personally conduct or supervise the investigation and provide appropriate delegation of responsibilities to other members of the research staff.   
8 SPONSOR SAFETY REPORTING  
 DEFINITIONS  
8.1.1 Adverse Event   
Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event (AE) can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product (ICH E6 (R2)). 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
78 
 8.1.2 Serious Adverse Event  (SAE) 
An adverse event or suspected adverse reaction is considered serious if in the view of the 
investigator or the sponsor, it results in any of the following: 
• Death,  
• A life -threatening adverse event (see Section  8.1.3 ) 
• Inpatient hospitalization or prolongation of existing hospitalization 
o A hospitalization/admission that is pre -planned (i.e., elective or schedul ed surgery 
arranged prior to the start of the study), a planned hospitalization for pre- existing 
condition, or a procedure required by the protocol, without a serious deterioration in 
health, is not considered a serious adverse event. 
o A hospitalization/admission that is solely driven by non-medical reasons (e.g., hospitalization for patient convenience) is not considered a serious adverse event.  
o Emergency room visits or stays in observation units that do not result in admission to the hospital would not be considered a serious adverse event. The reason for seeking medical care should be evaluated for meeting one of the other serious criteria. 
• Persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions 
• A con genital anomaly/birth defect.  
• Important medical events that may not result in death, be life -threatening, or require 
hospitalization may be considered a serious adverse drug experience when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. 
8.1.3 Life-threatening  
An adverse event or suspected adverse reaction is considered "life -threatening" if, in the view of 
either the in vestigator or sponsor, its occurrence places the patient or subject at immediate risk of 
death. It does not include an adverse event or suspected adverse reaction that, had it occurred in a more severe form, might have caused death. (21CFR312.32) 
8.1.4 Severity  
The severity of each Adverse Event will be assessed utilizing the CTCAE version 5.0. 8.1.5 Relationship to Study Product  
All AEs will have their relationship to study product assessed using the terms:  related or not 
related.   
• Related  – There is a reasonable po ssibility that the study product caused the adverse 
event. Reasonable possibility means that there is evidence to suggest a causal relationship between the study product and the adverse event. 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
79 
 • Not Related  – There is not  a reasonable possibility that the administration of the study 
product caused the event. 
 ASSESSMENT OF SAFETY EVENTS  
AE information collected will include event description, date of onset, assessment of severity 
and relationship to study product and alternate etiology (if not related to study product), date of resolution of the event, seriousness and outcome. The assessment of severity and relationship to the study product will be done only by those with the training and authority to make a diagnosis and listed on the Form FDA 1572 as the site principal investigator or sub-investigator.  AEs occurring during the collection and reporting period will be documented appropriately regardless of relationship.  AEs will be followed through resolution. 
SAEs wi ll be: 
• Assessed for severity and relationship to study product and alternate etiology (if not 
related to study product) by a licensed study physician listed on the Form FDA 1572 as the site principal investigator or sub-investigator. 
• Recorded on the appropriate SAE report form , the medical record and captured in the 
clinical database. 
• Followed through resolution by a licensed study physician listed on the Form FDA 1572 as the site principal investigator or sub-investigator. 
For timeframe of recording adverse events, please refer to S ection  6.1.  
 REPORTING OF SERIOUS ADVERSE EVENTS  
Any AE that meets protocol- defined serious criteria or meets the definitio n of Adverse Event of 
Special Interest that require expedited reporting must be submitted immediately (within 24 hours 
of awareness) to OSRO Safety using the CCR SAE report form. 
All SAE reporting must include the elements described in  Section 8.2. 
SAE reports  will be submitted to the Center for Cancer Research (CCR) at:  
OSROSafety@mail.nih.gov  and to the CCR PI and study coordinator.  CCR SAE report form 
and instructions can be found at: 
https://ccrod.cancer.gov/confluence/pages/viewpage.action?pageId=157942842   
Following the assessment of the SAE by OSRO, other supporting documentation of the event 
may be requested by the OSRO Safety  and should be provided as soon as possible. 
 REPORTING PREGNANCY  
8.4.1 Maternal  Exposure  
If a patient becomes pregnant during the course of the study, the study treatment should be discontinued immediately, and the pregnancy reported to the Sponsor no later than 24 hours of 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
80 
 when the Investigator becomes aware of it. The Investigator should notify the Sponsor no later 
than 24 hours of when the outcome of the Pregnancy become known, 
Pregnancy itself is not regarded as an SAE. However, congenital abnormalities or birth defects 
and spontaneous miscarriages that meet serious criteria ( Section 8.1.2) should be reported as 
SAEs .  
The outcome of all pregnancies (spontaneous miscarriage, elective termination, ectopic pregnancy, normal birth, or congenital abnormality) should be followed up and documented. 
8.4.2 Paternal Exposure 
Male patients should refrain from fathering a child or donating sperm during the study and for 90 
days after the last dose of  MVT -5873. 
Pregnancy of the patient’s partner is not considered to be an AE. However, the outcome of all pregnancies (spontaneous miscarriage, elective termination, ectopic pregnancy, normal birth, or congenital abnormality) occurring from the date of the first dose until 90 days after the last dose should, if possible, be followed up and documented. 
 REGULATORY REPORTING FOR STUDIES CONDUCTED UNDER CCR-S PONSORED IND 
Following notification from the investigator, CCR , the IND sponsor, will report any suspected 
adverse reaction that is both serious and unexpected.  CCR will report an AE as a suspected adverse reaction only if there is evidence to suggest a causal relationship between the study product and the adverse event.  CCR will notify FDA and all participating investigators (i.e., all investigators to whom the sponsor is providing drug under its INDs or under any investigator’s IND) in an IND safety report of potential serious risks from clinical trials or any other source, as soon as possible, in accordance to 21 CFR Part 312.32.  
All serious events will be reported to the FDA at least annually in a summary format.  
9 CLINICAL  MONITORING  
As a sponsor for clinical trials, FDA regulations require the CCR to maintain a monitoring 
program. The CCR’s program allows for confirmation of: study data, specifically data that could affect the interpretation of primary  and secondary study endpoints; adherence to the protocol, 
regulations, ICH E6, and SOPs; and human subjects protection. This is done through independent verification of study data with source documentation focusing on: 
• Informed consent process 
• Eligibility confirmation  
• Drug administration and accountability 
• Adverse events monitoring 
• Response assessment.  
The monitoring program also extends to multi-site research when the CCR is the coordinating center.  
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
81 
 This trial will be monitored by personnel employed by a CCR contractor. Monitors are qualified 
by training and experience to monitor the progress of clinical trials. Personnel monitoring this study will not be affiliated in any way with the trial conduct.   
10 STATISTICAL CONSIDERATIONS  
 STATISTICAL HYPOTHESES   
10.1.1 Primary E fficacy E ndpoints  
The primary objectives of this trial are to : 
1) Determine if the use of the monoclonal antibody in the immediate perioperative period is 
safe for subjects undergoing the  two main procedures: hepatic resection and pancreatic 
resection.  
2) Determine whether subjects  with pancreatic cancer, cholangiocarcinoma, or colorectal 
cancer metastatic to th e liver who undergo a resection and receive the anti -CA  
19-9 monoclonal antibody can decrease their 12- month recurrence probability from 50% to 
25% for pancreatic cancer, from 40% to 20% for colorectal cancer, and from 40% to 20% 
for cholangiocarcinoma.  
10.1.2 Secondary E fficacy E ndpoints  
The secondary end- point of disease -free survival, defined as the time of resection (D0) until the 
time of documented clinical recurrence (radiographically or pathologically) will be determined for each patient on study. In the absence of a knowable time of recurrence, time of death will be used as a surrogate. The data will be compared to data obtained from recent randomized clinical trials with adjuvant therapy, and each cohort will be analyzed separately. We anticipate maturation of this data will take ye ars to complete, and plan an analysis at 3 years from the time of accrual of 
the last patient in each cohort.  
 SAMPLE SIZE DETERMINATION : 
Sample sizes are calculated on the basis of 12- month recurrence probability for each of the three  
histologies accrued in this study (pancreatic cancer, cholangiocarcinoma and colorectal cancer): 
1. Pancreatic cancer:  Data from ESPAC4  indicate that the expected 12 -month recurrence 
probability is ~ 50%. The goal is to determine if use of the monoclonal antibody will be 
potentia lly associated with a decrease to a 25% recurrence probability, 12 months after 
surgery. As a means of determining the sample size for the study, with 23 evaluable subjects  with pancreatic cancer who receive surgery and the monoclonal antibody and are 
potentially followed for 12 months, there would be 80% power to rule out a 50% recurrence 
rate in favor of a 25% recurrence rate, with a one- sided 0.10 significance level exact 
binomial test. In practice, if 23 subjects  are treated and if 8/23 (34.8%) have rec urred by 
one year, then the upper one- sided 90% confidence bound on 8/23 is 50.3%, which would 
indicate a marginally improved recurrence probability compared to a historical 50%. In addition, the lower one -sided 90% confidence bound on 8/23 is 21.4%, which demonstrates 
that 8/23 could be shown to be consistent with as low as a 25% recurrence rate. In practice, 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
82 
 confidence intervals about the recurrence probabilities will be reported, but no formal 
hypothesis test will be undertaken. 
2. Cholangiocarcinoma:  Data from the BILCAP trial and single institution series  indicate 
that the expected 12 -month recurrence probability is 40%. The goal is to determine if use 
of the monoclonal antibody will be potentially associated with a decrease to a 20% recurrence probability , 12 months after surgery. As a means of determining the sample size 
for the study, with 24 evaluable subjects  with cholangiocarcinoma who receive surgery and 
the monoclonal antibody, and are potentially followed for 12 months, there would be 81% power to rule out a 40% recurrence rate in favor of a 20% recurrence rate, with a one -sided 
0.10 significance level exact binomial test. In practice, if 24 subjects are treated and if 6/24 
(25%) have recurred by one year, then the upper one -sided 90% confidence bound on 6/24 
is 39.8%, which would indicate a marginally improved recurrence probability compared to 
a historical 40%. In addition, the lower one -sided 90% confidence bound on 6/24 is 13.7%, 
which demonstrates that 6/24 could be shown to be consistent with a 20% recurrence rate. 
In practice, confidence intervals about the recurrence probabilities will be reported, but no 
formal hypothesis test will be undertaken. 
3. Colorectal cancer:  Data from MSKCC  indicate that the expected 12 -month recurrence 
probability is 40%. The goal is to determine if use of the monoclonal antibody will be potentially associated with a decrease to a 20% recurrence probability, 12 months after surgery. As a means of determining the sample size for the study, with 24 evaluable subjects  with colorectal  cancer who receive surgery and the monoclonal antibody, and are 
potentially followed for 12 months, there would be 81% power to rule out a 40% recurrence rate in favor of a 20% recurrence rate, with a one- sided 0.10 significance level exact 
binomial test. In practice, if 24 subjects  are treated and if 6/24 ( 25%) have recurred by one 
year, then the upper one -sided 90% confidence bound on 6/24 is 39.8%, which would 
indicate a marginally improved recurrence probability compared to a historical  40%. In 
addition, the lower one -sided 90% confidence bound on 6/24 is 13.7%, which demonstrates 
that 6/24 could be shown to be consistent with a 20% recurrence rate. In practice, 
confidence intervals about the recurrence probabilities will be reported, but no formal hypothesis test will be undertaken. 
This study contains the stratified accrual of two successive safety lead -in cohorts , there is the 
potential for up to 24 safety lead- in subjects to be enrolled. In addition, 71 (23+24+24) subjects 
will be enr olled in the expansion cohorts. As safety lean- in subjects treated at the MTD may be 
evaluated in the expansion cohorts, 83 (24-12+71) evaluable subjects will be required . It is 
expected that approximately 24-30 subjects  per year may enroll onto the study, with approximately  
8-10 subjects per year for each of the three histologies . Thus, it is expected that 3-4 years may be 
required to enroll up to 83 total evaluable subjects . To allow for unevaluable subjects  and screening 
failures , the total accrual ceiling for the trial will be set at 105 subjects . 
 POPULATIONS FOR ANALYSIS  
Modified intention to treat: all subjects  who receive at least one dose of the monoclonal antibody 
and undergo a resection will be included in the statistical analyses perf ormed. 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
83 
 10.3.1 Evaluable for Toxicity  
All patients will be evaluable for toxicity from the time of their first treatment with  MVT -5873. 
10.3.2 Evaluable for O bjective R esponse  
Only those patients who have measurable disease present at baseline, have received at least o ne 
dose of the monoclonal antibody, undergone a resection  and have had their disease re- evaluated 
will be considered evaluable for response. CA 19-9 will be measured for response. (Note:  Patients 
who exhibit objective disease progression prior to the end of C ycle 1 will also be considered 
evaluable.)  
10.3.3 Evaluable Non- Target Disease Response  
Patients who have lesions present at baseline that are evaluable but do not meet the definitions of 
measurable disease, have received at least dose of the monoclonal antibody, undergone a resection and have had their disease re -evaluated will be considered evaluable for non- target disease. The 
response assessment is based on the presence, absence, or unequivocal progression of the lesions.  
 STATISTICAL ANALYSES  
10.4.1 General A pproach  
Fractions of subjects  who recur by 12 months will be reported along with appropriate confidence 
intervals. Estimates of the fraction experiencing important side effects will be reported along with appropriate confidence intervals.  
10.4.2 Analysis of the P rimary E fficacy E ndpoints  
1. Safety: s ee Section 10.4.4. 
2. Recurrence -free survival at 12 months: s ee Section 10.4.1. 
10.4.3 Analysis of the S econdary E fficacy E ndpoints  
Disease Free survival (DFS) is the time from resection to the time of definitive evidence recurrence, defined radiographically or by biopsy  
DFS will be determined using the Kaplan -Meier method, along with 80% and 95% two- side 
confidence intervals at the 12- month time point as well as the median for each of the three 
histologies. Safety will be evaluated as stated in the next section . 
10.4.4 Safety Analyses 
AE’s will be captured with the first dose of MVT -5873 and continue until 28 days after the last 
dose of MVT 5873, or the start of additional therapy, whichever comes first. The primary outcome measure (1 of 2) for this trial is safety of immediate peri- operative  
MVT -5873. For these reasons, we have stratified accrual based on tw o successive safety lead -in 
cohorts, and predicated successive accrual to successful completion of the preceding cohort. For 
example, if we are unsuccessful accruing subjects  to lead -in Cohort 2, the remainder of accrual 
will only take place with subjects  meeting study inclusion criteria and safety lead -in C ohort 1 
criteria. As described in Section 3, the safety lead -in cohorts have been designed as a n extra safe 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
84 
 guard to ensure patient safety by accruing subjects with the least amount of transaminase and 
bilirubin abnormalities first.  
However, we also want to ensure that the use of MVT -5873 is not associated with an increase in 
procedure related comp lications. For this reason , we have added additional safe guards, which are 
procedure-related and irrespective of histology:  
1. For S ubjects  Undergoing a L iver R esection:  
The fraction of subjects  whose treatment results in hepatic insufficiency will be noted and 
reported along with two- sided 80% and 95% confidence intervals. The general expectation 
is that up to 10% of subjects undergoing a hepatic resection will experience hepatic 
insufficiency.  
If after the first 10 evaluable subjects  who receive this procedure, there are 3 or more who 
experience hepatic insufficiency, this will be considered excessive since the one -sided 
lower 90% confidence interval bound on 3/10 is 11.6%, which would demonstr ate potential 
inconsistency with 10%. T, the fraction of subjects who experience hepatic insufficiency 
(AST and/or ALT elevation in combination with ascites or altered mental status) will be 
reported, along with a 95% two- sided confidence interval. In addi tion, each patient will 
have slides made from the resected tissue and if a single patient within a cohort is noted to have significant necrosis and/or direct damage to the biliary tree, then no further subjects  
will be enrolled onto that cohort.  
2. For S ubje cts Undergoing a P ancreas R esection:  
For subjects who undergo a pancreatic resection, the fraction of subjects  whose treatment 
results in pancreatic leaks will be noted and reported along with two- sided 80% and 95% 
confidence intervals. The general expectation is that up to 20% of subjects  undergoing a 
pancreatic resection will end up with a leak.  
If after the first 10 evaluable subjects  who receive this procedure, there are 5 or more who 
experience a leak, this will be considered excessive since the one -sided lower 90% 
confidence interval bound on 5/10 is 26.7%, which would demonstrate potential inconsistency with 20% . 
10.4.5 Baseline Descriptive Statistics  
Demographic and baseline clinical characteristics of all subjects  will be reported.  
10.4.6 Planned I nterim A nalyse s 
For the two types of procedures, determination of whether there are excessive side effects after treatment of 10 evaluable subjects  receive each type of procedure will take place, as described in 
the section above.  
10.4.7 Exploratory Analyses 
The following objectives will be analyzed as indicated for each: 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
85 
 The Kaplan -Meier method will be used to determine OS  by disease type  for subjects treated with 
preoperative MVT -5873. 
For patients that experience a rise in AST, ALT or Bilirubin prior to surgery, the mechanism(s) of 
liver function test abnormalities associated with MVT -5873 administration will be determined by 
having liver tissue evaluated with a battery of immunohistochemical stains at the discretion of the 
liver pathologist, Dr. David Kleiner.  
In order to determine the tumor penetration of MVT -5873 in primary tumors of the pancreas and 
bile ducts, and in metastatic colorectal cancers to  the liver, antibody staining (using an antibody 
against MVT -5873) will be performed by the Hernandez Laboratory on each tumor sample 
removed. The samples will be scored for staining positivity.   Evaluation of CTCs obtained before receiving the monoclonal antibody and just prior to surgery 
will be undertaken  in order to determine the impact of MVT -5873 therapy on circulating tumor 
cells. The difference in the CTC levels between the time points will be determined and tested for 
significance by a Wilcoxon signed rank test. If multiple statistical tests of these laboratory -based 
parameters are performed, the results will be reported without any formal correction for multiple comparisons.   
Resected tumor -bearing liver and pancreas  will be perfused in  order to develop ex  vivo models for 
pancreatic cancer, cholangiocarcinoma, and metastatic colorectal cancer . A model will be deemed 
viable if the tissue remains intact and functional for 48 hours and if the transcriptome of the tumor 
changes less than 10% from baseline during the perfusion.  
Ex vivo  analysis of peritoneal tumor tissue with resected mesothelial metastases will be performed 
utilizing the SMART System to support the identification of underpinnings of interventional 
chemotherapeutic and immunomodulatory agent effects  in subjects after  undergoing pre -operative 
MVT -5873 therapy . 
11 COLLABORATIVE AGREEMENTS   
 MATERIAL TRANSFER AGREEMENT (MTA)  
There are MTAs in place with the following, see Section 5.2 for additional information on the 
information/materials being shared  with each:  
• Genomic Expression (43208-17). 
• Zamboni Laboratory – University of North Carolina at Chapel Hill (pending) 
12 HUMAN SUBJECTS PROTECTIONS  
 RATIONALE FOR SUBJECT SELECTION  
Subjects  with a diagnosis of colorectal cancer with predominantly hepatic metastases will be 
eligible for this study, as will subjects  with resectable pancreatic cancer and cholangiocarcinoma. 
Eligibility assessment will be made solely on the patient’s medical sta tus. Recruitment of subjects  
on this study will be through standard CCR mechanisms. The investigational nature and objectives of this trial, the procedure and the treatments involved, the attendant risks and discomforts, potential benefits and potential alternative therapies will be carefully explained to the subjects in 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
86 
 the clinic setting and in the hospital prior to treatment and prior to obtaining a signed informed 
consent. 
 PARTICIPATION OF CHILDREN  
Children are excluded from this study because n o dosing or adverse event data are currently 
available on the use of MVT -5873 in subjects  < 18 years of age . Since the efficacy of this 
experimental procedure is unknown, it does not seem reasonable to expose children to this risk without further evidence of benefit. Should results of this study indicate efficacy , which is not 
responsive to other standard forms of therapy, future research can be conducted in the pediatric population to evaluate potential benefit in that patient population. 
 PARTICIPATION OF SUBJECTS  UNABLE TO GIVE CONSENT  
Adults unable to give consent are excluded from enrolling in the protocol.  However , re-consent 
may be necessary and there is a possibility, though unlikely, that subjects could become decisionally impaired. For this reason and because there is a prospect of direct benefit from research participation ( Section  12.4), all subjects will be offered the opportunity to fill in their 
wishes for research and care, and assign a substitute decision maker on the “NIH Advance Directive for Health Care and Medical Research Participation” form so that another person can make decisions about their medical care in the event that they become incapacitated or cognitively impaired during the course of the study. Note: The PI or AI will contact the NIH Ability to Consent Assessment Team  (ACAT) for evaluation as needed for the following:  an independent assessment 
of whether an individual has the capacity to provide consent; assistance in identifying and assessing an appropriate surrogate when indicated; and/or an assessment of the capacity to appoint a surrogate.  For those subjects that become incapacitated and do not have pre -determined 
substitute decision maker, the procedures described in NIH HRPP SOP 14E for appointing a surrogate decision maker for adult subjects who are (a) decisionally impaired, and (b) who do not have a legal guardian or durable power of attorney, will be followed. 
 EVALUATION OF BENEFITS AND RISKS/DISCOMFORTS  
The potential benefit is increased likelihood of cure from complete tumor extirpation. Therefore, although this protocol involves greater than minimal risk, it presents the prospect of direct benefit to individual subjects. The major risk is that the use of peri -operative MVT -5873 may increase the 
likelihood of procedure related complications, although we believe this risk to be small. 
Risks and benefits will be carefully discussed with the patient at the time consent is obtained. 
Patients will be monitored throughout the study in order to limit the consequences of any adverse events.  
The risks and benefits of participation for adults who become unable to consent on study are no different than those described for the rest of the study population. 
12.4.1 Risks  
12.4.1.1 Abdominal Surgery 
The risks for this protocol include the risks associated with any abdominal surgery. This includes 
postoperative bleeding, intra -abdominal infection, wound healing complications including fascial 
dehiscence, enterocutaneous fistulas, anesthetic mishap and perioperative death. All attempts will 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
87 
 be made to avoid unnecessary enterotomies or a bowel resection where feasible. In the case of 
intra-abdominal catastrophe after surgery, subjects  may require reoperation.  
12.4.1.2 Study Drug Risks 
The use of peri -operative MV T-5873 may increase the likelihood of procedure related 
complications , although this risk is believed to be small. 
12.4.1.3 Blood Sampling 
Side effects of blood draws include pain and bruising, lightheadedness, and rarely, fainting.  
12.4.1.4 Urine Collection  
There is no physical risk involved with urine collection. 12.4.1.5 Tissue Collection Risks   
All care will be taken to minimize risks that may be incurred by tumor sampling. However, there 
are procedure -related risks (such as bleeding, infection and visceral injury) that will be  explained 
fully during informed consent. If subjects suffer any physical injury as a result of the biopsies, 
immediate medical treatment is available at the NCI’s Clinical Center in Bethesda, MD.  Although 
no compensation is available, any injury will be fully evaluated and treated in keeping with the benefits or care to which subjects  are entitle d under applicable regulations. 
Biopsy side effects may include a mild burning sensation when the numbing medicine is injected into the skin, small amounts of bleeding at the biopsy site, and rarely, a small infection at the site. Biopsy sites usually heal very well and with very little scarring. 
12.4.1.6 Electrocardiogram (EKG)  
This test is safe and side effects are unlikely,  but it may be uncomfortable when the electrodes are 
taken off after the test is completed .  
12.4.1.7 Scans  and Contrast  
The most common discomfort is the length of time a patient must lay still during a scan. P atient s 
may also become uncomfortable with the closed space of the machines.  
There is a small risk of reaction in scans involving contrast (including gadolinium). Common 
reactions  include pain in the vein where the contrast was given, a metallic or bitter taste in the 
mouth, headache, nausea and a warm or flushing feeling that last s from 1 -3 minutes. In very rare 
cases, severe reactions that affect breathing , heart rhythm or blood pressure have occurred. 
Gadolinium for research MRI scans will not be given to patients who have impaired kidney function or who received gadolinium within the previous month.  
An IV line may need to be inserted for administration of the contrast agent or anesthetic , which 
may cause pain at the site where the IV is placed and there is  a small risk of bruising or infection. 
12.4.2 Risks of Exposure to Ionizing Radiation  
This research study involves expos ure to radiation from  CT scans,  collected for research purposes 
only. Subjects will be exposed to approximately 8.5 rem. This amount of radia tion is above the 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
88 
 guideline of 5 rem per year, and will expose the subject  to the roughly the same amount of radiation 
as 28.3 years of background radiation. 
12.4.3 Non-Physical Risks of Genetic Research  
12.4.3.1 Risk of R eceiving Unwanted I nformation  
Anxiety and stress may arise as a result of the anticipation that unwanted information regarding 
disease related DNA sequencing or disease tendencies, or misattributed paternity. Subjects  will be 
clearly informed that the data related to DNA sequencing and genetic analysis is  coded, 
investigational and will not be shared with subjects , family members or health care providers. 
12.4.3.2 Risk R elated to P ossibility that Information M ay be R eleased  
This includes the risk that data related to genotype, DNA sequencing or risk for disease tendency or trait can be released to members of the public, insurers, employers, or law enforcement agencies. Although there are no plans to release results to the subjects , family members or health 
care providers, this risk will be included in the informed consent document.  
12.4.3.3 Risk to  Family or R elatives  
Family members or relatives may or may not want to be aware of familial tendencies or genetic 
risks of disease which may cause anxiety about possible future health problems.  
12.4.4 Benefits  
The potential benefit to subjects  undergoing this therapy would be cure, or  palliation  at a minimum,  
in terms of preventing or delaying i ntra-abdominal tumor recurrence  and metastases elsewhe re 
which can be a devastating and painful source of symptoms and cause for demise.  12.4.5 Certificate of Confidentiality  
As part of study efforts to provide confidentiality of subject information, this study has obtained  a 
Certificate of Confidentiality which he lps to prevent forced disclosure of personally identifiable 
research information.  The Certificate of Confidentiality allows investigators on this trial to refuse 
to disclose identifying information related to the research participants, should such disclosure have 
adverse consequences for subjects or damage their financial standing, employability, insurability or reputation. The informed consent includes the appropriate coverage and restrictions of the 
Certificate of Confidentiality  
 CONSENT PROCESS AND DOCUM ENTATION  
The informed consent document will be provided to the participant or consent designee(s) (e.g., the legally authorized representative [LAR] if participant is an adult unable to consent) for review prior to consenting.  A designated study investigator will carefully explain the procedures and tests involved in this study, and the associated risks, discomforts and benefits. In order to minimize potential coercion, as much time as is needed to review the document will be given, including an opportunity to discuss it with friends, family members and/or other advisors, and to ask questions of any designated study investigator. A signed informed consent document will be obtained prior to entry onto the study. 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
89 
 The initial consent process as well as re- consent, when required, may take place in person or 
remotely (e.g., via telephone or other NIH approved remote platforms) per discretion of the 
designated study investigator and with the agreement of the participant/consent designee(s).  Whether in person or remote, the privacy of the subject will be maintained. Consenting investigators (and participant/consent designee, when in person) will be located in a private area (e.g., clinic consult room). When consent is conducted remotely, the participant/consent designee will be informed of the private nature of the discussion and will be encouraged to relocate to a more private setting if needed.   
12.5.1 Request for Waiver of Consent for Screening Activities  
Prior to the subject signing the consent for this study pre- screening activities listed in Section 
2.2.1 may be performed.  
We request a waiver of consent for these activities as they involve only minimal risk to the 
subjects.  A waiver will not adversely affect the rights and welfare of the subjects given that the activities are only intended to determine suitability for screening for participation in research 
protocols.  These activities could not practicably be carried out without the wavier as central 
recruiting services, utilized in the NIH Clinical Center, perform pre- screening activities for 
multiple studies and obtaining consent for each one is beyond their resou rces.  The subjects will 
be provided with additional pertinent information after participation as they will be informed whether or not they are eligible to sign a consent for additional screening. 
 13 PHARMACEUTICAL AND INVESTIGATIONAL DEVICE INFORMATION   
 DRUG MVT -5873  (IND  # 144112) 
13.1.1 Source  
MVT -5873, also known as  HuMab -5B1, is a monoclonal human IgG1 lambda  antibody targeted 
against sLea. MVT -5873 is human derived and has a fully human sequence. MVT -5873 has been 
shown to bind  with high affinity and specificity to  sLea using in vitro cell- based assays , ELISA , 
and by glycan microarray analysis. MVT -5873 drug is manufactured  by AAIPharma   
13.1.2 Toxicity  
Based on early clinical data, MVT -5873 appears to demonstrate dose limiting toxicity manifest as 
increases in liver transaminases and blood bilirubin. When seen, liver toxicity generally occurs 
early (within a few days of drug administration) and appears to be reversible.  
As with other protein based therapeutics, subjects are at risk for infusion reactions during or shortly 
after completion of an infusion of MVT -5873. The reactions are consistent with infusion reactions 
reported for other intraven ous protein therapeutics and may consist of skin reactions (e.g., urticaria, 
pruritus, flushing), fever, chills, shortness of breath, and tachycardia. Reactions appear to respond to interruption of the infusion and administration of steroids. In many cases, following resolution of the infusion reactions, infusions may be restated at a lower infusion rate without return of infusion reaction symptoms. 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
90 
 Other side effects related to MVT -5873 are mostly low grade ( Grade 1 or 2) and are predominately 
GI in nature  (e.g., constipation, diarrhea, nausea, vomiting), or appear consistent with systemic 
immune activation (e.g., fever, fatigue, malaise, rash). 
13.1.3 Formulation and P reparation   
MVT -5873 i njection drug product contains  10 mg/mL MVT -5873 as the active ingredient.  Each 
vial contains  3.1 mL of MVT -5873 drug product formulated as a solution for  intravenous (IV) 
delivery. The table below provides a c omplete list of ingredients and quantitative formulation on 
a per mL basis . 
Ingredient  Function  Unit Formula  Quality Standard  
MVT -5873 Active Ingredient  10.0 mg/mL NA 
L-histidine  Buffer  3.88 mg/mL USP/NF  
Hydrochloric Acid  Buffer Modifier[1]  Q.S. to pH 6.0  USP/NF  
Sucrose Stabilizer  3.21 mg/mL USP/NF  
Sodium Chloride Tonicity Modifier 51.35 mg/mL USP/NF  
Polysorbate 80  Solubilizer  0.2 mg/mL  USP/NF  
Water for Injection  Solvent Q.S. to 1.0 mL USP 
[1] HCl may be added to the formulation buffer to attain the desired pH  
 13.1.4 Stability and Storage  
MVT -5873 Injection drug product is packaged in clear USP Type I borosilicate glass vials  
with 20 mm West 4432/5 - stoppers (grey colored coated closures) and 20 mm flip- off seals . MVT -
5873 Injection drug product is stored at -20
oC. 
13.1.5 Administration P rocedures 
MVT -5873 Injection drug product is provided in clear borosilicate glass vials which contain a 
sterile solution of 10 mg/mL MVT -5873, 25 mM L -histidine, 55mM sodium chloride, 150 mM 
sucrose, 0.02% Polysorbate 80, pH 6.0 in a total volume of 3.1 mL and stored at -20oC. Details of 
the method of administration are included in the Clinical Protocol and the Study Procedure Manual 
for each  study. 
13.1.6 Incompatibilities    
MVT -5873 should not be administered to subjects with a history of anaphylactic reaction to hum an 
or humanized antibody, or to subjects with known hypersensitivity to any of its components or excipients.  
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
91 
 14 REFERENCES  
1. D'Angelica, M., et al., Effect on outcome of recurrence patterns after hepatectomy for 
colorectal metastases.  Ann Surg Oncol, 2011. 18(4): p. 1096-103. 
2. Doussot, A., et al., Recurrence Patterns and Disease -Free Survival after Resection of 
Intrahepatic Cholangiocarcinoma: Preoperative and Postoperative Prognostic Models. J 
Am Coll Surg, 2016. 223 (3): p. 493-505 e2. 
3. Neoptolemos, J.P., et al., Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC -4): a 
multicentre, open -label, randomised, phase 3 trial. Lancet, 2017. 389 (10073): p. 1011-
1024. 
4. Rachman -Tzemah, C., et al., Blocking Surgically Induced Lysyl Oxidase Activity Reduces 
the Risk of Lung Metastases. Cell Rep, 2017. 19(4): p. 774-784. 
5. Arnoletti, J.P., et al., Portal Venous Blood Circulation Supports Immunosuppress ive 
Environment and Pancreatic Cancer Circulating Tumor Cell Activation. Pancreas, 2017. 
46(1): p. 116-123. 
6. Al Ustwani, O., et al., Detection of circulating tumor cells in cancers of biliary origin.  J 
Gastrointest Oncol, 2012. 3(2): p. 97-104. 
7. Court, C.M., et al., Circulating Tumor Cells Predict Occult Metastatic Disease and 
Prognosis in Pancreatic Cancer. Ann Surg Oncol, 2018. 25(4): p. 1000-1008. 
8. Tan, Y. and H. Wu, The significant prognostic value of circulating tumor cells in colorectal cancer: A systematic review and meta -analysis. Curr Probl Cancer, 2018. 42(1): p. 95-106. 
9. Magnani, J.L., et al., A monoclonal antibody -defined antigen associated with 
gastrointestinal cancer is a ganglioside containing sialylated lacto-N- fucopentaose II.  J 
Biol Chem, 1982. 257(23): p. 14365-9. 
10. Magnani, J.L., et al., Identification of the gastrointestinal and pancreatic cancer -
associated antigen detected by monoclonal antibody 19- 9 in the sera of patients as a mucin. 
Cancer Res, 1983. 43 (11): p. 5489-92. 
11. Ringel, J. and M. Lohr, The MUC gene family: their role in diagnosis and early detection of pancreatic cancer. Mol Cancer, 2003. 2: p. 9. 
12. Kannagi, R., Carbohydrate antigen sialyl Lewis a-- its pathophysiological significance and 
induction mechanism in cancer progression. Chang Gung Med J, 2007. 30(3): p. 189-209. 
13. Sato, M., et al., The association of sialyl Lewis(a) antigen with the metastatic potential of human colon cancer cells. Anticancer Res, 1997. 17(5A): p. 3505-11. 
14. Feizi, T., Demonstration by monoclonal antibodies that carbohydrate structures of 
glycoproteins and glycolipids are onco- developmental antigens. Nature, 1985. 314(6006): 
p. 53-7. 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
92 
 15. Loy, T.S., et al., Distribution of CA 19- 9 in adenocarcinomas and transitional cell 
carcinomas. An immunohistochemical study of 527 cases. Am J Clin Pathol, 1993. 99(6): 
p. 726-8. 
16. Passerini, R., et al., The pitfalls of CA19 -9: routine testing and comparison of two 
automated immunoassays in a reference oncology center. Am J Clin Pathol, 2012. 138(2): 
p. 281-7. 
17. Ballehaninna, U.K. and R.S. Chamberlain, The clinical utility of serum CA 19 -9 in the 
diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based 
appraisal. J Gastrointest Oncol, 2012. 3(2): p. 105-19. 
18. Dong, Q., et al., Elevated serum CA19 -9 level is a promising predictor for poor prognosis 
in patients with resectable pancreatic ductal adenocarcinoma: a pilot study. World J Surg 
Oncol, 2014. 12: p. 171. 
19. Locker, G.Y., et al., ASCO 2006 update of recommendations for the use of tumor markers 
in gastrointestinal cancer. J Clin Oncol, 2006. 24(33): p. 5313-27. 
20. Nakayama, T., et al., Expression of sialyl Lewis(a) as a new prognostic factor for patients 
with advanced colorectal carcinoma. Cancer, 1995. 75(8): p. 2051-6. 
21. Ben-David, T., et al., The involvement of the sLe- a selectin ligand in the extravasation of 
human colorectal carcinoma cells. Immunol Lett, 2008. 116(2): p. 218-24. 
22. Matsui, T., et al., Sialyl Lewisa expression as a predictor of the prognosis of colon carcinoma patients in a prospective randomized clinical trial. Jpn J Clin Oncol, 2004. 
34(10): p. 588-93. 
23. Kishimoto, T., et al., Phenotypes correlating to metastatic properties of pancreas 
adenocarcinoma in vivo: the importance of surface sialyl Lewis(a) antigen.  Int J Cancer, 
1996. 69(4): p. 290-4. 
24. Berger, A.C., et al., Undetectable preoperative levels of serum CA 19 -9 correlate with 
improved survival for patients with resectable pancreatic adenocarcinoma. Ann Surg 
Oncol, 2004. 11(7): p. 644-9. 
25. Von Hoff, D.D., et al., Gemcitabine plus nab- paclitaxel is an active regimen in patients 
with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol, 2011. 29 (34): p. 4548-
54. 
26. Yang, G.Y., et al., Change in CA 19- 9 levels after  chemoradiotherapy predicts survival in 
patients with locally advanced unresectable pancreatic cancer.  J Gastrointest Oncol, 2013. 
4(4): p. 361-9. 
27. Koprowski, H., et al., Colorectal carcinoma antigens detected by hybridoma antibodies.  
Somatic Cell Genet , 1979. 5(6): p. 957-71. 
28. Kim, J.E., et al., Clinical usefulness of carbohydrate antigen 19- 9 as a screening test for 
pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol, 2004. 19(2): p. 
182-6. 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
93 
 29. Morris -Stiff, G. and M.A. Taylor, Ca19- 9 and pancreatic cancer: Is it really that good? J 
Gastrointest Oncol, 2012. 3(2): p. 88-9. 
30. Zubarik, R., et al., Screening for pancreatic cancer in a high- risk population with serum 
CA 19 -9 and targeted EUS: a feasibility study. Gastrointest Endosc, 2011. 74 (1): p. 87-95. 
31. Ragupathi, G., et al., Synthesis of sialyl Lewis(a) (sLe (a), CA19-9) and construction of an 
immunogenic sLe(a) vaccine. Cancer Immunol Immunother, 2009. 58(9): p. 1397-405. 
32. Sawada, R., et al., Human monoclonal antibodies to sialyl- Lewis (CA19.9) with potent 
CDC, ADCC, and antitumor activity. Clin Cancer Res, 2011. 17(5): p. 1024-32. 
33. Kannagi, R., et al., Quantitative and qualitative characterization of human cancer -
associated serum glycoprotein antigens expressing epitopes consisting of sialyl or sialyl -
fucosyl type 1 chain. Cancer Res, 1988. 48(13): p. 3856-63. 
34. Ugorski, M. and A. Laskowska, Sialyl Lewis(a): a tumor -associated carbohydrate antigen 
involved in adhesion and metastatic potential of cancer cells. Acta Bi ochim Pol, 2002. 
49(2): p. 303-11. 
35. Ohshio, G., et al., Immunohistochemical distribution of CA19- 9 in normal and tumor 
tissues of the kidney.  Urol Int, 1990. 45(1): p. 1 -3. 
36. Terracciano, D., et al., Analysis of glycoproteins in human colon cancers, normal tissues 
and in human colon carcinoma cells reactive with monoclonal antibody NCL-19-9. Oncol Rep, 2005. 14(3): p. 719-22. 
37. Arends, J.W., et al., Distribution of monoclonal antibody -defined monosialoganglioside in 
normal and cancerous human tissues: an immunoperoxidase study. Hybridoma, 1983. 
2(2): p. 219-29. 
 
Abbreviated Title: Perioperative MVT- 5873  
Version Date: 08 /10/2020  
 
94 
 15 APPENDICES  
 APPENDIX A: PERFORMANCE STATUS CRITERIA  
ECOG Performance Status Scale 
Grade  Descriptions 
0 Normal activity.  Fully active, able to carry 
on all pre -disease performance without 
restriction.  
1 Symptoms, but ambulatory.  Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature (e.g., light housework, office work).  
2 In bed <50% of the time.  Ambulatory and capable of all self -care, but unable to carry 
out any work activities.  Up and about more than 50% of waking hours. 
3 In bed >50% of the time.  Capable of only limited self -care, confined to bed or chair 
more than 50% of waking hours. 
4 100% bedridden.  Completely disabled.  Cannot carry on any self- care.  Totally 
confined to bed or chair. 
5 Dead.  
 
MVTH 1  Version 1.0: 25-July 2018  
 
95 
 
 APPENDIX B: TOXICITY TABLES  
 
Adverse events reported by MabVax Therapeutics for their Phase I clinical t rial MV -0715 -CP-001.01 , Study Registry ID: [REMOVED]  are 
summarized below in Tables 1 to 5 Table 1 All AEs (related and unrelated); highest grade per subject reported by System Organ Class, Preferred 
Term, CTCAE Grade (as 15 -December -2017)  
 Cohort A1:  
1mg/kg 
Q2wk  
(n=6)  Cohort A2:  
3mg/kg Q2wk  
(n=3)  Cohort A4:  
1mg/kg wkly  
(n=6)  Cohort A5:  
2 mg/kg wkly  
(n=6)  Cohort A6:  
3mg/kg wkly  
(n=6)  Cohort A7:  
2.5mg/kg wkly  
(n=5)  Cohort B0:  
0.125mg/kg wkly  
(n=6)  Cohort B3:  
1mg/kg wkly  
(n=3)  
Grade  1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
System Organ 
Class  
Preferred 
Term                                          
Blood and 
lymphatic 
system 
disorders  1          1 1              2 1    1 4 1    2    
Anaemia  1          1 1              2 1    1 3     2    
Neutropenia                                  1        
Thrombocyto
penia                                 1         
Cardiac 
disorders                      2 1              1     
Atrial 
fibrillation                      1                    
Sinus 
tachycardia                                     1     
Tachycardia                      1 1                   
Ear and 
labyrinth 
disorders                           2 1              
Ear 
congestion                           1               
Ear 
discomfort                           1               
Vertigo                            1              
MVTH 1  Version 1.0: 25-July 2018  
 
96 
 Adverse events reported by MabVax Therapeutics for their Phase I clinical t rial MV -0715 -CP-001.01 , Study Registry ID: [REMOVED]  are 
summarized below in Tables 1 to 5 Table 1 All AEs (related and unrelated); highest grade per subject reported by System Organ Class, Preferred 
Term, CTCAE Grade (as 15 -December -2017)  
 Cohort A1:  
1mg/kg 
Q2wk  
(n=6)  Cohort A2:  
3mg/kg Q2wk  
(n=3)  Cohort A4:  
1mg/kg wkly  
(n=6)  Cohort A5:  
2 mg/kg wkly  
(n=6)  Cohort A6:  
3mg/kg wkly  
(n=6)  Cohort A7:  
2.5mg/kg wkly  
(n=5)  Cohort B0:  
0.125mg/kg wkly  
(n=6)  Cohort B3:  
1mg/kg wkly  
(n=3)  
Grade  1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
Endocrine 
disorders                 1                         
Hypothyroidi
sm                1                         
Eye disorders                 1          1     1          
Lacrimation 
increased                 1                         
Ocular 
icterus                           1               
Vision 
blurred                                1          
Gastrointestin
al disorders  6 5    3 2    1
2 2 4   1
4 1 1   6     9 3    1
4 4 1   6 1    
Abdominal 
discomfort                 1               1          
Abdominal 
distension            1               1               
Abdominal 
hernia  1                                        
Abdominal 
pain            3     2     1     2 1    2 2    1     
Abdominal 
pain upper  1                                        
Ascites   1         1       1         1              
Constipation  2 2         1 1    2          2     3 1    1     
Diarrhoea  1          2     1     2      1    1  1   1     
Dry mouth                      1                    
Dyspepsia            1                     1         
Epigastric 
discomfort                 1                         
MVTH 1  Version 1.0: 25-July 2018  
 
97 
 Adverse events reported by MabVax Therapeutics for their Phase I clinical t rial MV -0715 -CP-001.01 , Study Registry ID: [REMOVED]  are 
summarized below in Tables 1 to 5 Table 1 All AEs (related and unrelated); highest grade per subject reported by System Organ Class, Preferred 
Term, CTCAE Grade (as 15 -December -2017)  
 Cohort A1:  
1mg/kg 
Q2wk  
(n=6)  Cohort A2:  
3mg/kg Q2wk  
(n=3)  Cohort A4:  
1mg/kg wkly  
(n=6)  Cohort A5:  
2 mg/kg wkly  
(n=6)  Cohort A6:  
3mg/kg wkly  
(n=6)  Cohort A7:  
2.5mg/kg wkly  
(n=5)  Cohort B0:  
0.125mg/kg wkly  
(n=6)  Cohort B3:  
1mg/kg wkly  
(n=3)  
Grade  1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
Faeces 
discoloured                           1               
Flatulence                 1               2          
Gastrointesti
nal 
haemorrhage              1                            
Gingival 
bleeding                                1          
Haemorrhoid
al 
haemorrhage                 1                         
Impaired 
gastric 
emptying                      1                    
Nausea   1    1 1    2  1   4 1         2     3     1 1    
Oral pain            1                              
Stomatitis  1           1                             
Vomiting   1    2 1      2   1     1     1     1     2     
General 
disorders and 
administration 
site conditions  5 5 1    2 1   1
0 3    4     9 4 1   5  1   1
1 2    4 1    
Asthenia         1             1          1          
Chest 
discomfort                           1               
Chest pain  1                              1          
Chills  1          1     1     2 1         2          
Disease 
progression                                          
Fatigue  1 2     1    2 2    1     1 2 1   3     3     1 1    
MVTH 1  Version 1.0: 25-July 2018  
 
98 
 Adverse events reported by MabVax Therapeutics for their Phase I clinical t rial MV -0715 -CP-001.01 , Study Registry ID: [REMOVED]  are 
summarized below in Tables 1 to 5 Table 1 All AEs (related and unrelated); highest grade per subject reported by System Organ Class, Preferred 
Term, CTCAE Grade (as 15 -December -2017)  
 Cohort A1:  
1mg/kg 
Q2wk  
(n=6)  Cohort A2:  
3mg/kg Q2wk  
(n=3)  Cohort A4:  
1mg/kg wkly  
(n=6)  Cohort A5:  
2 mg/kg wkly  
(n=6)  Cohort A6:  
3mg/kg wkly  
(n=6)  Cohort A7:  
2.5mg/kg wkly  
(n=5)  Cohort B0:  
0.125mg/kg wkly  
(n=6)  Cohort B3:  
1mg/kg wkly  
(n=3)  
Grade  1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
Hernia pain            1                              
Hyperhidrosi
s 1          1                              
Inflammation                 1                         
Localised 
oedema                                     1     
Malaise   1     1    2                              
Mucosal 
inflammation                                1          
Oedema 
peripheral  1  1        1     1     3 1         1          
Pain   1                        1  1    1         
Pyrexia   1         2 1         2          2 1    2     
Hepatobiliary 
disorders  1  1     1                            1     
Hyperbilirubi
naemia    1     1                                 
Jaundice  1                                   1     
Immune 
system 
disorders   1 1                  1      1              
Infusion 
related 
reaction   1 1                  1      1              
Infections and 
infestations   1    1  1   1 1    2       1   2 2     2         
Candida 
infection                           1               
Clostridium 
difficile colitis   1                                       
MVTH 1  Version 1.0: 25-July 2018  
 
99 
 Adverse events reported by MabVax Therapeutics for their Phase I clinical t rial MV -0715 -CP-001.01 , Study Registry ID: [REMOVED]  are 
summarized below in Tables 1 to 5 Table 1 All AEs (related and unrelated); highest grade per subject reported by System Organ Class, Preferred 
Term, CTCAE Grade (as 15 -December -2017)  
 Cohort A1:  
1mg/kg 
Q2wk  
(n=6)  Cohort A2:  
3mg/kg Q2wk  
(n=3)  Cohort A4:  
1mg/kg wkly  
(n=6)  Cohort A5:  
2 mg/kg wkly  
(n=6)  Cohort A6:  
3mg/kg wkly  
(n=6)  Cohort A7:  
2.5mg/kg wkly  
(n=5)  Cohort B0:  
0.125mg/kg wkly  
(n=6)  Cohort B3:  
1mg/kg wkly  
(n=3)  
Grade  1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
Folliculitis                                 1         
Lung 
infection                        1         1         
Nail infection       1                                   
Pneumonia         1                                 
Rhinitis                            1              
Sinusitis                           1               
Upper 
respiratory 
tract infection             1    1                         
Urinary tract 
infection            1     1           1              
Injury, 
poisoning and 
procedural 
complications  1     2     2                              
Fall 1     1                                   
Incision site 
inflammation            1                              
Wound       1                                   
Wound 
complication            1                              
Investigations  5  4     1   6 1 4   1 2 8 1  1 3 4   5 5 1
0 1  1
3 8 6   5 5 5 1  
Activated 
partial thromboplast
in time 
prolonged                            1              
MVTH 1  Version 1.0: 25-July 2018  
 
100 
 Adverse events reported by MabVax Therapeutics for their Phase I clinical t rial MV -0715 -CP-001.01 , Study Registry ID: [REMOVED]  are 
summarized below in Tables 1 to 5 Table 1 All AEs (related and unrelated); highest grade per subject reported by System Organ Class, Preferred 
Term, CTCAE Grade (as 15 -December -2017)  
 Cohort A1:  
1mg/kg 
Q2wk  
(n=6)  Cohort A2:  
3mg/kg Q2wk  
(n=3)  Cohort A4:  
1mg/kg wkly  
(n=6)  Cohort A5:  
2 mg/kg wkly  
(n=6)  Cohort A6:  
3mg/kg wkly  
(n=6)  Cohort A7:  
2.5mg/kg wkly  
(n=5)  Cohort B0:  
0.125mg/kg wkly  
(n=6)  Cohort B3:  
1mg/kg wkly  
(n=3)  
Grade  1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
Alanine 
aminotransfe
rase                                1 1        
Alanine 
aminotransfe
rase increased  1       1    1      2     1     2 1  2 1 2    1 2   
Aspartate 
aminotransfe
rase                                2         
Aspartate 
aminotransfe
rase increased  1          1  1     1     2   1  3   4      2 1   
Blood 
alkaline 
phosphatase                            1              
Blood 
alkaline phosphatase 
increased  2          3  2     1    1 1   2  2    1     1    
Blood 
bilirubin 
increased    2        1      1 3    1    1 2 1   3     1  2   
Blood 
cholesterol 
increased                                1          
Blood 
creatinine 
increased  1                                        
Blood 
fibrinogen 
decreased    1                                      
MVTH 1  Version 1.0: 25-July 2018  
 
101 
 Adverse events reported by MabVax Therapeutics for their Phase I clinical t rial MV -0715 -CP-001.01 , Study Registry ID: [REMOVED]  are 
summarized below in Tables 1 to 5 Table 1 All AEs (related and unrelated); highest grade per subject reported by System Organ Class, Preferred 
Term, CTCAE Grade (as 15 -December -2017)  
 Cohort A1:  
1mg/kg 
Q2wk  
(n=6)  Cohort A2:  
3mg/kg Q2wk  
(n=3)  Cohort A4:  
1mg/kg wkly  
(n=6)  Cohort A5:  
2 mg/kg wkly  
(n=6)  Cohort A6:  
3mg/kg wkly  
(n=6)  Cohort A7:  
2.5mg/kg wkly  
(n=5)  Cohort B0:  
0.125mg/kg wkly  
(n=6)  Cohort B3:  
1mg/kg wkly  
(n=3)  
Grade  1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
Blood lactate 
dehydrogenas
e increased            1                              
Blood 
phosphorus 
decreased                                      1    
International 
normalised ratio 
increased    1              1                   1     
Lipase 
increased                    1         1    1         
Lymphocyte 
count 
decreased              1     1          1     1        
Neutrophil 
count 
decreased                            1     1 1      1  
Platelet count 
decreased                       1         2 1    1     
Weight 
decreased                 1     1          1     1     
White blood 
cell count 
decreased                           1       1   1     
Metabolism 
and nutrition 
disorders  1  2    1 1   9  5   1 1 1   3     4 2    8 3 3   2 2 1   
Decreased 
appetite        1    1     1     1     1               
MVTH 1  Version 1.0: 25-July 2018  
 
102 
 Adverse events reported by MabVax Therapeutics for their Phase I clinical t rial MV -0715 -CP-001.01 , Study Registry ID: [REMOVED]  are 
summarized below in Tables 1 to 5 Table 1 All AEs (related and unrelated); highest grade per subject reported by System Organ Class, Preferred 
Term, CTCAE Grade (as 15 -December -2017)  
 Cohort A1:  
1mg/kg 
Q2wk  
(n=6)  Cohort A2:  
3mg/kg Q2wk  
(n=3)  Cohort A4:  
1mg/kg wkly  
(n=6)  Cohort A5:  
2 mg/kg wkly  
(n=6)  Cohort A6:  
3mg/kg wkly  
(n=6)  Cohort A7:  
2.5mg/kg wkly  
(n=5)  Cohort B0:  
0.125mg/kg wkly  
(n=6)  Cohort B3:  
1mg/kg wkly  
(n=3)  
Grade  1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
Dehydration            1                              
Hyperglycae
mia 1            3    1 1         1    1 2 2    2    
Hyperkalaem
ia        1                       1          
Hypermagnes
aemia                                1          
Hypertriglyce
ridaemia                                1          
Hypoalbumin
aemia    1        2          1      1    1          
Hypocalcaem
ia                          1     1          
Hypoglycaem
ia                                 1        
Hypokalaemi
a                     1          1 1    1  1   
Hypomagnes
aemia            2               1     1          
Hyponatraem
ia   1        1  1                       1     
Hypophospha
taemia              1                            
Iron 
deficiency            1                              
Vitamin B12 
deficiency            1                              
Vitamin D 
deficiency                           1               
MVTH 1  Version 1.0: 25-July 2018  
 
103 
 Adverse events reported by MabVax Therapeutics for their Phase I clinical t rial MV -0715 -CP-001.01 , Study Registry ID: [REMOVED]  are 
summarized below in Tables 1 to 5 Table 1 All AEs (related and unrelated); highest grade per subject reported by System Organ Class, Preferred 
Term, CTCAE Grade (as 15 -December -2017)  
 Cohort A1:  
1mg/kg 
Q2wk  
(n=6)  Cohort A2:  
3mg/kg Q2wk  
(n=3)  Cohort A4:  
1mg/kg wkly  
(n=6)  Cohort A5:  
2 mg/kg wkly  
(n=6)  Cohort A6:  
3mg/kg wkly  
(n=6)  Cohort A7:  
2.5mg/kg wkly  
(n=5)  Cohort B0:  
0.125mg/kg wkly  
(n=6)  Cohort B3:  
1mg/kg wkly  
(n=3)  
Grade  1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
Musculoskelet
al and 
connective 
tissue 
disorders  1  3   2     2     3     6 2    3     2 2         
Arthralgia                 1     2                    
Back pain    1   1          1     3     1     1          
Muscle injury                                 1         
Muscle 
spasms                                 1         
Muscular 
weakness                       1    1               
Musculoskele
tal discomfort                                1          
Musculoskele
tal pain  1  1                   1                   
Myalgia                 1          1               
Neck pain       1     1                              
Pain in 
extremity    1        1          1                    
Neoplasms 
benign, 
malignant and 
unspecified 
(incl cysts and 
polyps)                                          
Malignant 
neoplasm 
progression                                          
MVTH 1  Version 1.0: 25-July 2018  
 
104 
 Adverse events reported by MabVax Therapeutics for their Phase I clinical t rial MV -0715 -CP-001.01 , Study Registry ID: [REMOVED]  are 
summarized below in Tables 1 to 5 Table 1 All AEs (related and unrelated); highest grade per subject reported by System Organ Class, Preferred 
Term, CTCAE Grade (as 15 -December -2017)  
 Cohort A1:  
1mg/kg 
Q2wk  
(n=6)  Cohort A2:  
3mg/kg Q2wk  
(n=3)  Cohort A4:  
1mg/kg wkly  
(n=6)  Cohort A5:  
2 mg/kg wkly  
(n=6)  Cohort A6:  
3mg/kg wkly  
(n=6)  Cohort A7:  
2.5mg/kg wkly  
(n=5)  Cohort B0:  
0.125mg/kg wkly  
(n=6)  Cohort B3:  
1mg/kg wkly  
(n=3)  
Grade  1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
Nervous 
system 
disorders  1 1    2 1         1     2          7 1 2   2     
Balance 
disorder       1                                   
Confusional 
state                      1                    
Dizziness       1                          1         
Encephalopat
hy                                         
Headache        1              1               1     
Neuropathy 
peripheral                 1               4  1   1     
Paraesthesia                                1          
Peripheral 
sensory 
neuropathy   1                             1  1        
Somnolence  1                                        
Syncope                                1          
Psychiatric 
disorders                 1     1 1    1     2     2     
Depression                 1     1               1     
Disorientatio
n                      1                   
Insomnia                           1     2     1     
Renal and 
urinary 
disorders  1          1          1     2 1              
Chromaturia                           2               
MVTH 1  Version 1.0: 25-July 2018  
 
105 
 Adverse events reported by MabVax Therapeutics for their Phase I clinical t rial MV -0715 -CP-001.01 , Study Registry ID: [REMOVED]  are 
summarized below in Tables 1 to 5 Table 1 All AEs (related and unrelated); highest grade per subject reported by System Organ Class, Preferred 
Term, CTCAE Grade (as 15 -December -2017)  
 Cohort A1:  
1mg/kg 
Q2wk  
(n=6)  Cohort A2:  
3mg/kg Q2wk  
(n=3)  Cohort A4:  
1mg/kg wkly  
(n=6)  Cohort A5:  
2 mg/kg wkly  
(n=6)  Cohort A6:  
3mg/kg wkly  
(n=6)  Cohort A7:  
2.5mg/kg wkly  
(n=5)  Cohort B0:  
0.125mg/kg wkly  
(n=6)  Cohort B3:  
1mg/kg wkly  
(n=3)  
Grade  1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
Chronic 
kidney 
disease            1                              
Pollakiuria  1                    1                    
Proteinuria                            1              
Respiratory, 
thoracic and 
mediastinal 
disorders  2     5     5     1     4 2    4 2    5  3   2     
Cough       1          1          1 1    2  1   1     
Dyspnoea  1     1     1          2     1          1     
Dyspnoea 
exertional       1                1         1          
Epistaxis            1                    2          
Hiccups  1                     1                   
Nasal 
congestion            1               1               
Paranasal 
sinus 
discomfort       1                                   
Pleural 
effusion                            1              
Pneumonia                                  1        
Pneumonitis                                  1        
Productive 
cough            1               1               
Pulmonary 
congestion                      1                    
Pulmonary 
embolism                      1                    
MVTH 1  Version 1.0: 25-July 2018  
 
106 
 Adverse events reported by MabVax Therapeutics for their Phase I clinical t rial MV -0715 -CP-001.01 , Study Registry ID: [REMOVED]  are 
summarized below in Tables 1 to 5 Table 1 All AEs (related and unrelated); highest grade per subject reported by System Organ Class, Preferred 
Term, CTCAE Grade (as 15 -December -2017)  
 Cohort A1:  
1mg/kg 
Q2wk  
(n=6)  Cohort A2:  
3mg/kg Q2wk  
(n=3)  Cohort A4:  
1mg/kg wkly  
(n=6)  Cohort A5:  
2 mg/kg wkly  
(n=6)  Cohort A6:  
3mg/kg wkly  
(n=6)  Cohort A7:  
2.5mg/kg wkly  
(n=5)  Cohort B0:  
0.125mg/kg wkly  
(n=6)  Cohort B3:  
1mg/kg wkly  
(n=3)  
Grade  1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
Rhinorrhoea       1     1                              
Skin and 
subcutaneous 
tissue 
disorders  1          2     2 1    1     3     5 2    4     
Alopecia                                2 2    1     
Contusion                 1                         
Hyperhidrosi
s           1          1                    
Night sweats                                1          
Pruritus            1               1          1     
Pruritus 
generalised  1                                        
Rash                                1     2     
Rash maculo -
papular                 1          2     1          
Urticaria                  1                        
Surgical and 
medical 
procedures            1                              
Wound 
drainage            1                              
Vascular 
disorders   1 1             1      3     1 1   3 1 1    1    
Deep vein 
thrombosis                       1     1     1         
Flushing                                1      1    
Hypertension   1              1      1      1   1          
Hypotension    1                   1         1  1        
*Unaudited data as of 15- Dec-2017  
MVTH 1  Version 1.0: 25-July 2018  
 
107 
  
 
 
MVT -5873 -Related AEs; highest grade per subject reported by System Organ Class, Preferred Term, CTCAE grade (as of 15-December -2017)  
 Cohort A1:  
1mg/kg 
Q2wks  
(n=6)  Cohort A2:  
3 mg/kg 
Q2wks  
(n=3)  Cohort A4:  
1mg/kg wkly  
(n=6)  Cohort A5:  
2mg/kg wkly  
(n=6)  Cohort A6:  
3mg/kg wkly  
(n=6)  Cohort A7:  
2.5mg/kg wkly  
(n=5)  Cohort B0:  
0.125mg/kg wkly  
(n=6)  Cohort B3:  
1mg/kg wkly  
(n=3)  
Grade  1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
System Organ 
Class  
   Preferred 
Term                                          
Blood and 
lymphatic 
system 
disorders                           2      1         
Anaemia                           2      1         
Cardiac 
disorders                       1              1     
Sinus 
tachycardia                                     1     
Tachycardia                       1                   
Eye disorders                           1               
Ocular icterus                           1               
Gastrointestin
al disorders  3 1         3     5          4     3 1    2 1    
Abdominal 
pain                          1               
Abdominal 
pain upper  1                                        
Constipation                                1          
Diarrhoea  1          1     1                1         
Faeces 
discoloured                           1               
Nausea            1     3          1     1     1 1    
Oral pain            1                              
Stomatitis  1                                        
MVTH 1  Version 1.0: 25-July 2018  
 
108 
 MVT -5873 -Related AEs; highest grade per subject reported by System Organ Class, Preferred Term, CTCAE grade (as of 15-December -2017)  
 Cohort A1:  
1mg/kg 
Q2wks  
(n=6)  Cohort A2:  
3 mg/kg 
Q2wks  
(n=3)  Cohort A4:  
1mg/kg wkly  
(n=6)  Cohort A5:  
2mg/kg wkly  
(n=6)  Cohort A6:  
3mg/kg wkly  
(n=6)  Cohort A7:  
2.5mg/kg wkly  
(n=5)  Cohort B0:  
0.125mg/kg wkly  
(n=6)  Cohort B3:  
1mg/kg wkly  
(n=3)  
Grade  1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
Vomiting   1              1          1     1     1     
General 
disorders and 
administratio
n site 
conditions  1 3         3 3    1     3 2         2 1    2     
Chest pain  1                                        
Chills            1     1     2 1         1          
Fatigue   2         1 2          1              1     
Malaise   1         1                              
Pyrexia             1         1          1 1    1     
Hepatobiliary 
disorders         1                                 
Hyperbilirubi
naemia         1                                 
Immune 
system 
disorders   1 1                  1      1              
Infusion 
related 
reaction   1 1                  1      1              
Infections and 
infestations                           1               
Candida 
infection                           1               
Investigations  3  1     1   1 1 2     8 1   3 3   4 3 9 1  7 4 2   3 5 4   
Alanine 
aminotransfer
ase                                1 1        
Alanine 
aminotransfer
ase increased         1    1      2     1     2 1  2 2 1    1 2   
MVTH 1  Version 1.0: 25-July 2018  
 
109 
 MVT -5873 -Related AEs; highest grade per subject reported by System Organ Class, Preferred Term, CTCAE grade (as of 15-December -2017)  
 Cohort A1:  
1mg/kg 
Q2wks  
(n=6)  Cohort A2:  
3 mg/kg 
Q2wks  
(n=3)  Cohort A4:  
1mg/kg wkly  
(n=6)  Cohort A5:  
2mg/kg wkly  
(n=6)  Cohort A6:  
3mg/kg wkly  
(n=6)  Cohort A7:  
2.5mg/kg wkly  
(n=5)  Cohort B0:  
0.125mg/kg wkly  
(n=6)  Cohort B3:  
1mg/kg wkly  
(n=3)  
Grade  1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
Aspartate 
aminotransfer
ase                                1         
Aspartate 
aminotransfer
ase increased  1            1     1     2   1  3   3      2 1   
Blood alkaline 
phosphatase                            1              
Blood alkaline 
phosphatase 
increased  1            1     1    1    2  2         1    
Blood 
bilirubin 
increased  1  1        1       3    1    1 2 1   1     1  1   
Blood 
phosphorus 
decreased                                      1    
International 
normalised 
ratio increased                                     1     
Lipase 
increased                    1                      
Lymphocyte 
count 
decreased                   1          1             
Platelet count 
decreased                       1         1          
White blood 
cell count 
decreased                                     1     
Musculoskelet
al and 
connective           1     1     2                    
MVTH 1  Version 1.0: 25-July 2018  
 
110 
 MVT -5873 -Related AEs; highest grade per subject reported by System Organ Class, Preferred Term, CTCAE grade (as of 15-December -2017)  
 Cohort A1:  
1mg/kg 
Q2wks  
(n=6)  Cohort A2:  
3 mg/kg 
Q2wks  
(n=3)  Cohort A4:  
1mg/kg wkly  
(n=6)  Cohort A5:  
2mg/kg wkly  
(n=6)  Cohort A6:  
3mg/kg wkly  
(n=6)  Cohort A7:  
2.5mg/kg wkly  
(n=5)  Cohort B0:  
0.125mg/kg wkly  
(n=6)  Cohort B3:  
1mg/kg wkly  
(n=3)  
Grade  1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
tissue 
disorders  
Arthralgia                      1                    
Back pain                 1     1                    
Neck pain            1                              
Psychiatric 
disorders                                     1     
Depression                                     1     
Renal and 
urinary 
disorders                           2 1              
Chromaturia                           2               
Proteinuria                            1              
Respiratory, 
thoracic and 
mediastinal 
disorders  1                    1            2   1     
Cough                                  1   1     
Dyspnoea  1                    1                    
Pneumonitis                                  1        
Skin and 
subcutaneous 
tissue 
disorders                  1              2     3     
Alopecia                                     1     
Rash                                1     2     
Rash maculo -
papular                                1          
Urticaria                  1                        
Vascular 
disorders   1              1      1               1    
Flushing                                      1    
MVTH 1  Version 1.0: 25-July 2018  
 
111 
 MVT -5873 -Related AEs; highest grade per subject reported by System Organ Class, Preferred Term, CTCAE grade (as of 15-December -2017)  
 Cohort A1:  
1mg/kg 
Q2wks  
(n=6)  Cohort A2:  
3 mg/kg 
Q2wks  
(n=3)  Cohort A4:  
1mg/kg wkly  
(n=6)  Cohort A5:  
2mg/kg wkly  
(n=6)  Cohort A6:  
3mg/kg wkly  
(n=6)  Cohort A7:  
2.5mg/kg wkly  
(n=5)  Cohort B0:  
0.125mg/kg wkly  
(n=6)  Cohort B3:  
1mg/kg wkly  
(n=3)  
Grade  1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
Hypertension   1              1      1                   
*Unaudited data as of 15- Dec 2017  
 
MVTH 1  Version 1.0: 25-July 2018  
 
112 
 Table 5 Serious Adverse Events Reported as of 15 December 2017 
Manufacturing  
Ctrl No.  Subject 
ID Drug  Dose and 
Frequency  Cycle Adverse Event 
(Verbatim Term)  CTCAE Grade  Relationship  
MVT5873- 2016-
001 02-004 MVT -5873  1mg/kg Q2W  1 Hypotension  3 (severe)  Unrelated  
MVT5873- 2016-
002 02-004 MVT -5873  1mg/kg Q2W  1 Hyperbilirubinemia  3 (severe)  Unrelated  
MVT5873- 2016-
003 01-012 MVT -5873  1mg/kg Q2W  1 Fever  2 (moderate)  Unrelated  
MVT5873- 2016-
005 01-012 MVT -5873  1mg/kg Q2W  2 Encephalopathy  5 (death)  Unrelated  
MVT5873- 2016-
006 02-007 MVT -5873  1mg/kg Q2W  4 Lung Infection*  3 (severe)  Unrelated  
MVT5873- 2016-
007 02-002 MVT -5873  1mg/kg Q2W  1 Clinical Progression 
of Pancreatic Cancer  5 (death)  Unrelated  
MVT5873- 2016-
010 02-028 MVT -5873  3mg/kg QW  1 Clinical Progression 
of Pancreatic 
Carcinoma 5 (death)  Unrelated  
MVT5873- 2016-
011 01-025 MVT -5873  3mg/kg QW  2 Progression of 
Disease  5 (death)  Unrelated  
MVT5873- 2017-
001 02-034 MVT -5873  3mg/kg QW  1 Lung Infection  3 (severe)  Unrelated  
MVT5873- 2017-
002 02-034 MVT -5873  3mg/kg QW  1 Lung Infection  3 (severe)  Unrelated  
MVT5873- 2017-
003 02-006 MVT -5873  3mg/kg Q2W  10 Weakness  3 (severe)  Unrelated  
MVTH 1  Version 1.0: 25-July 2018  
 
113 
 Manufacturing  
Ctrl No.  Subject 
ID Drug  Dose and 
Frequency  Cycle Adverse Event 
(Verbatim Term)  CTCAE Grade  Relationship  
MVT5873- 2017-
005 02-006 MVT -5873  3mg/kg Q2W  10 Headache  2 (moderate)  Unrelated  
MVT5873- 2017-
006 02-006 MVT -5873  3mg/kg Q2W  10 Clinical Disease 
Progression 5 (death)  Unrelated  
MVT5873- 2017-
009 01-024 MVT -5873  2mg/kg QW  2 Malignant neoplasm 
progression  5 (death)  Unrelated  
MVT5873- 2017-
010 03-014 MVT -5873  1mg/kg QW  2 Disease Progression  5 (death)  Unrelated  
MVT5873- 2017-
012 01-047 MVT -5873  1mg/kg QW  3 Fever  1 (mild)  Unrelated  
MVT5873- 2017-
013 03-046 MVT -5873  1mg/kg Q2W  5 Upper Gastrointestinal Hemorrhage**  3 (severe)  Unrelated  
MVT5873- 2017-
014 02-016 MVT -5873  1mg/kg QW  13 Gastrointestinal Bleeding*** 3 (severe)  Unrelated  
MVT5873- 2017-
015 02-016 MVT -5873  1mg/kg QW  13 Vomiting***  3 (severe)  Unrelated  
*Subject 02- 007 received a starting dose at 3 mg/kg and then received 6 doses at 1 mg/kg Q2W prior to SAE start date.  
**Subject 03- 046 received a starting dose at 2mg/kg QW and then received 1mg/kg Q2W beginning on C1D15  
***Subject 02- 016 dose escalated to 2mg/kg QW starting C6D15 through C7D15 and then dose reduced back to original dose of 1mg/kg 
QW 
 
 
MVTH 1  Version 1.0: 25-July 2018  
 
114 
 
 APPENDIX C: INVESTIGATOR AGREEMENT  
This form can be used to send to Participating site  PIs if the CCR is the coordinating center for 
the protocol. I have received and reviewed the Investigator Brochure for ( insert Study Agent) 
 I have read this protocol and agree that the study is ethical.  I agree to conduct the study as outlined and in accordance with all applicable regulations and 
guidelines.  
 I agree to maintain the confidentiality of all information received or developed in connection with  
this protocol.    Protocol Title:   Protocol Version Date:   _______________________________________             ___________________      Signature of Principal Investigator      Date  
  _________________________________________ Name of Principal Investigator (printed or typed)  